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ABSTRACT
The main objective of this body of work is to develop polymeric drug delivery systems for
cancer radiotherapy and the decorporation of radiological materials. The polymeric systems for
radiotherapy were evaluated in vitro and in vivo (in normal, prostate, and ovarian cancer mice
models). The polymeric system for radionuclide decorporation was also evaluated in vitro and in a
normal mouse model. Due to its attractive properties, the N-(2-Hydroxypropyl) methacrylamide
(HPMA) copolymer was utilized as the main carrier for the developed systems.
Chapter 1 provides an overview of prostate and ovarian cancer, targeted
radiopharmaceuticals, nanomedicine-based drug delivery for cancer, HPMA copolymers, and
decorporation agents of radiological materials.
In chapter 2, we aimed to develop targeted HPMA copolymers to improve prostate cancer
treatment. HPMA copolymers were modified with bombesin (BBN) peptide analogs to target the
gastrin-releasing peptide receptor (GRPR) that is overexpressed in several tumors, including
prostate cancer. Based on varying the content and charge, a total of ten BBN-HPMA copolymers
were synthesized and evaluated in GRPR-overexpressing prostate cancer cell line (PC-3), and the
biodistribution profile of the optimized copolymers was evaluated in a normal CF-1 mouse model.
The in vitro results showed enhanced internalization via GRPR targeting was charge- and BBN
density-dependent. While the negative and zwitterionic conjugates showed low PC-3 uptake
values, the positively-charged BBN-polymeric conjugates revealed a direct relationship between
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the extent of cellular internalization and BBN-incorporation density. In vivo studies of the
positively-charged copolymers resulted in rapid blood clearance by the mononuclear phagocyte
system (MPS)-associated tissues. Further optimization to avoid rapid MPS recognition is needed
in the future.
In chapter 3, we aimed to improve the radiotherapy of ovarian cancer by developing a
polymeric delivery system, using HPMA copolymer as a carrier, that overcomes the current
drawbacks of radiolabeled nanomedicine (e.g., retention in MPS-associated tissues and long
circulation times needed for tumor targeting). The new system (MP-90-TCO-C) combines two
strategies in one system. The first strategy is to enhance the clearance of retained large polymers in
the MPS-associated tissues via biodegradation, by cathepsin S enzyme (Cat S) that is abundantly
expressed in these tissues, into small and easily cleared fragments from the body. The second
strategy is based on employing bioorthogonal in vivo chemistry between a trans-cyclooctene(TCO) modified polymer (MP-90-TCO-C) and a tetrazine- (TZ) based radiotracer. Kinetic and in
vitro Cat S studies were evaluated. In vivo studies were performed using two ovarian cancer and a
normal CF-1 mouse models. The kinetic studies revealed ultra-fast reactions between MP-90-TCOC, and the TZ-radiotracer while MP-90-TCO-C was also found to be cleaved in vitro by Cat S. The
in vivo studies showed biodegradation of the copolymer in the CF-1 mouse model with excellent
in vivo TCO/TZ reactivity in ovarian cancer models with improved tumor to non-target ratios
observed. These results show the feasibility of this approach to enhance the treatment of ovarian
cancer.
In chapter 4, we aimed to design a polymeric system that can be suitable for prophylactic
applications to reduce the exposure to radioactive actinides, which can occur in case of accidental
internal contamination. DTPA is approved for actinide decorporation after exposure, but due to its
short half-life, DTPA is not ideal for prophylactic applications. To overcome this drawback, we
developed a DTPA-based polymeric system (P-DTPA) based on an HPMA copolymer. We
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evaluated its decorporation efficacy using an actinide model in vitro and in a normal CF-1 mouse
model under prophylactic settings. The in vitro results showed the tolerability of P-DTPA and the
ability to chelate the actinide model in the presence of competing biological metals. The in vivo
results showed the superiority of P-DTPA over DTPA in enhancing the excretion of the radioactive
material. This enhanced decorporation effect is mainly attributed to the longer circulation time of
P-DTPA compared to DTPA.
In chapter 5, all results from the three projects will be summarized, and future research
directions will be provided.
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1 Chapter 1. Introduction
1.1 Prostate cancer
According to the American Cancer Society, prostate cancer is the most common type of
cancer diagnosed (except for certain skin cancers) in men in the United States (US). (1). More than
191,000 and 33,000 new prostate cancer cases and deaths are expected in the US by the end of this
year. The 5-year relative survival rate for men diagnosed with early stage disease is nearly 100%,
but this percentage drops to nearly 31% in patients diagnosed at later stages of the disease.

1.1.1

Diagnosis of prostate cancer
Unfortunately with prostate cancer, there are no obvious symptoms associated with the

disease in the early stages. However, urinary (e.g., hesitancy and retention) and systemic symptoms
(e.g., fatigue and bone pain) are observed in patients with advanced disease (2). Fortunately, most
prostate cancer cases are diagnosed at the early stage through routine screening via a prostate
antigen test (PSA) or digital rectal examination (3). PSA is a glycoprotein produced by the
epithelial cells of normal prostate and prostatic cancer tissue (4). Although it is not definitive, a
high serum level of PSA (10 ng/mL) indicates a more likely (> 50%) issue of prostate cancer
presentation (3). A prostate biopsy is necessary to confirm the diagnosis.
The American Joint Committee on Cancer (AJCC) TNM system is the standard staging
system for staging prostate cancer (5). In cases of high risk for metastasis, conventional bone scans
using

99m

technetium methylene diphosphonate and cross-sectional body imaging (computed

tomography (CT) or magnetic resonance imaging (MRI)) are recommended (3). These imaging
modalities have limited sensitivity in detecting small malignant lesions (3). Therefore, there is a
growing interest in using highly sensitive nuclear medicine imaging modalities to detect disease
recurrence via the employment of radiotracers (6). 11C-choline and 18F-fluciclovine (a non-natural
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amino acid) radiotracers are examples of recently approved agents by the US Food and Drug
Administration (FDA) for detecting the recurrence of prostate disease (6). The sensitivity and
specificity of the currently approved drugs vary depending on several factors, including PSA level
and the location of the tumor (lymph nodes versus bone). For example, the sensitivity of 11C-choline
ranges from 38% to 98%, and its specificity ranges from 50% to 100% (3). Interestingly, a recent
report showed that the incidence of diagnosis with metastatic prostate cancer in the US was
increased between 2004 to 2013 (7). Therefore, the development of improved screening and
diagnostic tests are needed.

1.1.2

Treatment of prostate cancer
The treatment options for prostate cancer depends on the stage at which diagnosis occurs

(localized versus distant). For localized cancer cases (low, intermediate, and high risk), the options
include active surveillance, radical prostatectomy, and radiotherapy (8). Classification of patients
into the risk groups is dependent on PSA levels and Gleason score (9). Low-risk patients under
active surveillance undergo monitoring for disease progression with the intent to cure. However,
intermediate- and high-risk patients undergo either radical prostatectomy or radiotherapy
treatments (9). Reports indicated no difference in the mortality rates due to prostate cancer between
patients who underwent radical prostatectomy or radiotherapy (3). External-beam radiation therapy
(EBRT) is the standard approach for radiotherapy in prostate patients (9). Dose-escalated intensitymodulated radiation therapy (IMRT) is the most common technique for delivering EBRT. Unlike
conventional EBRT techniques, IMRT involves the delivery of multiple radiation beams from
different angles to intersect within the target volume. This technique is associated with a reduction
in the toxicities of adjacent tissues (9). However, short- and long-term urinary incontinence, bowel
toxicity, and erectile dysfunction are still commonly observed following radiotherapy. In addition,
treatment of metastatic disease using EBRT techniques remains a major challenge. Alternative
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strategies (e.g., radiopharmaceuticals) targeting the tumor cells and other cells in the tumor
microenvironment in the metastatic disease are needed (10, 11).
The standard treatment strategy of metastatic prostate cancer includes androgen
deprivation therapy (e.g., luteinizing hormone-releasing hormone (LHRH) therapy) (3, 8).
However, metastatic prostate cancer patients, eventually, become castration-resistant necessitating
the progression to other types of disease management strategies (8). Radiotherapy is generally not
recommended for metastatic prostate cancer patients. A recent clinical trial showed that performing
radiotherapy to the prostate of newly diagnosed metastatic patients failed to improve overall
survival rates (12). Other available treatment options mainly include chemotherapeutic and
hormonal agents. For example, docetaxel is a commonly prescribed chemotherapeutic drug for
metastatic prostate cancer patients (8). Docetaxel is an antimicrotubular agent that acts by
stabilizing the mitotic spindle during mitosis and interphase, which leads to mitosis and cell
proliferation arrest. Examples of hormonal agents include abiraterone and enzalutamide that have
gained FDA approval for the treatment of metastatic castration-resistant prostate patients in 2011
and 2012, respectively (8). However, despite these recent efforts, metastatic prostate cancer is still
considered a non-curable disease with the need for the development of new and innovative
treatment strategies.

1.2 Ovarian Cancer
According to the American Cancer Society, ovarian cancer accounts for the highest number
of deaths among gynecological tumors and ranks fifth in death-related cancer among American
women (1). It is estimated that 21,750 individuals will be diagnosed, and 13,940 patients will die
in the US in 2020 due to ovarian cancer (1). The 5-year relative survival rate for women diagnosed
at the localized stage is about 92% (13). However, this rate drops to nearly 30% with a metastatic
stage diagnosis. Unfortunately, nearly 58% of ovarian cancer patients are diagnosed with metastatic
disease.
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Based on the cell origin, ovarian cancer is categorized into either epithelial, germ cell, or
stromal tumor types. Epithelial ovarian cancer (EOC) is the most common type, and it accounts for
nearly 90% of cases (14). The majority of EOC patients are diagnosed at the advanced stages with
only 20% of patients being diagnosed with early stage disease (15). The 5-year relative survival
rate of EOC patients is about 70% if the disease is detected at the early stages; this rate drops to
nearly 35% in patients diagnosed at the advanced stages. EOC is a heterogeneous disease, which is
subclassified into high-grade serous carcinoma (70%), endometrioid (10%), clear-cell (10%),
mucinous (3%), and low-grade serous carcinomas (<5%) (16). These statistics highlight the lack of
effective screening tests for the disease at the early stages and the need for alternative therapeutic
agents for the patients at the advanced stages.

1.2.1

Diagnosis of ovarian cancer
There are no specific symptoms associated with ovarian cancer (14). Patients may

experience pelvic and abdominal pain, abdominal bloating, and other nonspecific gastrointestinal
symptoms (e.g., nausea and vomiting). A study reported that ovarian cancer patients might
experience these symptoms for 12 months before diagnosis (17). Currently, the only available
screening tests include performing a transvaginal ultrasound and a blood test for the ovarian cancer
marker CA125 (mucin 16) (18).The transvaginal ultrasound is not specific for the detection of
cancer, and the majority of masses found by transvaginal ultrasound are not malignant (19). Also,
an increase in the blood levels of the CA125 marker is observed in only 50% of patients with stage
I ovarian cancer (20). A randomized controlled trial of over 202,000 women divided into three
screening test groups (CA125 versus transvaginal ultrasound versus no screening test) was
performed to investigate the effects of early detection by screening on the resultant mortality rates.
After 11 years of follow-up, there was found to be no difference in the mortality rates between the
three groups (21). A follow-up trial (NCT00058032) is currently ongoing to investigate the late
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benefits (7–14 years after an index screening event) of the screening tests (CA125 and transvaginal
ultrasound) in postmenopausal women because of the stage shift of the cancer.
The International Federation of Obstetricians and Gynecologists (FIGO) differentiates
ovarian cancer based on surgical-pathological findings into four stages (22). Stage Ⅰ represents
confined tumor in the ovaries. Stage Ⅱ represents when tumor involves one/both ovaries with pelvic
extension or primary peritoneal cancer. Stage Ⅲ represents when tumor spreads to the peritoneum
outside the pelvis and/or metastasis to the retroperitoneal lymph nodes. Stage Ⅳ represents when
there is distant metastasis. Pre-operative imaging (at the primary disease site) is also used to identify
unresectable or difficult to resect disease, which employs CT, positron emission tomography
(PET)/CT and MRI (23). PET/CT has a major role in N and M staging, with a limited role in T
staging (23).

1.2.2

Treatment of ovarian cancer
The treatment of newly diagnosed ovarian cancer patients depends on the pathological

stage determined at diagnosis (24). The available options for treatment include chemotherapy,
radiation therapy, and surgery. The standard course of treatment is to perform surgical tumor
debulking, followed by chemotherapy (18). Neoadjuvant chemotherapy can also be used, although
its benefits are controversial (25). The chemotherapeutic agents are administered intraperitoneally
(i.p.), intravenously (i.v.), or both (mainly when the disease is already spread to the peritoneal
cavity) (25). One of the most frequently prescribed chemotherapeutics is a platinum agent
(carboplatin or cisplatin) as a monotherapy or in combination with a taxane (e.g., paclitaxel).
Platinum drugs act by forming DNA crosslinks with biomolecules such as proteins and lipids that
disrupt the cellular function of DNA, leading to the apoptosis of cancer cells (26). The majority of
ovarian cancer patients (70 – 80%) treated with a platinum-based therapy as a first-line
chemotherapy show response with an improved overall survival rate at both the localized and
metastatic stages (27). However, some patients are initially platinum-resistant, and most platinum-
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sensitive patients will eventually acquire platinum-resistance (26). Multiple mechanisms have been
proposed for the development of platinum resistance. These mechanisms are found to involve
transporters (i.e., interfere with the transport of platinum drugs into the cancer cell), on-target
(repair mechanisms), post-target, and off-target (signaling pathways leading to interfering with the
apoptosis caused by platinum drugs) (26). Alternative chemotherapeutics include the use of
doxorubicin (e.g., pegylated liposomal formulation) and antiangiogenic agents (e.g., bevacizumab)
(25). However, despite the initial response after chemotherapy, most patients develop a recurrence
of the disease (28). In the past six years, three poly-ADP-ribose polymerase (PARP) inhibitors
(olaparib, niraparib, and rucaparib) have gained approval from the FDA (29). These agents act by
trapping the PARP enzymes at the damaged DNA leading to an increase impairment of already
deficient DNA repair mechanisms (due to gene mutations in BRCA and homologous recombination
deficiency (HRD)) which are present in nearly 50% of ovarian cancer patients (15). Currently,
PARP inhibitors are only approved for patients with advanced stages, and their efficacy as a firstline therapy is still under evaluation (29). Unfortunately, multiple acquired drug resistance
mechanisms have already been associated with the use of PARP inhibitors, including ABCB1
fusions and BRCA mutation reversions (15). Therefore, alternative strategies to improve the
clinical outcomes of ovarian cancer patients are needed.

1.2.3

Radiotherapy as a treatment option for ovarian cancer
The use of radiotherapy in patients as a treatment strategy was frequently used three

decades ago in adjuvant and consolidation settings (18, 30). However, over time, it has been
replaced with more effective chemotherapy-based strategies (platinums and taxanes) due to the
consistently high toxicity profiles and contradictory antitumor efficacy results reported in clinical
trials (31). Whole abdomen irradiation (WAI) via conventional external beam was the standard
type of radiotherapy for ovarian cancer. Its acute (e.g., gastrointestinal and hematological) and
long-term (e.g., liver damage and pneumonitis) toxicities caused treatment interruptions.
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Performing WAI using a recent technique, IMRT, may provide an effective alternative radiotherapy
strategy due to its benefits in dose homogeneity and sparing organs at risk (31). A recent study
evaluating WAI via IMRT in advanced ovarian cancer patients in the consolidation setting
(following chemotherapy) showed no grade 4 toxicities and no treatment interruptions (32). While
these results indicate an enhancement in the safety profiles of WAI by IMRT, the efficacy in such
patients is yet to be determined.

1.3 Imaging and treatment of cancer using targeted radiopharmaceuticals
1.3.1

Imaging
Imaging modalities are valuable in cancer for the early detection, development of

appropriate treatment strategies, and monitoring the response of these treatments. The commonly
used modalities are based on ultrasound, CT, MRI, PET, and single photon emission computed
tomography (SPECT) (33, 34). PET (using positron emitting radionuclides) and SPECT (using
gamma emitting radionuclides) offer advantages over the other modalities because of their high
sensitivity and accuracy. A targeted radiopharmaceutical consists of a tumor targeting vehicle and
a radionuclide. After the injection of a targeted radiopharmaceutical, PET and SPECT provide
information about the distribution of the tracer, which reflects the tumor locations. Therefore,
effective PET or SPECT imaging is limited by the ability of the radiotracer to distinguish between
the malignant and non-malignant cells. While examples of radionuclides for PET imaging include
64

Cu,

68

Ga, and

18

F, radionuclides for SPECT imaging include

123

I,

99m

TC, and

111

In (35). An

example of a targeted radiopharmaceutical that was approved recently for PET imaging is

68

Ga-

DOTA-TOC (36). It binds to somatostatin receptor, which is overexpressed in some
neuroendocrine tumors (36). Therefore, its approval is for PET imaging of somatostatin receptor
positive gastroenteropancreatic neuroendocrine tumors. Emerging targeted radiotracers are based
on exploiting the overexpression of biomarkers found on cancer cells. For instance, targeting the
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overexpression of the αvβ3-integrin receptor, gastrin-releasing peptide receptor (GRPR), folate
receptor, and prostate-specific membrane antigen (PSMA) has shown promise for cancer diagnosis
(37-39).

1.3.2

Therapy
It is estimated that nearly 50% of cancer patients receive radiotherapy as a monotherapy or

in combination with other strategies (e.g., chemotherapy and surgery) (34). The ionizing radiation
effect includes damaging the tissue structure, ionization of cellular water, generation of free
radicals, and irreversible breaks of mitochondrial and nuclear DNA (34). EBRT is the most
common type of radiotherapy and involves the delivery of radiation into tumor tissues via an
external source using a linear accelerator (40). The other commonly used radiotherapy type is
brachytherapy, which involves surgically installing a radioactive source (e.g., radioactive wires and
seeds) internally in close proximity to tumor tissues. Recent advances in radiotherapy have led to
the introduction of new technologies that include intensity-modulated radiotherapy and imageguided radiotherapy (40). Despite these ongoing efforts, the inability to accurately target the
metastatic disease and the resulting toxicity to healthy tissues (especially the organs at risk) remain
significant challenges. The degree of toxicity depends mainly on the site of radiotherapy (40). For
example, radiotherapy at the pelvis region for the treatment of reproductive cancers has been shown
to cause male infertility and pre-term birth in females (40). Another example is radiotherapy for
the treatment of brain tumors directed at the central nervous system which showed cognitive and
neurosensory impairments (40).
The development of targeted radiotherapeutics for cancer therapy has been an active area
of research (41). Similar to a targeted radiotracer, targeted radiotherapeutics consist of a
radionuclide and a targeting vector (e.g., peptide, or antibody) that specifically binds to cells or
extracellular targets in the tumor microenvironment. As with any radiotherapeutic approach, the
objective for the development of targeted radiotherapeutics is to deliver a high radiation dose to the
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tumor while limiting radiotoxicities to healthy cells, especially for tumors that are difficult to
surgically excise or irradiate by conventional radiation such as metastatic tumors. Numerous
clinical trials are currently under evaluation using targeted radiotherapeutics that bind to tumor
cells (41-44). These efforts have led to the approval of two radio-immunotherapeutics, Bexxar®
(131I) and Zevalin® (90Y) based on a monoclonal antibody that binds to the CD20 antigen, which is
explicitly expressed by B cells (45). Nearly 85% of lymphomas are derived from B-cells (45).
Although these two drugs were approved for the treatment of non-Hodgkin's lymphoma, their use
in the clinic remains limited due to problems related to therapeutic (e.g., hematological toxicities)
and commercial reasons (46). In 2018, the FDA approved the first peptide-based radiotherapeutic
(177Lu-dotatate) to treat patients with somatostatin-positive gastroenteropancreatic neuroendocrine
tumors (47). Later, in this chapter, we will discuss an emerging strategy (a pretargeted approach)
currently under preclinical evaluation for improving the radiotherapy outcomes by minimizing nontarget toxicities.

1.4 Nanomedicine-based drug delivery for cancer
The development of drug delivery systems at the nanometric size range (commonly, 10 –
100 nm) for therapy has shown significant progress over the last few decades (48). These
nanometric drug delivery systems offer attractive properties such as the capacity to incorporate
multiple agents (e.g., chemotherapeutics, radionuclides, targeting agents, sensing agents),
modifying the physiochemical properties and pharmacokinetics of drugs (e.g., improving
solubility, increasing the circulation half-life), and enhancing the preferential drug delivery into
tumor tissues (48). Examples of drug delivery systems include liposomes, polymeric micelles,
inorganic nanoparticles, solid lipid nanoparticles, dendrimers, protein nanoparticles, and polymerdrug conjugates (49, 50). The first nanomedicine approved by the FDA for cancer therapy was a
liposomal formulation incorporating doxorubicin (Doxil ®) in 1995 (51). To this date, various
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nanomedicines have been approved for cancer treatment, with most of them being liposomal-based
formulations (52).

1.4.1

Drawbacks of conventional chemotherapeutics
Conventional small chemotherapeutics suffer from several drawbacks such as low

solubility, short-plasma half-life, and uncontrolled tissue distribution (48). These drawbacks can
lead to poor safety and efficacy profiles. For example, paclitaxel is a commonly prescribed
chemotherapeutic drug. It has low water solubility that requires the use of an organic solvent
(cremophor), which causes hypersensitivity reactions upon administration (53). Incorporation of
paclitaxel into albumin nanoparticles (Abraxane®) improves its solubility and prevents the use of
the toxic solvent. Also, the use of Abraxane® allows the clinical dose of paclitaxel to be increased
by nearly 50% (175 mg to 260 mg) compared to the smaller molecular weight formulation (Taxol ®)
(53). However, Abraxane® does not show significant improvements in terms of antitumor efficacy
(53). Currently, many clinical and preclinical trials are on-going to evaluate nanomedicines that
further exploit the abnormality of tumors (e.g., receptor overexpression, extracellular acidity) in
order to improve antitumor efficacy.

1.4.2

Biological barriers to drug delivery systems
The design of an effective drug delivery system is faced with many biological challenges

that may slow the clinical translation of these systems. These challenges can be generally
categorized into tumor-related and non-tumor related (54). Examples of tumor-related barriers
include tumor heterogeneity, hypoxia, and high interstitial fluid pressure. Non-tumor related
barriers include easy recognition by immune cells leading to premature sequestration by the
mononuclear phagocytic system (MPS).
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1.4.2.1

Uptake by the mononuclear phagocytic system (MPS)
The first step of clearance by the MPS is the adsorption of opsonins to the nanoparticles.

In general, opsonins are blood plasma proteins that aid in phagocytic recognition (55). The most
known opsonins are immunoglobulins and the complement proteins C3, C4, and C5 (55). The
second step involves the engulfment of the opsonin-nanoparticle by the phagocytes. Both bloodderived and tissue-resident (e.g., splenic macrophages and Kupffer cells in the liver) macrophages
are involved in the rapid removal of nanoparticles (55, 56). Most nanoparticles taken up by the
MPS end up retained in the liver and spleen. This process does not only lead to reducing the amount
of delivered incorporated drugs (or imaging agents) into the tumor but also causes toxicity to these
organs by the formation of lesions, microgranulation of hepatocytes and chronic inflammatory
responses (55).
Several strategies have been developed to reduce the MPS uptake, such as modifications
made to the physiochemical properties of nanomedicines and MPS blockage by another nanosized
formulation (55, 57, 58). Surface modification of nanoparticles with a hydrophilic (neutral or
zwitterionic) polymer has shown to reduce the MPS uptake via the reduction of opsonin adsorption
(steric hindrance). PEG polymer is the most investigated polymer to date for this purpose. In fact,
Doxil® is a PEGylated doxorubicin-liposomal formulation. Early studies using unmodified
doxorubicin-loaded liposomes (no PEG polymer) showed lower circulation times and higher MPS
uptakes than the PEGylated liposomes (51). Despite its popularity, surface PEGylation has several
drawbacks, including reducing tumor cellular internalization of nanoparticles and eliciting an
immune response (e.g., production of anti-PEG antibodies after repeated administration) (59, 60).
Additional other strategies for reducing the MPS uptake have already been explored.
Examples of these strategies include optimizing the size (larger nanoparticles are more rapidly
taken up) and the charge (positive nanoparticles are taken up faster than negative and neutral
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nanoparticles) (55, 61). Recent efforts to accelerate the release of already sequestered
nanomedicines from the MPS organs will be discussed later in this chapter.

1.4.3

Enhanced permeability and retention (EPR) effect in drug delivery
One of the significant differences between tumor and healthy tissues is the abnormality of

tumor vasculature. When a tumor reaches a specific size (1- 2 mm 3), the normal blood vessels
become insufficient to supply oxygen and nutrients (62). Therefore, new blood vessels are formed
in an irregular manner resulting in abnormal features, including the presence of fenestrations
between the endothelial cells. These fenestrations can range from 0.3 to 4.7 μm (depending on the
type, environment, and localization of the tumor). These leaky blood vessels allow the transport of
nanomedicines into tumor tissues (63). Also, due to the lack of normal lymphatic drainage in the
tumor tissues, nanomedicines can reside (inability to diffuse back into circulation) for a longer time
in these tissues when compared to than smaller molecules (63).
The enhanced permeability and retention (EPR) effect term was coined to describe the
inherent selective targeting of macromolecular agents to tumors due to the presence of vascular
fenestrations and the lack of lymphatic drainage described above (64). The delivery of
nanomedicines via the EPR effect is also referred to as passive delivery because the transport
mechanism does not require energy. The EPR effect was first reported in 1986 by the Maeda group
(64), and to date, it is considered by many investigators as the primary mechanism for the delivery
of nanomedicines (65-67).
However, the clinical practicality of the EPR effect is still controversial due to the relatively
limited clinical success of the nanomedicine field (68). A published report in 2016 showed the
median percentage of the injected dose (%ID) of nanomedicines into tumor tissues (regardless of
cancer type) in preclinical trials was nearly 0.7%, with no change in this percentage between 2005
and 2015 (69). Furthermore, a recent report showed that tumor blood vessels (ovarian,
glioblastoma, and breast) from cancer patients were continuous, with fenestrations rarely being
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observed (70). Additionally, the authors of the same study injected gold nanoparticles (15, 50, and
100 nm) in tumor-bearing mice to show that the primary entry mechanism of nanoparticles was
transcytosis (active transport requires energy) instead of passive delivery. These results need to be
considered in order to improve the drug delivery efficiency of nanomedicines.

1.4.4

Beyond the EPR effect (active targeting and pretargeted therapy as examples)
The modifications of nanomedicine systems with the addition of a targeting agent (e.g.,

antibody, aptamer, peptide, small molecule) has been widely investigated (71). These targeting
agents are mainly selected based on the expression of specific biomarkers within the tumor
microenvironment and/or tumor endothelial cells. Numerous nanocarriers with incorporated
targeting ligands have demonstrated enhanced tumor accumulation when compared to analogous
non-targeted nanocarriers (71). Despite these efforts, the toxicity of the incorporated agents (e.g.,
radionuclides and chemotherapeutics) to the non-target tissues (e.g., liver and spleen) remains a
significant challenge. To address this challenge, a pretargeted approach has been utilized to
selectively deliver radio- and chemotherapeutics to tumor cells (72, 73). In our work, we have
explored both active targeting using the GRPR and pretargeted constructs. In the next sections, we
will summarize the field specifically for the utilization of the GRPR and pretargeted approach for
nanomedicine constructs.
1.4.4.1

Targeting GRPR
GRPR is a G protein-coupled receptor expressed in the gastrointestinal tract and central

nervous system (74). Stimulation of GRPR causes a variety of biological responses, including
contractions of smooth muscles in the gastrointestinal/urogenital tract, stimulation, and secretion
of hormones (e.g., insulin), and exhibiting potent CNS effects (e.g., regulation of circadian rhythm)
(74). Relative to normal tissues, GRPR is overexpressed in several tumors, including prostate,
pancreatic, small-cell lung cancer, and colorectal cancers (38). The elevated expression of GRPR
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promotes the proliferation and invasion of tumor cells by activating epidermal growth factor
receptor pathways, intermediate early genes c-fos 9, and transcription factors, Elk-1 (75).
Due to this overexpression, the GRPR has been widely investigated as a means to improve
cancer imaging and therapy (38, 76). Bombesin (BBN) is a 14-amino-acid amphibian peptide that
exhibits a high affinity and specificity towards GRPR. Studies have shown that truncated BBN
peptides containing BBN(7-14)NH2, Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2, retain nanomolar
binding affinities (38, 77). Currently, several GRPR-targeted constructs are undergoing clinical
evaluations (38).
The majority of work regarding GRPR-targeted constructs has focused on developing small
molecular BBN-based peptides for radioimaging and radiotherapy (38). Recent studies have
investigated the incorporation of GRPR-targeted peptides as targeting ligands to improve the tumor
accumulation of nanomedicines, mainly nanoparticles, and showed promising results (38, 78-81).
For example, compared to unmodified nanoparticles, 64Cu-sulfide nanoparticles affixed with BBN
peptide moieties had nearly three times higher tumor accumulation in an orthotopic prostate cancer
model after 1 and 6 hours (h) of administration (82). Interestingly, the uptakes in the liver and
spleen were lower for the BBN-modified versus unmodified

64

Cu-sulfide nanoparticles. These

results indicate the potential of using GRPR-targeted peptides as targeting ligands for improving
the performance of nanomedicines.
1.4.4.2

Pretargeted approach: Bioorthogonal reactions via inverse electron-demand Diels–
Alder reaction (IEDDA)
The term bioorthogonal reaction describes a chemical reaction between two functional

groups that can occur inside the cell/body. There are certain requirements for the bioorthogonal
reactions to be utilized in the development of radiopharmaceuticals. These requirements include
reaction selectivity between the two functional groups, inertness and non-toxic functional groups,
and fast reaction kinetics at submicromolar concentrations (83). Early work in the field of
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bioorthogonal chemistry was based on strain-promoted alkyne–azide cycloaddition (SPAAC) (84).
This reaction is faster than previously tested click chemistry reactions (e.g., Staudinger ligation),
and it does not require a catalyst (Cu-catalyzed azide–alkyne cycloaddition). SPAAC can proceed
in vitro and in vivo. However, its second-order rate constants (K2) are generally less than 1 M-1 S-1
(K2 = 0.0076 – 0.96 M-1 S-1), which is not suitable for in vivo applications at the radiotracer level
(73). In contrast, the inverse electron-demand Diels–Alder reaction (IEDDA) is very fast with K 2
values ranging between 100 and 1000,000 M-1 S-1 (depending on the system type), which makes
this reaction ideal for tracer level bioorthogonal chemistry (85).
Joseph Fox’s group pioneered the development of constructs for IEDDA, and the first
report by the group was published in 2008 (86). Fox’s group demonstrated that the reaction between
trans-cyclootenes (TCOs) and tetrazines (TZs) is fast (K2 = 1000 M-1 S-1) and selective, and can be
performed under physiological conditions (87). The only byproduct of the reaction is N 2. The
proposed TCO/TZ mechanism is shown in Figure 1.1. Interestingly, the cis-analog (CCO) of TCO
is at least seven-folds lower in reactivity than TCO. Therefore, the CCO isomer must be converted
into TCO to obtain a fast reaction with TZ, mainly by a photochemical isomerization. Upon
irradiating the CCO moiety, two TCO isomers (major and minor) are produced (Figure 1.2)Error!
Reference source not found..
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Figure 1.1 The proposed reaction mechanism between the tetrazine (TZ) and dienophile (e.g.,
TCO).
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Figure 1.2 Photochemical isomerization of Cis-cyclooct-4-enol to provide the two possible TCO
diastereomers.
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The attractive properties of IEDDA using TCO/TZ chemistry allows for broad biological
and biomedical applications, including in vivo drug activation and in vivo pretargeted radioimaging
and radiotherapy (73). In particular, the latter has gained interest over the last decade because of
the drawbacks related to radioimmunotherapy. The long-circulation times of radiolabeled
monoclonal antibodies are known to increase radiotoxicities to non-targeted tissues, particularly
hematological toxicities (73). To limit these toxicities, a two-step strategy is employed with in vivo
IEDDA. The initial step involves injecting a non-radiolabeled antibody modified with TCO tags.
After a certain time (e.g., 3 days), the antibody is expected to be cleared from blood circulation and
accumulated in the tumor tissues at a high tumor to non-target ratio. The second step involves
injecting a radiolabeled TZ probe that reacts with the TCO-tagged antibody accumulated in the
tumor tissues (Figure 1.3). The TZ probe has a short plasma half-life (several minutes (min)), and
therefore unreacted radiolabeled probe will be cleared (mainly via kidneys) from the body rapidly
(88). The utilization of TCO-masking agents (e.g., TZ-modified dextran polymer) to further
enhance the tumor to normal tissue (T/NT) ratio has been also explored (89, 90). This strategy is
based on the injection of compounds that can deactivate the residual TCO in the blood without a
significant effect on TCO in the tumor tissues.
The validity of the IEDDA pretargeted approach has been demonstrated in several tumors,
such as prostate, pancreatic, colorectal, and ovarian cancers (91). For example, the TCO-modified
CC49 monoclonal antibody, which targets the pan-adenoma TAG-72 antigen, was injected into
mice implanted with a human colon cancer cell line (LS174T) (92). After three days, 111In-labelled
TZ-PEG11-DOTA was injected and followed up by performing SPECT/CT imaging at two time
points, 1.5 h and 3 days later. After the first time point (1.5 hr), there was already a high tumor
radiation signal with low background except for the bladder (due to rapid renal clearance) (Figure
1.4). After the second time point (3 days), the radiation signal was still observed in the tumor with
no background signal from the non-target tissues.
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Figure 1.3 Illustration for steps of in vivo IEDDA chemistry using antibody.
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Figure 1.4 Small animal SPECT/CT imaging colon carcinoma animal model preinjected with
TCO-modified CC49 monoclonal antibody followed 72 h later by 111In-labeled TZ probe. The
imaging was performed 1.5 h (A) and 3 days after injection of the radiolabeled probe. This figure
was adapted from (92).
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1.4.4.2.1

The rationale for the development of bioorthogonal nanomedicines

Unlike antibodies, drug delivery systems can be multifunctional. They can be designed to
carry several agents, including a targeting ligand, imaging agent and therapeutic agent (e.g., small
molecular drugs or radioisotopes). Furthermore, unlike antibodies, drug delivery systems can be
manipulated (e.g., size, charge, architecture, and functionalities) to achieve the optimal in vivo
performance. In addition, drug delivery systems can provide a higher loading capacity than
antibodies. The average number of TCO units per antibody is generally ≤ 7 units (93, 94). On the
contrary, the TCO capacity of drug delivery systems can be several folds higher (depending on the
system). There is limited research regarding the use of bioorthogonal IEDDA drug delivery
systems, but early data indicates great promise in this field (91). For instance, a recent paper
reported the synthesis and biodistribution studies of polymeric crosslinked nanostars (13 nm)
modified with an average of 20 TCO units (90). The nanostars were injected into colorectal tumorbearing mice. After 3 days, the mice were injected with the radiolabeled TZ probe ( 18F-TZ-PEG11NODA) and the animals were sacrificed 4 h later. The results showed in vivo reactivity at the tumor
tissues with high tumor to muscle and tumor to spleen ratios (> 1) and good tumor to liver ratio (=
1). However, the tumor to blood ratio was less than 1. These results indicate the feasibility of the
in vivo IEDDA, but further improvements are needed.
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1.4.5

Polymer-drug conjugates as drug delivery systems
Polymer-drug conjugates, a type of drug delivery system, are macromolecular constructs

containing bioactives (e.g., small molecules and proteins) bound via covalent bonds. The concept
of the polymer-drug conjugate was first proposed in 1955 by Von Horst Jatzkewitz (95). Jatzkewitz
reported that by conjugating a small molecular agent (a psychedelic alkaloid called mescaline) to a
copolymer of N-vinylpyrrolidone and acrylic acid resulted in increasing the mescaline residence
time in mice. However, most current work using polymer-drug conjugates was based on a report
by Helmut Ringsdorf in 1975 (96). He proposed using a biocompatible and biodegradable polymer
containing three elements: soluble monomeric units or polymeric blocks, a drug bound via a linker,
and a targeting agent.
In the 1970s, Jindřich Kopeček pioneered the synthesis of N-(2-Hydroxypropyl)
methacrylamide (HPMA) copolymer, which later in 1994 became the first polymer to enter into
clinical trials as a polymer conjugating a chemotherapeutic drug (doxorubicin) (97). In 1990, PEG
polymer-adenosine deaminase conjugate was the first approved polymer-drug conjugate, classified
as a polymer-protein conjugate, used in the treatment of severe combined immunodeficiency
caused by an inherited deficiency of the adenosine deaminase enzyme (98). There are various
polymer conjugates (mainly based on PEG polymer conjugating proteins) approved by the FDA
and currently in the market (Table 1.1). The majority of polymer conjugates under clinical
evaluations are based on two polymers, PEG polymers and HPMA copolymers.
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Table 1.1 Examples of marketed polymer-drug conjugates (99)
Tradename
Esperoct
Palynziq

Type of
polymer
carrier
PEG
PEG

Drug

Indication

Year of
approval

Movantik

PEG

Factor VIII
Phenylalanine
ammonia lyase
Naloxone

Hemophilia A
Phenylketonuria

2019
2018

Opioid-induced
constipation
Chronic gout
Acute
lymphoblastic
leukemia
Renal and liver
cancer

2014

Krystexxa
Oncaspar

PEG
PEG

Uricase
L- asparaginase

Smancs

Poly(styreneco-maleic acid)

Neocarzinostatin

2010
1994
1993
(Japan)

24

1.4.6

HPMA copolymer as a polymer-drug conjugate
The HPMA copolymer is a water-soluble polymer that has been demonstrated to be

effective in carrying biological and non-biological agents, including proteins, peptides, low
molecular weight drugs, imaging agents, and radioisotopes (97, 100). It possesses attractive
properties, including non-immunogenicity, biocompatibility, and ease of multifunctionality. An
example of a multifunctional HPMA copolymer is shown in Figure 1.5. In this example, an HPMA
copolymer incorporates a chelator (used either for radioimaging and/or radiotherapy), a fluorescent
imaging agent, a monomer with free amine (used for conjugating carboxylic acid derivatives of
agents such as drugs or ligands), and thiol groups on both copolymer ends for post modifications
(e.g., maleimide-containing peptides)
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Figure 1.5 Example for the synthesis of a multifunctional HPMA copolymer intermediate for
further post-modification.
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1.4.6.1

Synthesis of HPMA-drug conjugates
The Kopecek group in the 1960s conducted a series of studies to develop a water-soluble

polymeric carrier that can improve the physiochemical properties of drugs (97). These efforts
resulted in the development of the HPMA monomer used for the synthesis of HPMA polymers, as
first reported in 1973 (97). HPMA-drug conjugates are synthesized via either copolymerization or
polymer-analogous reaction routes (97, 101). Copolymerization, which is a polymerization that
involves more than one monomer, is a one-step synthetic route. A polymerizable derivative of the
therapeutic agent (or targeting ligand/imaging agent) is copolymerized with the HPMA monomer
(100). The final concentrations of the agent on the copolymer is controlled by adjusting the
comonomer to the HPMA monomer feed ratio. The copolymerization reaction can be performed
by employing several polymerization reactions, including reversible addition-fragmentation chain
transfer (RAFT), atom transfer radical polymerization (ATRP), or polymerization free radicalmediated polymerization (SFRP) (100).
RAFT polymerization is commonly employed because it offers the advantages of
producing polymers with a predetermined controlled molecular weight with narrow dispersity as
well as the ease of introducing reactive terminal groups (for post-modification) at the two ends of
the HPMA copolymer (102). With this polymerization, a chain transfer agent (CTA) and a
polymerization initiator (e.g., 2,2′-Azobis(2-methylpropionitrile) (AIBN)) are dissolved in a
solution containing the monomers followed by purging with N 2 and finally heating the mixture (40
– 80 °C) (102). The feed ratio of the monomers, CTA: AIBN, determines the final molecular weight
of the copolymer. The type of CTA determines the terminal groups of the copolymer. For example,
RAFT polymerization using a CTA agent with a disulfide group results in yielding a copolymer
with a terminal thiol (protected) functionality as depicted in Figure 1.5.
After the synthesis, the HPMA copolymer is efficiently purified from the unreacted
comonomers and characterized using size exclusion chromatography (SEC). While
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copolymerization itself is only one step, it requires prior modifications made to the comonomers
(e.g., therapeutic agent) that can become expensive and time-consuming. Also, in some cases, it is
challenging to synthesize polymerizable therapeutic agents (e.g., proteins) that are stable under the
polymerization conditions (e.g., high temperatures) (103, 104). Alternatively, the polymeranalogous reaction provides an effective way of synthesizing HPMA-drug conjugates (100). This
method requires the synthesis of an intermediate HPMA copolymer containing a comonomer with
the appropriate chemical handle. For example, a copolymer contains an amine group that can react
with a carboxylic acid-containing drug. Another advantage of the polymer-analogous reaction is
the synthesis of multiple HPMA-drug conjugates (with variations in the density of conjugated
agent) from only one intermediate copolymer simply by reacting with varying concentrations of a
drug (103).
1.4.6.2

Physiochemical factors affecting the in vitro and in vivo performance of HPMA
copolymers
Several factors affect the in vitro and in vivo performance of HPMA copolymers, including

the architecture (e.g., linear versus dendrimer), type and number of conjugated hydrophobic agents,
and presence of conjugated ligands. However, the size and charge of the copolymer are the most
addressed factors.
1.4.6.2.1

Charge: Effect on the in vitro and in vivo behavior

The HPMA homopolymer, which only consists of the HPMA monomer, is neutral since
the HPMA monomer does not have a charged group. The inclusion of charged peptides, proteins,
small molecules, and/or charged functional groups (e.g., amines and carboxylic acid) would impact
the overall charge of the resulting copolymer. It is known that the overall charge of the polymeric
construct can substantially impact cellular uptake. For example, the Kopecek group reported the
charge effect on the cellular uptakes of HPMA copolymers (105). The cellular uptakes of five
HPMA copolymers, having similar molecular weights (nearly 60 kDa) but varying in charge type
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and content (weak negative, strong negative, weak positive, strong positive, and neutral charge)
were investigated in a prostate cancer cell line (C4-2 cells). Compared to the neutral copolymer,
the weak and strong negative copolymers had nearly 30% and 45% lower cellular uptakes (due to
repulsive interactions with the negatively charged cell membranes) after 12 h of incubation. In
contrast, the weak and strong positive copolymers had 17- and 28-fold increased cellular uptakes
due to the electrostatic interactions with the negatively charged membranes.
The presence of positive charges on HPMA copolymers is also associated with enhancing
the in vitro cellular uptake when incorporated with receptor-targeted agents. The Huang group
reported the cellular uptake of folic acid (a small molecular ligand that binds to folate receptors)
incorporated into neutral (contains no N-(3-aminopropyl)methacrylamide (APMA) monomer) and
positive (contains ~22% mol. of APMA monomer) HPMA copolymers and examined these agents
in a folate receptor-overexpressing cell line (106). The cellular uptake due to folic-acid receptor
binding was more than two-fold higher for the positive than neutral copolymers. In competitive
binding studies using a folic acid receptor monoclonal antibody (Mov-18) as a competitor, the
cellular uptakes of positive and neutral copolymers were reduced by nearly 60 and 15%,
respectively. The authors concluded that the receptor-mediated uptake was amplified in the positive
copolymer because of the proximity of the positive charge to the cell surface increased the
electrostatic interactions with the negatively charged cell membrane (106).
Furthermore, the charge of the polymer plays a significant effect on the in vivo behavior of
the drug conjugate. A charged copolymer (positive or negative) is generally more efficiently
cleared from circulation than its uncharged counterpart (107). In a study of three HPMA
copolymers having similar molecular weights (nearly 30 kDa) but varying in charge, the blood
circulation times were investigated after i.v. injection of the conjugates in tumor-bearing rats.
Compared to the neutral copolymer, the positive and negative copolymers had lower blood level
values by 50% and 15%, respectively, over the monitoring period (168 h) (107). Similarly, the
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content of folic acid (negatively charged ligand) on the HPMA copolymer was associated with
lower blood concentrations. The higher the folic acid content, the faster the copolymer is cleared
from the circulation (107).
The retention of charged copolymers in the liver and spleen due to the MPS uptake has
been demonstrated to be size and chemical group dependent (108-111). For instance, carboxylic
acid- and hydrazide-modified copolymers generally have lower retention in MPS-associated tissues
than neutral copolymers (due mainly to the efficient body clearance) (108, 109). In contrast, the
quaternary amine-modified copolymers are taken up by the MPS more efficiently. A study reported
that nearly 70% of the i.v. injected dose (in rats) of the HPMA copolymer (62 kDa) containing
16.3% mol. of a quaternary comonomer (trimethylammonioethyl methacrylate) accumulated in the
liver after only 30 mins (110). Another study from the same group using the same copolymer and
animal model reported more than 50% of the dose found in the liver after 5 min compared to only
4% for a neutral copolymer with a similar molecular weight (111).
1.4.6.2.2

Size: Effect on the in vitro and in vivo behavior

An inverse relationship between the cellular uptake and the molecular weights of HPMA
copolymers is observed (105). A report explored the cellular uptakes of ten narrowly polydisperse
HPMA copolymers with molecular sizes of the smallest and largest copolymers between 10 and
200 kDa, respectively. The separation of these ten fractions was performed using SEC, which elutes
the larger copolymer first followed by smaller copolymers. The fractions containing the small
copolymeric sizes (e.g., fraction 8) had higher uptakes than the fractions containing the larger
copolymeric sizes (e.g., fraction 4). However, the charge effect generally has more impact on the
cellular uptake than the molecular size.
It is generally accepted that the renal clearance threshold for the non-biodegradable
polymers is < 50 kDa (97). A polymeric construct with a higher molecular weight has longer
circulation times and a lower renal clearance rate relative to a polymeric construct with less than
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50 kDa molecular weight. The longer circulation time of a large copolymer leads to higher liver
and spleen retentions (100). Since the HPMA copolymer is non-biodegradable, choosing a lower
molecular weight to overcome the renal threshold limit is crucial. However, larger HPMA
constructs circulate for longer times leading to enhanced tumor accumulation (100). A study
reported the effect of molecular size of the polymer on the biodistribution in tumor-bearing rats by
testing three HPMA copolymers of various sizes (23, 31, and 65 kDa) (109). After 168 h, there was
observed a direct relationship between the molecular size and the concentration of the copolymers
in the blood (and most of the organs including liver, spleen, lungs, heart, and kidneys). The tumor
accumulation for the largest copolymer (65 kDa) was nearly three and six folds higher than the 31
and 23 kDa-sized copolymers, respectively. Therefore, HPMA copolymers with higher molecular
weights than the renal threshold limit can improve the efficacy of the conjugated drug (by
enhancing the tumor accumulation) but an increase in side effects (due to the retention in off-target
tissues) is a consequence.
1.4.6.3

Overcoming the non-biodegradability and MPS retention of HPMA copolymers by the
incorporation of a cathepsin S (Cat S) cleavable linker (CL)
Cysteine cathepsins are lysosomal proteases with diverse functions, but are mainly

involved in protein degradation in the endolysosomes (112). The tissue distribution of these
enzymes varies depending on the type of cysteine cathepsins. These enzymes can be found
ubiquitously in most tissues (e.g., cathepsin B) or within specific tissues (e.g., cathepsin S (Cat S)).
For example, cathepsin B is expressed at a higher level in the tissues of the liver, spleen, kidneys,
and thyroid. On the other hand, Cat S is mainly expressed abundantly in immune cells such as
macrophages and antigen-presenting cells (e.g., B cells and dendritic cells) (112).
Aside from their physiological roles, many of these cysteine cathepsins play roles in cancer
development (112). For instance, Cat S is associated with driving angiogenesis in a hypoxic
environment and promoting a pro-inflammatory tumor microenvironment by transcriptionally
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regulating cytokine CCL2 via cleavage of CD74 (113). The expression of cysteine cathepsins is
heterogenous across cancer types (112, 114, 115). For instance, cathepsin B is upregulated in breast,
prostate, and ovarian cancers but downregulated in kidney cancer. Cat S is upregulated in prostate
and lung cancers but downregulated in kidney cancer (112).
Efforts have been made to design large HPMA copolymers ( > renal threshold limit) that
have extended circulation times before being metabolized into smaller fragments (by the
cathepsins) leading to their excretion by the kidneys (116-118). The Kopeček group published
several papers regarding the use of long-circulating HPMA copolymers cleaved by lysosomal
proteases (mainly, cathepsin B). For example, an extension for a doxorubicin-HPMA copolymer
(20 kDa) with the peptidic linker (glycine, phenylalanine, leucine, and glycine (GFLG)) was
reported (118). The resulting multi-block HPMA copolymer was fractionated into a series of
segments using size exclusion chromatography to afford copolymers of 93, 184, and 348 kDa.
These copolymers had higher antitumor efficacy when compared to the smaller studied copolymer
(20 kDa) in tumor-bearing mice. A follow-up report from the same group investigated the
biodistribution data of a smaller copolymer (48 kDa) and a multi-block copolymer (335 kDa) and
illustrated the same conclusion (119). However, the multi-block copolymer had more than twofolds higher liver and spleen retention compared to the smaller copolymer.
Inspired by this work, Dr. Garrison’s lab has started working on improving the imaging of
pancreatic cancer by developing a multi-block HPMA copolymer containing a Cat S enzyme
biodegradable linker (117, 120). Initially, the peptide sequence of PMGLP, a known Cat S
substrate, was synthesized with two incorporated maleimide groups at each terminus to afford a
Cat S susceptible linker (CL). A bis-thiol terminated HPMA telechelic copolymer (18 kDa)
containing 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), as a chelator, was
synthesized. Finally, a thiol-ene click reaction was performed between the linker and the copolymer
to obtain the multi-block HPMA copolymer (80 kDa). Compared to two copolymers having the
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same molecular size but lacking CL, the Cat S cleavable multi-HPMA copolymer was observed to
have lower retention values in the blood, liver, and spleen. After 72 h, the retention in these organs
was already about 50% lower compared to the non-cleavable copolymers. Interestingly, tumor
accumulation did not vary among the tested copolymers. These results indicate the benefits of
incorporating a linker that is susceptible to Cat S in enhancing the safety and efficacy of large
HPMA copolymers.
1.4.6.4

HPMA copolymers in clinical trials
To date, there is no approved drug based on HPMA copolymers. However, several

conjugates are under clinical evaluations (Table 1.2). The first HPMA copolymer that was tested
clinically was PK1 (doxorubicin-bound HPMA copolymer) reported in 1999 (97). PK1 had a
molecular weight (30 kDa) of less than the renal threshold to allow for renal clearance. In
preclinical trials, PK1 extended the circulation time of doxorubicin with better safety and efficacy
profiles than free doxorubicin (97). In clinical trials (in patients with different types of cancer), PK1
showed extended blood circulation with improved overall safety profiles. Nevertheless, its
antitumor efficacy was observed in only a subset of the population; 6 out of 56 patients had a partial
response. These results led to the discontinuation of its further clinical testing (100).
PK2 is the second drug-HPMA conjugate to enter the clinical trials (121). It is also
doxorubicin-based and has a molecular weight similar to PK1. However, PK2 is modified with a
targeting ligand (galactosamine) that binds to the asialoglycoprotein receptor expressed mainly on
hepatocytes. In liver cancer patients, the first phase clinical trial of PK2 showed nearly 17% of the
injected dose accumulated in the liver, and 3.3% accumulated in the tumor after 24 h of
administration. Interestingly, PK1 was used as a control and showed no liver targeting. The
maximum tolerated toxicity doses for PK1 and PK2 were 320 and 160 mg/m 2, respectively and
based on that, a dose of 120 mg/m2 was recommended for PK2 in the phase 2 clinical trial. The
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other clinical trials based on HPMA copolymer are in phase 1 and phase 2 stages, with no
formulations having progressed to phase 3 studies to date (Table 1.2).
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Table 1.2 HPMA-drug conjugates in clinical trials
Name

Drug

Cancer
type
Solid
tumors

Clinical
trial
Phase 2

PK1

Doxorubicin

PK2

Doxorubicin

Liver

Phase 1

PNU166945 Paclitaxel

Solid
tumors

Phase 1

AP5280

Platinum

Solid
tumors

Phase 1

AP5346

Platinum

Phase 1/2

P-THP

Pirarubicin

Solid
tumors
Prostate
(stage IV)

One case

Main results

Reference

Improved
(122)
safety
profiles but
minimal
response is
observed
Active
(121)
targeting to
the liver and
tumor,
compared to
PK1.
MTD is 160
mg/m2 (half
of PK1).
Water-soluble (123)
and therefore
no organic
solvent is
needed
Prolonged the
plasma
concentration
of the drug
MTD was
(124)
found to be
4500 mg/m2
3300 mg/m2
was
recommended
for the phase
2 trial.
Tolerable
(125)
side effects
No serious
(126)
toxicities
No relapse
within 20
months of
monitoring
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1.5 Decorporation in the case of the release of radiological materials
Radionuclides are commonly used for industrial, commercial, and military (nuclear
reactors and the production of nuclear weapons) purposes (127). Their uncontrolled release into the
environment (due to accidents, natural causes, or terrorist attacks) remains a significant public
health concern (127). For example, on March 11 of 2011, a catastrophic earthquake (with a
magnitude of 9.0) and tsunami occurred in Japan that damaged the Fukushima Daiichi nuclear
power plant (NPP). Due to the failure of the cooling systems of the nuclear reactor, explosions
occurred that led to a release of radioactive materials (~ 900 PBq) into the atmosphere and
subsequent deposition on the ground. This incident led to the immediate evacuation of people living
within a 20 km radius surrounding NPP (128). Numerous studies over the following years were
conducted to evaluate the potential health impact (e.g., water or crop contamination) of these
released radioactive substances (129-132).
The radioisotopes of actinides (e.g., plutonium (Pu) and americium (Am)) are among the
most highly used radionuclides (133). For example, 239Pu is the main isotope for the production of
nuclear weapons. It is produced from uranium-238 ( 238U). It undergoes alpha decay with a half-life
of 24,000 years. Another example is

238

Pu, mainly used as a heat source in radioisotope

thermoelectric generators (e.g., applications in spacecraft). It also undergoes alpha decay with a
half-life of 87.7 years. One last example is 241Am, which is produced from 241Pu. It undergoes alpha
decay with a half-life of 430 years. It is used in the manufacturing of smoke detectors and the
production of heavier americium isotopes.
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Depending on the type of actinide, the internal biological contamination of radioactive
substances can occur either via oral (ingestion), inhalation, or skin (open wound) routes (134). This
internal contamination can lead to serious health effects, including genetic changes, impairment of
organ function, carcinogenesis, fibrosis, and vascular pathology (135, 136). The radionuclides that
emit alpha particles cause more damaging effects than beta and gamma emitters. Unfortunately,
upon contamination, actinides deposit in various organs (e.g., kidneys, liver, and bone), leading to
further local effects at the deposited organ (134). The pharmacokinetics and biodistribution profiles
for actinides are different based on the radionuclide type. For example, the biodistribution profiles
of the i.v. injected 239Pu and 241Am in rats showed high retentions in the liver and skeletons but at
different percentages (135). The percentage of the injected dose of 239Pu in the liver and skeletons
was 11% and 60% after seven days. In contrast, the percentage of injected dose for

241

Am in the

liver and skeletons were 40% and 31%, respectively. Nevertheless, only 29% of the injected doses
for both radionuclides were either excreted or retained in other tissues.
Unfortunately, many actinides can be retained in the liver and skeleton for long term. 241Am
has been shown to have a slow excretion in nonhuman primates (baboon) with only 50% excreted
after two years of administration. The estimated percentage of the injected dose in the skeletons
and liver were 37% and 22.2%, respectively, three months post 241Am injection (137).

1.5.1

Treatment of contaminated individuals
Currently, the chelator diethylentriamene pentaacetate (DTPA) is the only FDA approved

agent (Ca-DTPA or Zn-DTPA formulations) for the treatment of contaminated individuals by the
actinides: Pu, Am, or curium (Cm). Due to its low bioavailability (< 3%), it is given as either an
injectable or inhalable (138). DTPA has a short plasma half-life (< 2 h), with the kidneys being the
main route for clearance (139, 140). DTPA is a chelator, that has high affinity to complex actinides
in physiological fluids. Unlike the free actinides, the DTPA-actinide complex does not remain
retained in the bones and liver. This actinide complexation by DTPA leads to increasing the
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clearance of internalized radioactive actinides. The dose of DTPA usually administrated is 1 g/day,
but due to its short half-life (< 2 h) more than one daily dose may be needed (139). The most
common side effect of DTPA is the loss of essential minerals (e.g., Ca, Zn, and Mg) which can lead
to severe health issues (e.g., nephrotoxicity and instant cardiac arrest) (141).
The timing of DTPA treatment is crucial. The efficiency of DTPA to remove the
internalized actinides from the body is inversely related to the time after contamination. DTPA is
considered inefficient to remove the actinides already deposited in organs (e.g., liver and skeletons)
due to poor DTPA distribution to such organs (134). A study reported that a delay in the initiation
of the DTPA treatment from 1 h to 5 h post-contamination with 238Pu resulted in a nearly 2.5 folds
increase in the radioactivity retained in mice after one day (142). Therefore, DTPA can be
administered at repeated daily or weekly doses for months, depending on the case. Despite the
repeated administration, removal of only 50% of the already deposited actinides is considered a
good result (143). Therefore, it is essential for the DTPA to be administered as soon as the internal
contamination is confirmed to limit the organ deposition of the radionuclides.

1.5.2

The need for a prophylactic formulation
The current chelation therapy for actinide contamination is only based on post-exposure

treatment using DTPA. A prophylactic formulation is an ideal solution to eliminate the lag time
between internal contamination and DTPA administration. Such a formulation can be administered
for high-risk individuals such as personnel who respond to emergency incidents where
radionuclides have been or may be potentially released. Due to its short half-life, DTPA is not an
appropriate drug to be administered for prophylaxis. To date, there is limited research concerning
the development of such formulations. For example, a longer circulating DTPA formulation based
on liposomal encapsulation of DTPA was investigated as prophylactic therapy in rats (144). The
DTPA-liposomal formulation was injected as a 5 µmol/kg dose (based on DTPA content) three
days before injection of

238

Pu. After seven days, the

238

Pu retention in the liver and bones was
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reduced by 47% and 29%, respectively, compared to no treatment. Other studies were focused on
developing strategies using small-molecular or nanoparticle-based formulations to improve the
clearance of the already deposited actinides for treatment purposes (142, 145, 146).
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2 Chapter 2. In Vitro Evaluation and Biodistribution Studies of
HPMA Copolymers Targeting the Gastrin Releasing Peptide
Receptor in Prostate Cancer
2.1 Introduction
Prostate cancer is currently the most prevalently diagnosed and second-deadliest form of
cancer for men in the U.S. (1). The gastrin-releasing peptide receptor (GRPR) has been shown to
be expressed on a large fraction of human prostate cancers (147). This has given the impetus for
the development of GRPR-targeted diagnostic agents with the purpose of detecting, staging and/or
monitoring therapeutic treatment efficacy as well as differentiating indolent from aggressive forms
of prostate cancer (148). Bombesin (BBN) is a fourteen amino acid peptide that exhibits nanomolar
binding affinity to the GRPR. Studies have shown that only the C-terminal fragment BBN(714)NH2 (Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2) is needed to retain nanomolar binding affinity
(77). A number of truncated (e.g., BBN(7-14)) and modified BBN based agents have been
developed (148-151) and several have entered clinical trials (e.g., NCT02624518 and
NCT03872778) for imaging prostate and other GRPR-positive cancers (152-154).
Over the last few decades, the development of cancer diagnostic and therapeutic agents
based on nanomedicine platforms have been explored by numerous laboratories (155-157). These
constructs offer many attractive attributes for this purpose, including their drug loading capacity
and ability to be multi-functional (e.g., theranostic). Nanomedicine platforms are able to selectively
target cancers based on two distinct mechanisms: passive and active targeting. The passive
targeting capability of nanomedicine constructs is due to the enhanced permeability and retention
(EPR) effect which principally involves vasculature and lymphatic irregularities in cancerous tissue
relative to normal tissue (158). Active targeting involves the modification of the nanomedicine
construct with targeting vectors that are capable of recognizing molecular markers on the surface
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of tumor cells or within the tumor microenvironment. Through this mechanism, actively targeted
nanomedicine constructs are conceivably able to enhance the delivery of the construct to tumors.
To date, numerous targeting vectors have been explored including those based on small
molecules, peptides and antibody (159). Indeed, several investigators have explored the utilization
BBN peptides to enhance the delivery of nanomedicine constructs (e.g, gold, glycol chitosan, and
copper sulfide nanoparticles) to GRPR-positive cancers (81, 82, 160, 161). The efficiency of active
targeting has been found to be associated with molecular size (162, 163). Nanomedicine constructs
with lower molecular sizes (< 50 nm) generally exhibit a higher level of tumor delivery
enhancement due to active targeting (163).
N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers have emerged as a promising
nanomedicine platform due to their nontoxic and nonimmunogenic nature (97, 164). Our laboratory
and others have explored HPMA copolymer constructs as nuclear medicine diagnostics (117, 120,
165-167). Furthermore, several laboratories have demonstrated that in vivo targeting using HPMA
copolymers (i.e., < 50 nm) can be enhanced through the inclusion of targeting ligands (e.g., integrin
targeting using cRGD) (165). In this work, we explore the development of HPMA copolymers
incorporated with BBN(7-14)NH2 peptides to examine if GRPR-targeting can enhance
accumulation in GRPR-positive prostate cancer. Specifically, we examine what impact BBN
incorporation density and peptide charge has on the biological performance of these constructs in
an in vitro human PC-3 prostate cancer model and in an in vivo mouse model. By better
understanding these parameters, we aim to develop improved diagnostic and therapeutic GRPRtargeted nanomedicine constructs for prostate and other GRPR-positive cancers.
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2.2 Materials and methods
2.2.1

Chemicals
If not otherwise indicated, all solvents used for polymer reactions and silica gel purification

were ACS grade and obtained from Fisher Scientific. Water was deionized using a Milli-Q®
Integral Water Purification System (Millipore Corp., U.S.). Acetonitrile (ACN) and formic acid
were HPLC grade and purchased from Fisher Scientific (U.S). Dichloromethane (DCM), N,Ndimethylformamide (DMF), trifluoroacetic acid (TFA) were peptide synthesis grade and purchased
from

Fisher

Scientific

(U.S).

Fluorescein

isothiocyanate

(FITC),

1-Ethyl-3-(3-

dimethylaminopropyl)carbodiimide (EDC), N-hydroxysuccinimide (NHS), triisopropylsilane
(TIS),

4-cyano-4-(phenylcarbono-thioylthio)pentanoic

acid

(CTA),

and

2,2′-Azobis(2-

methylpropionitrile) (AIBN), Tris(2-carboxyethyl)phosphine (TCEP), ethylenediaminetetraacetic
acid (EDTA), and methacrylic acid were purchased from Sigma-Aldrich (U.S). N-(2Hydroxypropyl)methacrylamide (HPMA) and N-(3-Aminopropyl)methacrylamide (APMA) were
obtained from Polysciences (U.S.). Unless indicated, Fmoc-protected amino acids were purchased
from NovaBiochem. Boc-cystamine hydrochloride, Fmoc-D-His(Trt)-OH, Fmoc-D-Trp(Boc)-OH,
Fmoc-D-Ala-OH, Fmoc-D-Leu-OH, and Fmoc-D-Val-OH were obtained from Chem-Impex Int’l
Inc. (U.S.). Fmoc-D-Met and 6-Maleimidohexanoic acid were obtained from Alfa Aesar (U.S.).
Fmoc-D-Gln was purchased from AstaTech (U.S.). Fmoc-D-Phe(4-F)-OH and N,NDiisopropylethylamine (DIEA) were obtained from ChemPep (U.S.). Rink amide and 3-([ethylfmoc-amino]-methyl)-indol-1-yl]-acetyl

am

resins,

Fmoc-NH-(PEG)₂-COOH,

and

O-

(Benzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium tetrafluoroborate (HBTU) were purchased
from NovaBiochem. L-Cysteine hydrochloride and sodium tetrafluoroborate (NaBF 4) were
purchased from Acros (U.S.). Piperidine and phenol were purchased from Sigma-Aldrich (U.S).
Phosphate buffered saline (PBS), and 1-piperazineethanesulfonic acid (HEPES) were purchased
from Fisher Scientific (U.S.). Ham's F-12K Medium and fetal bovine serum (FBS) were obtained
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from Gibco (U.S.). 5,5-dithio-bis-(2-nitrobenzoic acid) (Ellman’s reagent), L-glutamine, Hoechst
33342, and LysoTracker® Red DND-99, sodium dodecyl sulfate (SDS) were purchased from
Thermo Fisher Scientific (U.S.). CF-1 female mice were purchased from Charles River
Laboratories. All procedures on animals were consistent with the Guide for the Care and Use of
Laboratory Animals by the National Institutes of Health and were approved by the Institutional
Animal Care and Use Committee (IACUC) at the University of Nebraska Medical Center.

2.2.2

Instrumentation
A Liberty microwave peptide synthesizer (CEM, U.S.) was used to synthesize peptides via

solid phase peptide synthesis (SPPS). Equipped with a Waters 2489 absorption detector and a
Waters Qtof Micro electrospray ionization mass spectrometer, a Waters (U.S.) e2695 system was
used to perform reversed phase-high performance liquid chromatography/mass spectrometry (RPHPLC/MS) analyses. A Bruker Avance-III HD 500 MHz instrument (U.S.) was used to record 1HNMR and 19F-NMR spectra using either deuterated dimethyl sulfoxide or deuterium oxide as a
solvent. A Phenomenex (U.S.) Jupiter C12 Proteo 250 x 10.0 mm semiprep column was used to
purify peptides. Weight and size measurements of HPMA copolymers were performed using a
Viscotek TDA max system (Malvern Instruments Inc., U.S.) equipped with Shodex Asahipak GF510 HQ GPC column. Biochrom WPA Biowave II UV/Visible Spectrophotometer was obtained
from Biochrom (U.S.). An LSM 710 confocal microscope (Carl Zeiss Microimaging, Inc., U.S.)
was used to visualize stained cells. Multi-Wiper nuclear medicine gamma counter (LTI, U.S.) was
used for counting the activity bound to cells. Gamma decay detection of injected radiolabeled
conjugates was performed using NaI (Tl) well detector constructed by AlphaSpectra Inc. (U.S.).
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2.2.3
2.2.3.1

Synthesis and characterization of BBN peptides and BBN-HPMA conjugates
Synthesis of BBN peptides
The synthesis of the BBN peptides (BBN-RR, D-BBN-RR, BBN-EE, and BBN-DOTA)

was performed using an automated solid-phase peptide synthesizer on a Rink Amide resin. Briefly,
the resin (100 µmol of the resin substituted peptide anchors) was first deprotected using 20%
piperidine in DMF, resulting in the formation of the primary amine. Fmoc protected amino acids
(0.5 mmol) were activated using HBTU and added to the growing peptide of the resin. The
synthesized peptide was cleaved from the resin using a cleavage cocktail containing
TFA/phenol/water/TIS (88/5/5/2). The cleaved peptide was precipitated in cold methyl-tert-butyl
ether and filtered. The crude product was dried, and the desired peptide was purified using LC/MS.
BBN-Anta was synthesized under similar conditions, except that 3-([ethyl-fmoc-amino]-methyl)indol-1-yl]-acetyl am resin was used. Before any in vitro and in vivo studies, all peptides were
purified to give ≥ 95% purity based on LC/MS.
2.2.3.2

Synthesis of monomers
FITC-APMA was synthesized according to a literature reports (168). A synthesized

DOTA-tris(tBu)-NHS (169) was reacted with APMA to synthesized DOTA-tris(tBu)-APMA
according to a literature report (170). To synthesize the N-tert-butoxycarbonyl-N′-methacryloylcystamine (Boc-Cyst-MA) monomer, methacrylic acid (46.5 mg, 0.54 mmol), EDC (115 mg, 0.6
mmol) and NHS (79.4 mg, 0.69 mmol) were dissolved in 500 µL of DCM and allowed to stir for 2
h. Boc-cystamine (0.45 mmol) was added followed by the addition of DIEA (0.9 mmol). After 16
h, the reaction mixture was washed with DI water three times, dried over MgSO 4, and concentrated
under vacuum. The product was purified by silica gel chromatography using petroleum
ether:acetone (10:1) as the eluent solvent system to yield the pure product (99.2 mg, 0.31 mmol,
71%). The product was characterized by ES-MS ([M+H] + = 321.1) and 1H-NMR.
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2.2.3.3

Synthesis of HPMA copolymers
With modifications made from a previously described method (117), reversible addition-

fragmentation chain transfer (RAFT) polymerization was employed to synthesize two batches of
HPMA-SS copolymers. Briefly, HPMA, Boc-Cyst-MA, APMA-FITC, and DOTA-tris(tBu)APMA monomers were dissolved in a dioxane/DI water (2:1) solution at a molar ratio of
84:15:0.5:0.5, respectively (with the total monomer amount summing to 0.5 mmol). AIBN initiator
(0.33 mg, 2.01 µmol) and CTA (0.49 mg, 1.75 µmol) were added to make the final volume of 0.5
mL. The resultant mixture was transferred to a glass ampule and purged with nitrogen for 40 min.
The ampule was subsequently flame sealed and the polymerization allowed to proceed at 50 °C for
48 h. The reaction mixture was cooled to room temperature and loaded onto an LH-20 column
using methanol as an eluent to yield the HPMA polymer (71 mg, 82% yield). The molecular weight
analysis was performed using gel permeation chromatography (GPC) with an elution mixture of
ACN/PBS (40:60). To determine FITC content, a standard curve was prepared of known FITCAPMA monomer concentrations (0.92 to 14.65 µM, PBS) using a UV/Vis spectrophotometer
(absorbance wavelength = 494 nm). Then, 667 µg of the HPMA copolymer was dissolved in 1 mL
PBS, and the absorbance at 494 nm was recorded (n = 2). The FITC concentration was extrapolated
from the prepared standard curve. The content of DOTA was determined by signal integration from
1

H-NMR spectroscopy.

2.2.3.4

Synthesis of BBN-HPMA conjugates
The BBN-HPMA conjugates were synthesized by coupling the HPMA-SH copolymer with

BBN-RR (or D-BBN-RR), BBN-EE, or both BBN-RR and BBN-EE to give positive, negative, or
zwitterionic conjugates, respectively. HPMA-SH-1 (batch 1) was used to synthesize the positive
and zwitterionic BBN-HPMA conjugates, while HPMA-SH-2 (batch 2) was used for the synthesis
of the negative BBN-HPMA conjugates.
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The synthesis of BBN-HPMA conjugates was performed in two steps. First, the HPMA
copolymer (10 mg) from either batch 1 or 2 was dissolved in DI water (500 µL), and TCEP (100
times more than the equivalent theoretical content of the Boc-Cyst-MA monomer) was added to
the solution to generate the free thiol groups on the polymer side chains. After 4 h, the mixture was
loaded on an LH-20 column using methanol as the eluent. The collected fractions were evaporated
to give the HPMA-SH copolymers. To estimate cystamine incorporation, Ellman’s reagent was
utilized to estimate the thiol content of the HPMA-SH (batch 1 and 2) (171). Briefly, 2.5 mL of the
reaction buffer (0.1 M sodium phosphate buffer (pH = 8.0) containing 1 mM EDTA) was mixed
with 50 µL of a solution of Ellman’s reagent (4 mg/1 mL reaction buffer). Then, 100 µg of either
the HPMA-SH-1 or -2 copolymer (dissolved in 250 µL of the reaction buffer) was mixed with the
previous solution and incubated at room temperature for 15 min. The absorbance (λ = 412 nm) was
measured for the mixture using a UV/Vis spectrophotometer. The concentration of the free thiol
groups was extrapolated from a standard curve prepared from the absorbance of known
concentrations (0.1 – 1.0 mM) of L-cysteine hydrochloride reacted with Ellman’s reagent under
the same conditions.
Next, conjugation of the BBN peptides to the HPMA-SH copolymers was performed
through thiol-ene “click” chemistry. The amount and type of BBN peptide used for the synthesis
of each BBN-HPMA conjugate are displayed in Table 2.1. The desired amount of a BBN peptide
was dissolved in DI water and added to a solution of HPMA-SH (5 mg) to make the final volume
of mixture 500 µL. The reaction mixture was purged with N2 for 40 min and stirred at room
temperature for 16 h. The non-conjugated BBN peptide was removed by LH-20 column using
methanol as an eluent. The fractions of the BBN-HPMA conjugates were collected and evaporated
to dryness. P-RREE-1 and P-RREE-2 were synthesized similarly by adding the desired BBN-EE
amount to a solution containing 7.30 mg of the already characterized P-RR-2. The amount of
peptide content per BBN-HPMA conjugate was determined by

19

F-NMR spectroscopy using
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NaBF4 as an internal reference (average peptide conjugation yield for the synthesized BBN-HPMA
conjugates: 76.6 ± 14.8%, n = 11). Before any radiolabeling experiments, the BBN-HPMA
conjugates were exposed to a TFA cleavage cocktail (TFA/phenol/water/TIS (88/5/5/2)) to
deprotect the DOTA-tris(tBu). After 1 h, the TFA was evaporated under N2 flow, and then the
conjugates were solubilized in methanol and purified using an LH-20 column.
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Table 2.1 Feed BBN peptide amount for BBN-HPMA conjugation reaction
BBN-HPMA conjugate†
Group

Type of BBN peptide*

Name

BBN-RR (µmol)
++
Positive

Negative

Zwitterionic
†

P-RR-1
P-RR-2
P-RR-3
P-RR-4
P-D-RR-3
P-EE-1
P-EE-2
P-EE-3
P-EE-4
P-RREE-1
P-RREE-2

D-BBN-RR (µmol)
++

BBN-EE (µmol)
−−

0.17
0.57
1.14
2.29
1.14

0.57
0.57

0.17
0.57
1.14
2.29
0.17
0.57

The numbers 1 through 4 indicate the increasing peptide content with 1 and 4 being the lowest and highest peptide
content in each group of BBN-HPMA conjugates.
*
Values in the table are normalized based on the calculations for 1 mg of HPMA-SH.
+ + and − − represent the number and type of charges added to the active moiety BBN(7-14)NH 2 .
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2.2.4

Radiolabeling of the BBN-HPMA copolymer conjugates and BBN-DOTA peptides
Radiolabeling of BBN-HPMA copolymer conjugates was performed by dissolving 200 µg

of the conjugates in 100 µL DI water, followed by the addition of 3.7 MBq of

177

LuCl3. The

resultant solution was heated at 90 °C for 60 min. After cooling, the radiolabeled BBN-HPMA
conjugates were purified using an Agilent PL aquagel-OH MIXED-H GPC column with an
ACN/PBS (40:60) elution. A radio-HPLC equipped with a Bioscan flow count radiometric detector
and Waters 2489 UV detector (λ = 494 nm) was used to identify the radiolabeled BBN-HPMA
conjugates. After collection, the radiolabeled conjugates were buffer exchanged to PBS and
concentrated using an Amicon Ultra-4 centrifugal filter (10 kDa) before continuing on to any in
vitro or in vivo studies.
BBN-DOTA was radiolabeled by dissolving 25 µg of the peptide in an ammonium acetate
buffer (0.5 M, 100 µL, pH = 5.5) followed by the addition of 3.7 MBq (100 μCi) of 177LuCl3. The
solution was heated to 90 °C for 60 min. To enhance the ease of purification of the radiolabeled
BBN-DOTA from the unlabeled peptide, 4-6 mg of CoCl 2 was added, and the solution was heated
for an additional 5 min at 90 °C. The radiolabeled BBN-DOTA was purified using radio-HPLC
employing an analytical Proteo C12 column with a 1.5 ml/min flow rate and a gradient from 89%
to 83% of ACN in DI water (containing 0.1% formic acid) over 15 min. The radiolabeled BBNDOTA was concentrated using solid phase extraction employing a C18 extraction disk (3M
Empore) with an ethanol/PBS (60/40) elution before any further studies were performed.

2.2.5

In vitro studies

2.2.5.1

Cell Culture
PC-3 cells were cultured in our laboratory, as per ATCC protocol, in Ham’s F-12K medium

containing 10% FBS, 2.5 mM L-glutamine, 15 mM HEPES, and 0.5 mM sodium pyruvate. Cells
were incubated at 37 °C at 5% CO2.
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2.2.5.2

Competitive cell-binding studies of BBN peptides
The inhibitory concentrations (IC50) for the peptides (BBN-RR, D-BBN-RR, and BBN-

EE) were determined using a PC-3 cell line. Before the day of experiment, PC-3 cells were plated
in 6-well plates at a seeding density of 0.5 x 106 per well. The next day, the cells were washed with
PBS and 1 mL fresh medium was added to each well. The cells were then incubated at 37 °C for 1
h in the presence of
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Lu-radiolabeled BBN-DOTA (100,000 counts per minute) and at varying

concentrations (3.33 10-12 to 3.33 10-6 M) of BBN-RR, D-BBN-RR, or BBN-EE, with each
concentration point made in duplicate. At the end of the incubation period, the cells were washed
three times with PBS to remove any unbound peptide. Cells were incubated with acidic buffer (50
mM glycine-HCl/0.1 M NaCl buffer, pH = 2.8) for 5 min and lysed with SDS to collect surfacebound and internalized fractions for the peptide, respectively. The radiation signal was measured
using a gamma counter. The experiment was done in two biological replicates. One-binding site
model Graphpad PRISM 7 (U.S.) was used to obtain the corresponding curves and determine the
IC50 values.
2.2.5.3

Cellular uptake studies of BBN-HPMA conjugates
Cellular uptake studies were performed for all BBN-HPMA conjugates. PC-3 cells were

plated in 6-well plates at a seeding density of 0.5 x 106 per well. On the day of the experiment, the
medium was replaced with 1 mL of fresh medium and then 100,000 cpm of the desired BBNHPMA conjugate (dissolved in 100 µL medium) was added per well. Cells were then incubated at
37 °C/5% CO2 for 30 min, 1 h, 2 h, 3 h, and 4 h (five wells per compound per time point). At the
end of each time point, cells were washed three times with PBS followed by incubating with an
acidic buffer (0.2 M glycine-0.15 M NaCl, pH = 2.8) for 5 min to isolate the surface-bound
radioactivity and SDS to lyse the cell and obtain the internalized radioactivity. A gamma counter
was used to measure the radioactivity signal. Each experiment was done in two biological
replicates.
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2.2.5.4

Competitive blocking experiments of BBN-HPMA conjugates
Competitive blocking experiments were performed for P-RR-2, P-RR-3, P-D-RR-3, and

P-RR-EE-1. BBN-Anta, a known GRPR antagonist (172), was used as a blocking agent. PC-3 cells
were seeded on 6-well plates at a seeding density of 0.5 x 10 6 cells/well. The following day, a fresh
medium containing 300 µM of BBN-Anta was added, and the desired BBN-HPMA conjugate (five
wells per compound) was added. After 1 h incubation at 37 °C/5% CO2, the cells were washed three
times with PBS, incubated with the previously described acidic buffer (pH = 2.8) for 5 min and
SDS to obtain surface-bound and internalized activity, respectively, and the radioactivity was
measured. Each experiment was performed in two biological replicates.
2.2.5.5

Confocal microscopy of BBN-HPMA conjugates
Confocal microscopy studies were performed for P-RR-3 and P-D-RR-3. PC-3 cells were

incubated in a 4-well Lab-Tek II chamber coverglass (Thermo Scientific) at a seeding density of 5
x 104 cells per well (two wells per compound). The next day, the cells were washed three times
with PBS and then, a fresh 400 µL medium containing an equivalent FITC concentration of 6 µM
of the desired BBN-HPMA conjugate was added. The cells were incubated for 4 h at 37 °C/5%
CO2. The cells were then washed three times with PBS and fresh medium containing 150 nM of
LysoTracker Red DND-99 was added. After 2 h, the cells were washed three times with PBS and
incubated with 1 nM of Hoechst® 33342 dye for 5 min. Finally, the cells were washed with PBS
and imaged using an excitation wavelength of 405 nm, 488 nm and 568 nm for blue, green and red
excitations, respectively. The intensity of fluorescent signals was quantified using ZEN (blue
edition) software.

2.2.6

Biodistribution studies
The biodistribution studies were performed on normal female CF-1 mice weighing ∼ 35 g.

The mice were randomly divided into five groups (five mice/group). After radiolabeling and
purification, 0.37 MBq (10 μCi) of the desired
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Lu-BBN-HPMA conjugate was injected

51
intravenously via tail. After 4 h, the mice were sacrificed, and their tissues were excised and
weighed. The tissue radioactivity was measured using a gamma counter. The percent injected dose
(%ID) for each tissue was calculated by dividing the radioactivity of each tissue by the total counts
of all excised tissues, the remaining carcass, and the bedding materials. Data are expressed in terms
of %ID/g of tissue to normalize differences in tissue masses.

2.2.7

Statistics
Statistical analyses were performed using a two-tailed unpaired Student's t-test (two

groups) or one-way ANOVA (more than two groups) with Bonferroni post-tests. A value of p <
0.05 was considered statistically significant.

2.3 Results
2.3.1

Design and Synthesis of BBN-HPMA conjugates
Herein, we examine the potential of BBN peptides to enhance the delivery of diagnostic or

therapeutic HPMA copolymers to GRPR-positive prostate cancer. To that end, BBN peptides in
varying densities and charges were incorporated into the polymeric construct to examine how these
factors affected in vitro and in vivo performance. Through this incorporation, the resulting BBNincorporated HPMA copolymers (BBN-HPMA) were either positive (modified with BBN-RR),
negative (modified with BBN-EE), or zwitterionic (modified with both BBN-RR and BBN-EE),
Figure 2.1 and Figure 2.2.
All of the BBN peptides incorporated into the HPMA copolymers contain the BBN(714)NH2 sequence which is capable of yielding low nanomolar GRPR binding (77). BBN-RR
includes two positively charged Arg (R) residues, while BBN-EE contains two negatively charged
Glu (E) residues. In the case of BBN-EE, a PEG2 spacer was included that separates the Glu
residues from the GRPR-targeting vector. An earlier attempt to synthesize the above BBN-EE
without the PEG2 spacer resulted in a peptide with poor aqueous solubility. All of the peptides
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designed for polymeric integration included a D-Phe(4-F) moiety which allowed for easy
quantification of polymer-peptide incorporation by

19

F-NMR. Lastly, these peptides included a

terminal maleimide group to facilitate incorporation into the HPMA copolymer through thiomaleimide click chemistry.
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Figure 2.1 Structures of synthesized peptides (BBN-RR, D-BBN-RR, and BBN-EE).
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A number of control peptides (D-BBN-RR, BBN-DOTA and BBN-Anta) were also
synthesized for the planned studies. For D-BBN-RR, D-configured amino acids were utilized to
assemble the BBN(7-14)NH2 sequence. This provided a matched control with the same
physiochemical properties of the BBN-RR without the capability to bind to the GRPR. BBNDOTA and BBN-Anta (a known GRPR antagonist) were generated as controls and utilized in the
investigation of the GRPR binding of the polymeric constructs. All of the peptides described above
were successfully synthesized using SPPS. The yields and mass spectrometric identifications of the
resulting peptides are provided in Table 2.2Error! Reference source not found.Error! Reference
source not found.. The corresponding MS spectra for these peptides can be found in Figure 2.3.
The two batches of HPMA copolymers (HPMA-SS-1 and HPMA-SS-2) were successfully
synthesized using RAFT polymerization chemistry (Figure 2.2). Deprotection of the disulfides with
TCEP yielded the free thiols. The molecular weight of the resulting HPMA copolymers were 43.4
(Ð = 1.1) and 35.1 (Ð = 1.06) kDa for HPMA-SH-1 and -2, respectively. Corresponding free thiol
content for the two copolymer batches were 18.5 and 16.4 mol%, respectively. Incorporation of the
BBN peptides into the HPMA copolymers were carried out using thiol-maleimide click chemistry.
Variation in peptide loading onto the copolymer was accomplished by adjusting the concentration
of the BBN peptide (Table 2.1) for the conjugation reaction. The HPMA-SH-1 was utilized to yield
P-RR and P-RREE copolymer constructs while HPMA-SH-2 was utilized to generate the P-EE
copolymers. Deprotection of the tert-butyl protecting groups from the DOTA chelator was achieved
using TFA to give the final polymeric constructs. The composition of the various HPMA
copolymers generated are provided in Table 2.3. Representative examples of 1H and
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F-NMR

spectra utilized in the characterization of the polymeric constructs are given in Figure 2.4 and
Figure 2.5. Depending on the extent of the peptide incorporation, molecular weights of the HPMA
copolymers varied from 55.0 – 117.80 kDa with BBN peptide content ranging from 0.12 – 0.39
mmol/g polymer. The radiolabeling of BBN-incorporated HPMA copolymers was accomplished
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by incubation with 177LuCl3 in DI water at 90°C for 60 min. These radiolabeling conditions gave
moderate radiochemical yields of 55 - 75%.
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Figure 2.2 Schematic representation of A) RAFT polymerization, B) Thiol deprotection, C) BBN
peptide conjugation, D) Deprotection of DOTA-tris(tBu) and E) radiolabeling with 177Lu.
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Table 2.2 Mass spectrometric identification and IC50 values of the peptides
Peptides

Molecular formula

Mass
calculateda

Mass founda

Yield
(%)

IC50 (nM)

BBN-RR

C74H108FN23O15S

1610.8

1610.6

21.7

18.6 ±1.0

D-BBN-RR

C74H108FN23O15S

1610.8

1610.7

19.8

NIb

BBN-EE

C78H109FN18O22S

1701.8

1701.4

17.1

31.2 ±1.7

BBN-DOTA

C71H115N25O18S

1638.8

1638.6

18.3

-

BBN-Anta
C49H69N13O9
984.1
984.3
25.4
+
Mass calculated and found are for [M+H]
b
No competitive inhibition was observed at the highest concentration used (3.33 µM)
a
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Figure 2.3 MS spectra of the synthesized BBN peptides.

59
Table 2.3 Characteristics of HPMA copolymers
Copolymers

MWc
(kDa)

Ð

Total
peptide
weight
(%)

Peptide content by typej
(mmol/g polymer)

HPMA-SS-1

50.6

1.0

HPMA-SH-1a

43.5

1.1

HPMA-SS-2

40.0

1.07

HPMA-SH-2b

35.1

1.06

P-RR-1

55.0

1.11

19.8

0.12

P-RR-2

67.1

1.06

38.5

0.24

53.5

0.33

63.1

0.39

j

APMACys-Bocd
(Mol.%)

FITCe
(Mol.%)

DOTAf
(Mol.%)

0.24

0.54

ND

ND

BBN-RR

D-BBN-RR BBN-EE

18.5

16.5

P-RR-3

93.5

P-RR-4

117.8j

P-D-RR-3

99.2

1.10

50.6

P-EE-1

42.3

1.06

23.6

0.14

P-EE-2

62.6

1.10

37.9

0.22

P-EE-3

70.2

1.09

54.5

0.32

P-EE-4

78.4

1.06

61.8

0.36

P-RREE-1

88.2

1.09

51.0

0.19

0.11

P-RREE-2

101.2j

57.0

0.17

0.18

a

0.314

Intermediate polymer for the synthesis of P-RR-1, P-RR-2, P-RR-3, P-RR-4, P-D-RR-3, P-RREE-1, and P-RREE-2
Intermediate polymer for the synthesis of P-EE-1, P-EE-2, P-EE-3, and P-EE-4
c
Estimated by gel permeation chromatography
d
Determined by Ellman’s essay
e
Determined by UV/Visible spectrophotometry
f
Determined by 1H-NMR spectroscopy
j
Determined by 19F-NMR spectroscopy
b
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A

a
b+c
a
b
c

B

a
c

Figure 2.4 1H-NMR spectra of HPMA-SS (top) and HPMA-SH 1 (bottom) using D2O.
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Figure 2.5 19F-NMR spectra of both BBN-RR and P-RR-3. The bottom spectrum
shows P-RR-3 (9.8 mg) is integrated to 3.31 µmol in presence of 5.69 µmol of NaBF4
(control).
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2.3.2

In vitro studies
In vitro studies were conducted in the GRPR-positive, PC-3 human prostate cancer cell

line (173). Competitive binding studies (Table 2.2) were conducted for BBN-RR, BBN-EE and
D-BBN-RR vs BBN-DOTA (positive control radioligand) to establish the GRPR affinity of the
three experimental peptides prior to polymeric incorporation. The GRPR-affinities (IC50 values)
of BBN-RR and BBN-EE were 18.6 ± 1.0 and 31.2 ± 1.7 nM (p < .001), respectively. As
expected, no GRPR-affinity for the D-BBN-RR was observed at the tested concentrations (Table
2.2).
Once the GRPR-affinities of the BBN peptides were established, the cellular uptake of
the BBN-HPMA conjugates were investigated over 4 h using the PC-3 cell line (Figure 2.6). For
the positive BBN-HPMA copolymers, uptake of P-RR-1 was negligible over the time frame, see
Fig. 3A. However, as BBN-RR incorporation increased in the polymer construct, marked
increases in cellular uptake rates were seen. By the end of the 4 h period, the trend of P-RR-4, PRR-3, P-RR-2 and P-RR-1 was observed to have 20, 17, 7 and 0.7 of the added radiolabeled
construct internalized, respectfully. Interestingly, the negative control P-D-RR-3, which has a
similar peptide content compared to P-RR-3 but has no GRPR binding capabilities, had
approximately half (9%) of the cellular uptake of P-RR-3. This suggests that GRPR-mediated
uptake is not the only mechanism by which these constructs enter cells. The negatively charged
BBN-HPMA constructs (P-EE-1, P-EE-2, P-EE-3, and P-EE-4) had distinctly different
internalization profiles, see Figure 2.6B. With exception to P-EE-4, all of the negatively charged
polymeric constructs exhibited less than 0.2% of internalization over the 4 h time frame. P-EE-4,
which contained the largest BBN-EE peptide content, had just less than 0.6% of cellular
internalization during that time.
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Based on the above results, we decided to examine what impact combining positive
(BBN-RR) and negative (BBN-EE) peptides in a single HPMA copolymer had on cellular
internalization. Two constructs, P-RREE-1 and P-RREE-2, with similar peptide contents, 0.30
and 0.35 mmol/g polymer, correspondingly, but different positive to negative peptide ratios of
approximately 1.7:1 and 1:1 were synthesized. The cellular internalization of these constructs
along with P-RR-2 (positive control) were investigated using PC-3 cells, see Figure 2.6C. The
cellular uptake profiles for both of these constructs were significantly below that of the control. PRREE-1 resulted in 1.5% internalization of the radiolabeled polymer over 4 h, while P-RREE-2
exhibited only a 0.2% uptake over the same time frame. This indicates that the inclusion of the
negative charged BBN-EE deleteriously impacted cellular uptake with the degree of impact
increasing with the amount of BBN-EE incorporated.
Using a GRPR blocking agent, BBN-Anta (300 µM), the impact of GRPR blocking on
the cellular internalization of the P-RR-2, P-RR-3, P-RREE-1 and P-D-RR-3 constructs was
examined at the 1 h time point, see Figure 2.6D. In the presence of the GRPR-blocking agent, a
60 and 33 % reduction in cellular internalization for P-RR-2 and P-RR-3, correspondingly, was
observed. However, no change in cellular uptake was observed for P-RREE-1 and P-D-RR-3
when blocking the GRPR. Based on these results, GRPR-mediated internalization of the BBNHPMA constructs is only relevant, at least in the context of this study, for the positively charged
P-RR constructs. Overall, these results indicate that the percent incorporation and charge of the
BBN peptide play an important role in the cellular uptakes of the BBN-HPMA conjugates.

64

Figure 2.6 Cellular internalization of positive BBN-HPMA conjugates (A), negative BBN-HPMA
conjugates (B), zwitterionic BBN-HPMA conjugates (C), and GRPR blocking experiments after
1 h (with or without BBN-Anta) (D). Data expressed as Mean ± SD. *** Indicates significance at
p < 0.001.
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Confocal microscopy studies were performed to examine the uptake pattern of BBNHPMA constructs that do and do not undergo GRPR-mediated internalization. Specifically, the
cellular uptake of P-RR-3 and P-D-RR-3 were examined in PC-3 cells at 4 h post-incubation, see
Figure 2.7. Consistent with previous cellular uptake studies, the FITC-labeled (green) P-RR-3,
capable of GRPR-mediated uptake, exhibited a two-fold higher uptake in PC-3 cells relative to
the P-D-RR-3 which is incapable of GRPR-mediated internalization. Focal points of subcellular
accumulation were observed for both polymeric constructs. These accumulation sites overlapped
well with the endolysosomal marker (LysoTracker Red). These findings suggest that whether
GRPR-mediated or not, the cellular uptake of BBN-HPMA polymeric constructs are internalized
through the endocytic pathways.

66

Figure 2.7 Confocal microscopy images of P-D-RR-3 (top) and P-RR-3 after incubation for 4 h.
Lysotracker (red), FITC (green) and Hoechst® 33342 dye (blue) visualize endosomal
compartments, peptide-polymer conjugates and nucleus, respectively. The corresponding
fluorescence signals are shown to the right (mean ± SEM).
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2.3.3

Biodistribution studies
Based on our in vitro work, only the P-RR constructs demonstrated significant levels of

GRPR-mediated internalization. Therefore, we decided to restrict the biodistribution studies to PRR-1, P-RR-2, P-RR-3, P-RR-4 and P-D-RR-3 (control) using a normal CF-1 mouse model. The
results of these biodistribution studies are illustrated in Figure 2.8 and Table 2.4. Blood retention
for all conjugates was less than 0.5 %ID/g at 4 h with exception to P-RR-1, which had a markedly
higher value of 14.0 ± 0.6 %ID/g (p < .001). Liver and spleen uptakes for P-RR-1 (12 ± 3 and 2.8
± 0.4, respectively) were also substantially lower than the other constructs with values ranging
from 39 ± 4 – 57 ± 8 %ID/g for the liver and 16 ± 3 – 121 ± 41 %ID/g for the spleen. The rapid
blood clearance and accumulation of the P-RR constructs in the liver and spleen suggest these
positively charged polymeric systems are removed from the blood by phagocytic cells of the
mononuclear phagocyte system (MPS) (55, 110). Interestingly, doubling of the BBN-RR content
from 0.12 mmol/g to 0.24 mmol/g for P-RR-1 and P-RR-2, respectively, led to a marked increase
in blood clearance and uptake in MPS-associated organs. In particular, increased spleen uptake of
the P-RR constructs correlated well with increasing BBN-RR polymeric content. Overall, these
studies demonstrate that the clearance profile of these agents are directly related to BBN-RR
content and this observation is mostly likely tied to the charge and size of the constructs.
The mouse pancreas is known to highly express the GRPR and has been utilized as an in
vivo control for low-molecular-weight GRPR-targeted agents (81, 174). The pancreas uptake of
P-RR-1 (1.4 ± 0.3 %ID/g) was significantly (p < .001) higher than the other polymeric constructs
(< 0.64 ± 0.17 %ID/g). Prior in vitro studies demonstrated that P-RR-1 demonstrated poor GRPRtargeting. Therefore, the increased pancreatic uptake of P-RR-1 relative to the other constructs is
likely due to the higher blood retention/longer circulation time of the construct.
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Figure 2.8 Biodistribution profiles (in selected organs) of P-RR-1, P-RR-2, P-D-RR-3, P-RR-3,
and P-RR-4 after 4 h in normal mice. # indicates significance (p < 0.001) for P-RR-1 in
comparison with any other group. NS no significance, * p < 0.05, ** p < 0.01, *** p < 0.001.
Data expressed as mean ± SD.
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Table 2.4 Biodistribution of BBN-HPMA conjugates in CF-1 female mice after 4 h
Organ/Conjugate P-RR-1

P-RR-2

P-RR-3

Blood
Heart

14 ± 1
4.1 ± 0.4

0.20 ± 0.02 0.40 ± 0.14 0.29 ± 0.09 0.28 ± 0.10
1.3 ± 0.3
11 ± 2
3.9 ± 0.8
8.5 ± 2.7

Lung

5.6 ± 1.7

7.1 ± 2.0

22 ± 5

38 ± 4

8.4 ± 3.0

Liver

12 ± 3

56 ± 8

43 ± 6

47 ± 10

39 ± 4

Pancreases

1.4 ± 0.3

0.18 ± 0.03 0.64 ± 0.17 0.43 ± 0.23 0.45 ± 0.18

Stomach

0.82 ± 0.20

0.41 ± 0.15 0.76 ± 0.21 0.58 ± 0.25 0.85 ± 0.44

Spleen

2.8 ± 0.4

16 ± 3

Small intestine

1.6 ± 0.5

0.20 ± 0.03 0.26 ± 0.05 0.24 ± 0.07 0.28 ± 0.12

Large intestine

2.5 ± 1.6

0.43 ± 0.16 0.35 ± 0.16 0.25 ± 0.17 0.29 ± 0.17

Kidney

3.8 ± 0.7

2.8 ± 0.4

Bladder

1.6 ± 0.3

0.34 ± 0.08 0.31± 0.22

Muscle

0.69 ± 0.05

0.11 ± 0.02 0.33 ± 0.14 0.38 ± 0.43 0.17 ± 0.15

Bone

1.2 ± 0.2

0.75 ± 0.27 0.70 ± 0.39 0.73 ± 0.29 0.73 ± 0.23

Brain

0.51 ± 0.05

0.02 ± 0.01 0.05 ± 0.03 0.05 ± 0.02 0.04 ± 0.03

Tail

3.3 ± 2.8

1.00 ± 0.27 1.24 ± 0.55 1.32 ± 0.56 1.4 ± 0.6

Excretion (% ID)

6.9 ± 0.7

0.67 ± 0.11 0.56 ± 0.32 0.34 ± 0.29 0.53 ± 0.14

66 ± 17

3.7 ± 0.5

P-D-RR-3

86 ± 8

3.1 ± 0.7

P-RR-4

121 ± 41

2.8 ± 0.6

0.93 ± 0.81 0.94 ± 0.73

Data represented as %ID / g tissue. Values are mean ± SD (n = 5 for all conjugates except P-D-RR-3, n = 4)
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2.4 Discussion

Nanomedicines, including drug-polymer conjugates, are able to target tumors through the
use of passive and active targeting mechanisms (157, 158). Passive tumor uptake through the
enhanced permeability and retention (EPR) effect relies on imperfections (i.e., fenestrations) in
the tumor vasculature to allow for the selective delivery of high molecular weight nanocarriers to
tumors. For active targeting, incorporation of targeting vectors (e.g., peptides or antibodies) onto
the surface or into the structure of nanocarriers allows for the possibility of increased tumor
accumulation through active targeting of antigens expressed on the surface of tumor cells and/or
in the tumor microenvironment. While active targeting offers the possibility of efficient
intracellular delivery through receptor-mediated endocytosis, the ability of targeting ligands to
actually increase overall tumor delivery has been generally restricted to constructs with lower
molecular size (< 50 nm) (163). HPMA copolymers are one such delivery vehicle (< 20 nm) and
have been demonstrated to be able to enhance tumor uptake through the incorporation of small
molecules and peptide targeting vectors (175, 176).

The GRPR has been shown to be a clinically validated target for prostate, breast and
other cancers (76). Trials have been performed and are currently underway to examine the
clinical potential of low-molecular weight GRPR-targeting vectors based on the bombesin
peptide (177). Our aim in this study is to exploit BBN(7-14)NH2, a truncated form of bombesin
that is a known GRPR-targeting vector, to examine if its incorporation into HPMA copolymer
constructs can enhanced tumor uptake in GRPR-positive cancers. Based on previous reports (105,
178, 179), targeting vector charge and incorporation densities can have significant impact on in
vitro and in vivo performance. To examine these factors, we synthesized HPMA copolymers
incorporated with positive (P-RR), negative (P-EE) or a combination of both (P-RREE) charged
BBN(7-14)NH2 constructs. The in vitro GRPR-targeting of these polymeric constructs were
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investigated in the human PC-3 prostate cancer cell line and the preliminary in vivo
biodistribution of the constructs were investigated in a normal mouse model.
The GRPR-targeting vectors, BBN-RR and BBN-EE, both demonstrated nanomolar
binding affinities to the GRPR. The higher affinity of BBN-RR is likely attributable to the
positive charges on the N-terminal side of the pharmacophore which has been observed
previously with similar constructs (180). Once incorporated into the HPMA constructs, the GRPR
targeting vectors have distinctly different uptake patterns in the PC-3 cell line. The P-RR
constructs demonstrated substantially higher uptake relative to P-EE or P-RREE constructs.
Incorporation of higher BBN-RR densities promoted cellular uptake while the inclusion of BBNEE in negative and zwitterionic constructs seemed to inhibit cellular uptake. It is known that the
charge of HPMA constructs can have a profound effect on cellular uptake (105). Positively
charged constructs are believed to promote surface cell binding/internalization due to favorable
electrostatic interactions with the negatively charged plasma membrane.
To determine if the cellular uptake of P-RR constructs were due to charge alone, we
completed follow-up studies that examined P-RR-3 to a matched control (P-D-RR-3) that has
similar peptide density and charge but is unable to undergo GRPR-mediated internalization. P-DRR-3 demonstrated roughly one-third the uptake as P-RR-3. Additionally, blocking of the GRPR
with a known GRPR antagonist reduced P-RR-3 internalization but, as expected, had no effect on
P-D-RR-3. Further analysis by confocal microscopy confirmed these findings and demonstrated
that cellular uptake resulted in trafficking to the endolysosomal compartments of the cell. The
findings are in accordance with GRPR-mediated internalization (78, 181) and other endocytic
routes for HPMA copolymers and other nanomedicine constructs (105, 182). Overall, these
studies demonstrate that the internalization of the P-RR-3 constructs are due to both GRPRmediated uptake and non-specific charge-associated uptake mechanisms. The inability of P-EE
and P-RREE constructs to internalize as efficiently as the positively charged analogs suggests that
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the negative charge or decreased positive charge of the copolymer constructs inhibit plasma
membrane association and, as a consequence, inhibit the ability to bind to and be internalized by
the GRPR.
Preliminary biodistribution studies of the P-RR constructs were examined in a normal
CF-1 mouse model at the 4 h time point. With exception to P-RR-1, all of the constructs denoted
rapid clearance from the blood and substantial uptake in MPS-associated tissues, particularly the
liver and spleen. P-RR-1 was the only construct with significant blood pool retention at 4 h
suggesting that the lower peptide density reduces recognition and clearance by the MPS. This
observation is consistent with other peptide-incorporated nanomedicine constructs (179, 183). It
suggests the higher peptide content of the copolymers increases opsonization and recognition by
the phagocytic cells of the MPS (184).
The pancreas is known to contain a high density of the GRPR and has been utilized as a
control tissue to examine in vivo GRPR-targeting (81, 174). P-RR-1 did demonstrate higher levels
(1.4 ± 0.3 %ID/g) of pancreatic uptake compared to the other constructs. However, this level of
uptake is far below what is normally seen with other low and high molecular weight GRPRtargeted agents (80, 81, 160, 185). Additionally, the blood to pancreas ratio for P-RR-1 (10:1) is
similar to analogous HPMA copolymers (~ 6:1 to 10:1) we have previously reported that are not
active targeting (117, 186). Given this and the relatively poor in vitro GRPR-targeting capabilities
of P-RR-1 lead us to conclude that the higher pancreatic signal for P-RR-1 corresponds to a
substantially higher blood pool activity and not GRPR-mediated uptake. Overall, the poor in vitro
GRPR-targeting profile of P-RR-1 and the rapid MPS clearance of the remaining P-RR constructs
prevented us from pursuing follow up studies in the GRPR-positive, PC-3 mouse model.

2.4.1

Conclusion
In this study, BBN-modified HPMA copolymer conjugates were synthesized and

investigated to examine their GRPR-targeting capabilities. The BBN(7-14)NH2 pharmacophore
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was modified with either positively-or negatively-charged linkers before conjugation to HPMA
copolymers. Our in vitro studies showed that both the amount of BBN and the charge of the
conjugate has a significant effect on GRPR-mediated internalization in PC-3 cells. Positive
HPMA copolymer conjugates demonstrated increasing cellular internalization with increase BBN
peptide content and charge. In contrast, the incorporation of negatively charged BBN peptides
had a deleterious effect on GRPR-mediated internalization. However, the in vivo biodistribution
profiles of the positive conjugates in normal mice demonstrated rapid recognition and clearance
by the MPS. Overall, these results indicate that the modification of HPMA copolymers with BBN
peptides could be a promising approach to exploit the GRPR-overexpression in cancers but the
effects of peptide content and charge on MPS recognition and clearance should be carefully
considered.
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3 Chapter 3. Bioorthogonal pretargeting of multi-block cathepsin
S-cleavable HPMA copolymers: In vitro and in vivo
evaluations for improved ovarian cancer treatment
3.1 Introduction
Nanosized delivery systems (e.g., polymeric conjugates, micelles, and liposomes) has been
a promising approach in the development of more effective therapies for cancer (50). These
platforms are capable of multifunctional applications and are designed to incorporate substantial
quantities of diagnostic and/or therapeutic agents by physical entrapment or chemical conjugation.
These nanomedicine constructs are able to selectively deliver their payload to tumors by means of
the enhanced permeability and retention (EPR) effect (158), which is associated with the
abnormalities of the tumor vasculature and lymphatic vessels. To date, numerous nanomedicines
have already been clinically approved for treating different types of cancers, with many others
under clinical evaluations (187). However, the development of drug delivery platforms for nuclear
imaging or targeted radionuclide therapeutic applications has been a more dormant area of research.
While exceptional work by numerous laboratories has demonstrated the potential of radionuclideincorporated nanomedicine platforms (173, 188-191), the clinical translation of these systems has
been hampered by their slow pharmacokinetics and sites of non-target accumulation (e.g., normal
liver and spleen) (50). This is particularly the case for radiotherapeutic drug delivery platforms
which often have significant dose-limiting toxicities that prevent the administration of radiative
doses capable of achieving the desired therapeutic outcomes.
To address dose-limiting radiotoxicity issues and the poor overall tumor-non-target (T/NT)
ratios exhibited by nanomedicine and other high-molecular weight radiotherapeutics, pretargeting
has become a strategy of interest (90, 94, 192, 193). This two-step process relies on highly efficient
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in vivo bioorthogonal conjugation chemistry to lower non-target radiotoxicity while still yielding
selective tumor targeting. An example of this bioorthogonal chemistry is the inverse electrondemand Diels–Alder (IEDDA) reaction between trans-cyclooctene (TCO) and 1,2,4,5-tetrazine
(TZ), which can exhibit outstanding reaction kinetics (second-order rate constants (K 2) of up to 106
M-1 S-1) (73). In practice, these very large rate constants mean that this conjugation reaction is very
efficient even at tracer level quantities of radiopharmaceuticals. The first step in this process
involves administration of a non-radiolabeled, tumor targeted construct (e.g., antibody or drug
delivery system) functionalized with the necessary component for bioorthogonal conjugation (e.g.,
TCO). In the second step, after allowing the necessary time (e.g., 2 – 3 days) for the high molecular
weight construct to achieve sufficient T/NT ratios (192), a low-molecular weight radiotherapeutic
is administered that contains the complementary functionality (e.g., TZ) needed for bioconjugation.
Upon encountering the high-molecular weight construct, the small molecule radiotherapeutic will
be sequestered by irreversible covalent bond formation between the bioorthogonal functional
groups (e.g., TCO/TZ) contained in each component. The uncaptured pretargeted small molecule
radiotherapeutic will be quickly cleared from the body, typically with plasma half-life lives on the
minutes timescale (88, 194). In this manner, substantial decreases in blood circulation times and
increases in T/NT ratios can be achieved relative to direct-labeled high-molecular weight
constructs. Recent examples of this approach applied to nanomedicine platforms have shown
promise and yielded substantial gains in T/NT ratios due predominately to a lower blood retention
profile (90, 195, 196). Even with these exciting gains due to pretargeting, significant amounts of
mononuclear phagocyte system (MPS)-associated tissue retention (e.g., liver and spleen) have been
observed and this sequesterization impedes the translative potential of these systems as
radiotherapeutics.
The design and synthesis of biodegradable polymers as a way of controlled drug release
and decreasing long-term retention and associated toxicities has been an active area of research
(197, 198). Our laboratory (117, 120) and others (118, 199, 200) have explored biodegradable
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polymer conjugates based on N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers.
Recently, we reported the development of an HPMA copolymer that was selective for degradation
by cathepsin S (Cat S), a cysteine protease that is highly expressed in certain immune cells (e.g.,
macrophages and monocytes) responsible for the MPS-associated uptake of HPMA copolymers
and other drug delivery platforms (117, 120). Using this Cat S-degradable HPMA copolymer, a
significant reduction in the MPS-associated retention (e.g., blood, liver, and spleen) was observed
without substantially impacting tumor uptake or retention in a pancreatic cancer model. This
enhanced clearance in non-target tissues led to significant (2- to 3-fold) gains in T/NT ratios and
represented an interesting pathway to improve the clinical potential of nanomedicine-based
radiopharmaceuticals.

Herein, we explore the potential of this Cat S-degradable HPMA copolymer design in the
context of pretargeting using the IEDDA biorthogonal reaction. Specifically, we designed Cat Sbiodegradable,

TCO-incorporated

HPMA

copolymers

and

small

molecule

TZ-based

radiotherapeutic. Our hypothesis was that the Cat S-degradable HPMA copolymer design could
reduce non-target uptake of the TCO-incorporated platform and lower the non-target tissue
sequestration of the administered TZ-based radiotherapeutic. If successful, the reduced non-target
uptake, along with other advantages (e.g., large TCO payload), could make polymer conjugates
and other nanomedicine-based constructs more attractive for the development of radiotherapeutics
for oncology. In this manuscript, the synthesis and characterization of the two-component
pretargeting system, TCO-incorporated HPMA copolymer and the TZ-based radiotherapeutic
“chaser agent”, is described. Additionally, the influence of the molecular weight of the copolymer
and the type of TZ (tetrazine versus methyltetrzaine) on the kinetics of the IEDDA reaction is
explored. Lastly, the in vivo performance of the CatS-biodegradable, TCO-incorporated HPMA
copolymers is evaluated in comparison to a non-biodegradable control using an OVCAR-3
subcutaneous ovarian cancer model.
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3.2 Materials and methods
3.2.1

Chemicals
If not otherwise indicated, all solvents used for polymer reactions and silica gel purification

were ACS grade and obtained from Fisher Scientific (U.S.). Water was deionized using a Milli-Q ®
Integral Water Purification System (Millipore Corp., U.S.). Acetonitrile (ACN) and formic acid
were HPLC grade and purchased from Fisher Scientific (U.S). Dichloromethane (DCM), N,Ndimethylformamide (DMF), trifluoroacetic acid (TFA) were peptide synthesis grade and purchased
from

Fisher

Scientific

(U.S).

Fluorescein

isothiocyanate

(FITC),

1-ethyl-3-(3-

dimethylaminopropyl)carbodiimide (EDC), N-hydroxysuccinimide (NHS), triisopropylsilane
(TIS),

4-cyano-4-(phenylcarbono-thioylthio)pentanoic

acid

(CTA

1),

2,2′-Azobis(2-

methylpropionitrile) (AIBN), tris(2-carboxyethyl)phosphine (TCEP), ethylenediaminetetraacetic
acid (EDTA), N-Boc-ethylenediamine, N,N′-Diisopropylcarbodiimide (DIC), and 2,3,5,6Tetrafluorophenol (TFP) were purchased from Sigma-Aldrich (U.S). Cis-cyclooct-4-enol (CCO)
was

purchased

from

Click

Chemistry

Tools

oxoethylidenaminooxy)dimethylamino-morpholino-carbenium

(U.S.).

(1-Cyano-2-ethoxy-2-

hexafluorophosphate (COMU)

was purchased from Chem-Impex International (U.S.). N-(2-Hydroxypropyl)methacrylamide
(HPMA) and N-(3-Aminopropyl)methacrylamide (APMA) were obtained from Polysciences
(U.S.). Fmoc-Gly-OH and Fmoc-D-Gln(trt)-OH were purchased from NovaBiochem (U.S.) and
eMolecules (U.S.), respectively. N,N-Diisopropylethylamine (DIEA) was obtained from ChemPep
(U.S.). Fmoc-(PEG)₂-COOH and Fmoc-(PEG)₄-COOH were purchased from NovaBiochem
(U.S.). Fmoc-D-Asp(OtBu)-OH, 2,2,2-Trifluoroethylamine hydrochloride, and glycolic acid were
purchased from TCI America (U.S.). 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid
mono-N-hydroxysuccinimide ester (DOTA-NHS-ester) was purchased from Macrocyclics (U.S.).
Tetrazine-NHS ester, methyltetrazine-NHS ester, and TCO-PEG4-NHS ester (TCO-A-NHS) were
purchased from BroadPharm (U.S.). A 2000-kDa amino dextran (AD2000 x 750) was purchased

78
from FinaBio (U.S.). Piperidine, pyridine, phenol, Fmoc-Gly-Wang resin, sodium dodecyl sulfate
(SDS), and dithiothreitol (DTT) were purchased from Sigma-Aldrich (U.S). Phosphate buffered
saline (PBS) and 1-piperazineethanesulfonic acid (HEPES) were purchased from Fisher Scientific
(U.S.). RPMI-1640 Medium and fetal bovine serum (FBS) were obtained from Gibco (U.S.).
Bovine insulin was obtained from Cell Applications Inc. (U.S.). Human cathepsin S recombinant
protein was purchased from R&D Systems (U.S.).

3.2.2

Instrumentation
A Liberty microwave peptide synthesizer (CEM, U.S.) was used to synthesize peptides via

solid phase peptide synthesis (SPPS). Equipped with a Waters 2489 absorption detector and a
Waters Qtof Micro electrospray ionization mass spectrometer, a Waters (U.S.) e2695 system was
used to perform reversed phase-high performance liquid chromatography/mass spectrometry (RPHPLC/MS) analyses. A Phenomenex (U.S.) Jupiter C12 Proteo 250 x 10.0 mm semiprep column
was used to purify the desired molecules. Evaluation and purification of radiolabeled conjugates
were performed on a Waters 1515 binary pump equipped with a Waters 2489 absorption detector
and a Bioscan (U.S.) Flow Count radiometric detector system. A Bruker Avance-III HD 500 MHz
instrument (U.S.) was used to record 1H-NMR,

13

C-NMR, and

19

F-NMR spectra using either

deuterated dimethyl sulfoxide, deuterated chloroform, or deuterium oxide as a solvent. Weight and
size measurements of polymers were performed using a Viscotek TDA max system (Malvern
Instruments Inc., U.S.) equipped with Shodex Asahipak GF-510 HQ GPC column (TDA-SEC).
Biochrom WPA Biowave II UV/Visible Spectrophotometer was obtained from Biochrom (U.S.).
A Multi-Wiper nuclear medicine gamma counter (LTI, U.S.) was used for counting the activity
when conducting kinetic experiments utilizing HPMA copolymers. Gamma decay detection of
injected radiolabeled constructs was performed using NaI (Tl) well detector constructed by
AlphaSpectra Inc. (U.S.).
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3.2.3

synthesis and characterization

3.2.3.1

Synthesis of TZ intermediates and TZ final compounds

3.2.3.1.1

Synthesis of Fmoc-PEG2-Boc

Fmoc-PEG2-COOH (300 mg, 0.778 mmol) was dissolved in 10 mL DCM. To this was
added a solution of EDC (149 mg, 0.778 mmol) and NHS (99.0 mg, 0.86 mmol) in 10 mL DCM
followed by stirring for 2 h. To this mixture was added a solution of N-Boc-ethylenediamine
(124.64 mg, 0.778 mmol) in 10 mL DCM and followed by the addition of DIEA (273 µL, 1.56
mmol). The reaction mixture was stirred at room temperature. After 18 h, the mixture was
partitioned between DCM (100 mL) and diluted aqueous HCL (100 mL). The organic layer was
washed three times with water and dried over MgSO4. The organic solvent was evaporated under
vacuum and the product was purified by silica gel chromatography (1:4 ethyl acetate/hexane) to
afford Fmoc-PEG2-Boc as a white solid (291.2 mg, 0.552 mmol, 71.0% yield).
3.2.3.1.2

Synthesis of NH2-PEG2-Boc

Fmoc deprotection of Fmoc-PEG2-Boc (100 mg, 0.19 mmol) was carried out in 3 mL of
20% piperidine in DCM. After 20 min, the product was precipitated in cold ethyl ether, filtered,
and washed three times with ethyl ether to yield a white solid (48.82 mg, 0.16 mmol, 84.2%).
3.2.3.1.3

Synthesis of DOTA-PEG2-Boc

DOTA-NHS-ester (60.16 mg, 0.079 mmol) was dissolved in 300 µl anhydrous DMF. To
this solution was added drop-wise a solution of NH2-PEG2-Boc (20 mg, 0.066 mmol) in 300 µL
anhydrous DMF followed by the addition of DIEA (28.88 µL, 0.165 mmol). The reaction mixture
was stirred at room temperature for 18 h. The product was precipitated in cold ethyl ether and
purified by RP-HPLC/MS using an 88% to 80% gradient separation with solvents consisting of
solvent A (0.1% formic acid in DI water) and solvent B (0.1% formic acid in ACN) to afford a
white solid (34.56 mg, 0.05 mmol, 75.8%).
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3.2.3.1.4

Synthesis of DOTA-PEG2-NH2

DOTA-PEG2-NH2 was obtained by the removal of the Boc group from DOTA-PEG 2-Boc
(30 mg, 0.043 mmol) using 95% TFA in DCM solution. The mixture was stirred at room
temperature for 1 h. The product was precipitated in cold ethyl ether, filtered, washed three times
with ethyl ether to afford 21.9 mg (0.037 mmol, 86.1%) of the product.
3.2.3.1.5

Synthesis of DOTA-TZ probes

DOTA-PEG2-NH2 (10 mg, 0.017 mmol) was dissolved in 300 µL anhydrous DMF and a
solution of methyltetrazine-NHS ester (8.5 mg, 0.026 mmol) in 200 µL anhydrous DMF was added
followed by the addition of DIEA (7.4 µL, 0.042 mmol). The reaction mixture was stirred at room
temperature for 6 h. The crude product was precipitated in cold ethyl ether. The product was
purified by RP-HPLC/MS using 90% to 80% gradient separation (over 15 min time period) with
solvents consisting of solvent A (0.1% formic acid in DI water) and solvent B (0.1% formic acid
in ACN) to afford DOTA-TZ-1 as a pink solid (10.1 mg, 0.0126 mmol, 73.6%). DOTA-TZ-2 was
similarly synthesized using tetrazine-NHS ester (8.1 mg, 0.026 mmol) and purified by RPHPLC/MS using 92% to 82% gradient separation to afford a pink solid (9.3 mg, 0.0118 mmol,
69.4%).
3.2.3.2

Synthesis of TCO intermediates and TCO final compounds

3.2.3.2.1

Synthesis of Fmoc-D-Asp(OtBu)-NH-F3 and Fmoc-D-Asp(OH)-NH-F3

Fmoc-D-Asp(OtBu)-OH (500 mg, 1.215 mmol) was dissolved in 10 mL DCM and
solutions of EDC (233 mg, 1.215 mmol) in 5 mL DCM and NHS (154 mg, 1.34 mmol) in 5 mL
DCM was added, and the mixture was stirred for 2 h. A solution of 2,2,2-Trifluoroethylamine
hydrochloride (164.66 mg, 1.215 mmol) in 10 mL DCM was added followed by the addition of
DIEA (424 µL, 2.43 mmol). The reaction mixture was stirred at room temperature for 18 h then
partitioned between dilute aqueous HCL (100 mL) and DCM (100 mL). The organic layer was
washed three times with water (50 mL), dried over MgSO4, and evaporated under vacuum. The
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product was purified by silica gel chromatography (1:9 ethyl acetate/hexane) to afford Fmoc-DAsp(OtBu)-NH-F3 as a white solid (411 mg, 0.94 mmol, 71% yield).
The intermediate Fmoc-D-Asp(OtBu)-NH-F3 (350 mg, 0.82 mmol) was then added to a
solution consisting of 95:5 TFA/DCM (3 mL). After stirring for 2 h, the mixture was concentrated
under vacuum, diluted in DCM and loaded on a silica gel column using (1:1 ethyl acetate/hexane)
to afford Fmoc-D-Asp(OH)-NH-F3 as a white solid (310 mg, 0.71 mmol, 86.1%).
3.2.3.2.2

Synthesis of peptides

The synthesis of peptides (linker-B and linker-C) was performed using an automated solidphase peptide synthesizer on a Fmoc-Gly-Wang resin. Briefly, 164 mg (0.1 mmol) of the resin was
deprotected using 20% piperidine in DMF. Fmoc protected compounds (0.5 mmol) were coupled
to the growing peptide of the resin using COMU (0.5 mmol) and DIEA (1 mmol). The synthesized
peptide was cleaved from the resin using a cleavage cocktail (TFA/phenol/water/TIS (88/5/5/2)).
The cleaved product was precipitated in cold ethyl ether, filtered, and washed three times. The
crude peptide was dried, and the desired peptide was purified by RP-HPLC/MS. The synthesis and
characterization of Cat S-cleavable peptidic linker (Maleimide-PMGLPG)2K) (CL) was performed
according to our previously published report (117).
3.2.3.2.3

Synthesis of TCO

Photochemical synthesis of TCO was carried out according to a previously published
method with modifications (86). CCO (500 mg) and methyl benzoate (500 mg) was added to 250
mL solvent (Ether:Hexane = 9:1) in a 500 mL quartz reaction vessel. No attempt to degas the
solution was made. The vessel was irradiated with 254 nm light in a UV reactor (CL-1000
Ultraviolet Crosslinker, UVP) under constant stirring. At 30 min intervals, the irradiation was
stopped, and the entire solution was passed through a column packed with silver nitrate (10%)
impregnated silica. The solution that passes through was then transferred back into the quartz flask
and irradiation was continued. After ten rounds, the irradiation was stopped, and the silica was
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added to a solution of ammonium hydroxide and stirred for 5 min after which DCM was added and
stirring continued for another 5 min. The mixture was filtrated and the organic phase was separated
out, washed with brine and purified with chromatography (hexane/ethylacetate = 30:1/10:1) to give
250 mg TCO (50%) as a mixture of isomers, major and minor. No attempt was made to separate
the isomers at this step.
3.2.3.2.4

Synthesis of TCO-NO2

Synthesis of the title compounds was adapted from a previously reported synthesis (201).
Briefly, to a stirring solution of TCO (major and minor) (200 mg, 1.59 mmol) in DCM (50 mL)
was added pyridine (309 µL, 3.17 mmol). To this mixture, 4-nitrophenylchloroformate (480.8 mg,
2.38 mmol) dissolved in 10 mL DCM was added and was allowed to stir at room temperature for
1 h. The reaction was quenched by the addition of aqueous NH4Cl and the organic layer was
separated. The remaining aqueous layer was extracted twice with DCM and the combined organic
layers were dried over MgSO4 and concentrated under vacuum. Purification was performed by
using silica gel chromatography (1:200 ethyl acetate/hexane) to afford 301.1 mg of the combined
two compounds (1.034 mmol, 65%); TCO-NO2 major and TCO-NO2 minor were found to be in
66.2% and 33.8% yield of the total product, respectively.
3.2.3.2.5

Synthesis of TCO-B and TCO-C

Linker-B (16 mg, 0.028 mmol) was dissolved in 300 µL anhydrous DMSO, purged with
N2, and stirred. To this mixture a solution of TCO-NO2 major (12.24 mg, 0.042 mmol) in 200 µL
anhydrous DMSO under N2 was added dropwise. The reaction tube was capped, and the mixture
was stirred for 4 h. To the reaction mixture DI water (3 mL) was added and the resultant suspension
was spun down to remove the precipitate. The filtrate was lyophilized to provide the crude product.
The product (TCO-B) was purified by RP-HPLC/MS using a 65% to 58% gradient separation to
afford 11.4 mg (0.016 mmol, 56%) as a white solid. The solvent system consisted of 0.01% TFA
in DI water (solvent A) and 0.01% TFA in ACN (solvent B).
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Synthesis of TCO-C was similarly performed using linker-C (16 mg, 0.017 mmol) and
TCO-NO2 major (7.28 mg, 0.025 mmol). The product was purified by RP-HPLC/MS using a 75%
to 70% gradient separation, employing the same solvent system as previously described, to afford
10.1 mg (0.009 mmol, 52.9%) of the product as a white solid.
3.2.3.2.6

Synthesis of TCO-B-TFP and TCO-C-TFP

The synthesis of TCO-B-TFP and TCO-C-TFP was accomplished according to previously
reported literature procedures with minor modifications (202). Briefly, 7.2 µmol of TCO-B or
TCO-C was dissolved in anhydrous DMF (200 µL) and a solution of TFP (3.6 mg, 21.6 µmol) in
anhydrous DMF (100 µL) and DIC (3.6 µL, 21.6 µmol) was added and the reaction mixture was
allowed to stir for 6 h. The products were precipitated in cold ethyl ether, filtered, washed three
times with cold ethyl ether, and dried under vacuum to afford 5.1 mg (5.8 µmol, 80.6%) of TCOB-TFP and 7.5 mg (5.9 µmol, 82.0%) of TCO-C-TFP as white solids.
3.2.3.3

Synthesis of HPMA copolymers

3.2.3.3.1

Reversible addition-fragmentation chain transfer (RAFT) polymerization reactions

The synthesis of HPMA copolymers employing reversible addition-fragmentation chain
transfer (RAFT) polymerization was performed and modified following a previously published
paper (203). Three copolymers were synthesized and used as precursors, which included the noncleavable (NP-18, NP-82) and telechelic-block (BP-20) HPMA copolymers. The general procedure
for the synthesis of each copolymer includes dissolving HPMA, APMA, FITC-APMA, and DOTAt(Bu)-APMA monomers at a molar ratio of 88.5:10.0:0.5:1.0, respectively, in a dioxane/DI water
(2:1) solution. The total monomer amount was 0.5 mmol. To this mixture was added AIBN initiator
(7.7 µmol for NP-18 and BP-20, and 1.6 µmol for NP-82). A solution consisting of either 8.9 µmol
CTA-1 (for NP-18), 8.9 µmol CTA-2 (for BP-20), or 1.4 µmol CTA-1 (for NP-82) was also added
to keep the final volume 500 µL. The mixture was transferred into a glass ampule, purged with N 2
for 30 min, flame sealed, and stirred for 48 h at 50 °C. The mixture was cooled to room temperature
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and purified by a LH-20 column using methanol as an eluent to afford the desired copolymer as a
yellow solid. Measurement of molecular weights were performed by size exclusion
chromatography (SEC) using TDA-SEC.
3.2.3.3.2

Synthesis of deprotected block copolymer (d-BP-20)

The synthesis of d-BP-20 was performed over three steps, according to a published report
(117). First, to a solution of BP-20 (50 mg) in 1 mL methanol was added 100 µL of hexylamine
and the reaction was allowed to stir for 2 h at room temperature. The copolymer was then
precipitated in cold ethyl ether to afford a yellow solid. Next, the copolymer was dissolved in 1 mL
DI water followed by the addition of excess TCEP (100 times the molar equivalent to the initial
amount of BP). The mixture was stirred for 4 h at room temperature. The copolymer was purified
by a LH-20 column using methanol as an eluent to afford a yellow solid. Lastly, the copolymer was
dissolved in 2 mL of a 95:5 TFA/DCM solution and stirred at room temperature. After 1 h, the
solvent was evaporated by a N2 flow. The copolymer was redissolved in methanol and purified
using a LH-20 column to afford d-BP-20 as a yellow solid (41.2 mg, 82.4%).
3.2.3.3.3

Synthesis of multi-block HPMA copolymer (MP-90)

The Cat S-cleavable peptidic linker (CL) (5.1 mg, 3 µmol) was dissolved in methanol (100
µL) and added to a solution of d-BP-20 copolymer (36 mg) in 200 µL PBS (pH = 6.8). The mixture
was purged with N2 for 30 min and stirred for 48 h at 40 °C. The reaction mixture was filtered using
a 0.22 mm filter and fractionated using a HPLC equipped with an Asahipak GF-510 HQ column
(eluent = 40% ACN in PBS). The desired fraction was desalted (Amicon Ultra-4 centrifugal filter,
30 kDa) using DI water and evaporated under vacuum to afford MP-90 as a yellow solid (5.7 mg,
15.9 %).
3.2.3.4

TCO-polymer conjugations
The polymer-analogous reactions were performed according to the following general

procedure. The desired amount (4 mg) of the copolymer was dissolved in anhydrous DMSO
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followed by the addition of an anhydrous DMSO solution containing 4 µmol of either TCO-ANHS, TCO-B-TFP, or TCO-C-TFP to keep the final volume at 300 µL. The reaction mixture was
stirred at room temperature for 4 h. The reaction mixture was concentrated under N 2 and then
diluted with methanol. The product was purified using a LH-20 column and dried under vacuum to
afford a yellow solid.
The unreacted primary amines of APMA within NP-18-TCO-3, NP-18-TCO-3, and MP90-TCO-3 were capped with excess glycolic acid. Briefly, glycolic acid (1.5 mg, 19.8 µmol), EDC
(3.75 mg, 19.8 µmol), and NHS (2.52 mg, 21.8 µmol) were dissolved in DMSO (50 µL). The
reaction mixture was stirred at room temperature for 4 h. To this mixture was added a solution
containing DIEA (25 µmol) and the desired TCO-HPMA copolymer (3 mg, a portion of each TCOcopolymer was kept uncapped) in 100 µL DMSO. After 4 h, the reaction mixture was diluted with
DI water, and the TCO-HPMA copolymer was purified using an Amicon Ultra-4 centrifugal filter
(3 kDa). Quantification of the primary amine content after capping was evaluated using a Ninhydrin
assay according to our previously reported literature procedure (204). Unless otherwise indicated,
the uncapped portion of each of the TCO-HPMA copolymers was used for characterization ( 19FNMR, 1H-NMR, and molecular weight estimations) and kinetic studies. The capped portion was
used for in vitro Cat S cleavage and in vivo studies.
3.2.3.5

Synthesis of dextran polymer-tetrazine (DP-TZ)
The synthesis of dextran polymer-TZ (DP-TZ) was performed following a modified

literature procedure (89). Briefly, 8 mg (4 nmol) of dextran polymer-NH 2 (DP) was dissolved in
800 µL PBS (pH = 7.4) followed by the addition of 40 μL Na2CO3 (0.1 M). To this mixture a DMF
solution (20 µL) containing tetrazine-NHS (5.3 mg, 16.8 µmol) was slowly added. The reaction
mixture was incubated at room temperature with agitation (700 rpm) for 2 h. DI water (3 mL) was
added and the reaction mixture was spun down by centrifugation (15 s at 1000 g) to remove the
precipitates. The product (supernatant) was purified using an Amicon Ultra-4 centrifugal filter (100
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kDa) and afforded a pink solid. The content of TZ was characterized using UV/Vis spectroscopy,
based on a standard curve prepared for the absorbance of the tetrazine-NHS-ester (27 – 217 µM)
(solvent = 50% methanol in DI water) at 269 nm.

3.2.4

Radiolabeling of DOTA-TZ probes and TCO-HPMA copolymers
The DOTA-TZ probes were radiolabeled by dissolving 25 µg of the desired probe in an

ammonium acetate buffer (0.5 M, 100 µL, pH = 5.5) and adding 3.7 MBq (100 µCi) of 177LuCl3 to
the solution. The mixture was heated for 65 °C. After 30 mins, 4-6 mg of CoCl 2 was added, and the
mixture continued stirring at 65 °C for an additional 5 min. The radiolabeled DOTA-TZ probe was
purified using a radio-HPLC with solvent gradient methods similar to the procedure used in the
synthesis of the DOTA-TZ probes. The radiolabeled DOTA-TZ probes were concentrated using N 2
flow before any further studies. The natLu-DOTA-TZ probes were similarly prepared using natLuCl3
and purified by RP-HPLC/LC.
Radiolabeling of TCO-HPMA copolymers were performed by dissolving 100 µg of the
desired compound in 100 µL DI water and followed by the addition of 3.7 MBq (100 µCi) of
177

LuCl3 or 111InCl3. The mixture was heated at 65 °C for 30 min. A radio-SEC-HPLC, equipped

with an Asahipak GF-510 HQ column, Bioscan flow count radiometric detector, and a Waters 2489
UV detector (λ = 494 nm), was used to identify and purify the radiolabeled copolymers. The
purified radiolabeled copolymers were buffer exchanged in PBS and concentrated using an Amicon
Ultra-4 centrifugal filter (3 kDa) before continuing on to any further studies.

3.2.5

Kinetic studies
Kinetic studies were performed between the DOTA-TZ-probes and either the TCO-

linkers (TCO-B and TCO-C) or the desired TCO-HPMA copolymers in pseudo-first order
conditions (92). The reaction between a DOTA-TZ probe (DOTA-TZ-1 or DOTA-TZ-2) and a
TCO-linker was monitored using radio-HPLC. Briefly, a

177

Lu-DOTA-TZ probe in PBS was
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mixed with a known amount of natLu-DOTA-TZ probe (to make 0.5 µM) in PBS and incubated at
37 °C. To this mixture was added a solution of a TCO-molecule (2 or 4 μM) in PBS to keep a final
volume of 800 µL and a radioactivity concentration of 0.74 MBq (20 μCi) per 50 µL. At the desired
time point, 50 µL of the reaction mixture was pipetted out and quenched immediately with the
corresponding DOTA-TZ-NHS ester (100 folds greater than the DOTA-TZ probe concentration)
dissolved in 50 µL ACN. At the end of the last time point, each fraction was injected into the radioHPLC (85% to 65% gradient separation over 15-min run using 0.1% formic acid in DI water and
0.1% formic acid in ACN for solvents A and B, respectively) to obtain the corresponding radiochromatogram. The integrations of formed radioactive peaks (products) were divided by the total
value for the integrations of starting and formed radioactive peaks to obtain the reaction yield (%).

Additional kinetic studies with the DOTA-TZ probes (DOTA-TZ 1 or DOTA-TZ 2)
reacted with the desired TCO-HPMA copolymers were performed. Briefly, the

177

Lu-DOTA-TZ

probe in PBS was mixed with a known amount of natLu-DOTA-TZ probe in PBS (to make 0.5 µM)
and incubated at 37 °C. To this mixture was added a solution of the desired TCO-HPMA copolymer
in PBS to achieve a final volume of 800 µL with a radioactivity concentration of 100,000 cpm/50
µL. At each time point, a 50 µL aliquot of the reaction mixture was removed and immediately
quenched with an excess (100 X) amount of the corresponding DOTA-TZ-NHS ester dissolved in
50 µL ACN. The copolymer was then purified using an Amicon Ultra-4 centrifugal filter (3 kDa).
The radioactivity bound to the copolymer was measured using a gamma counter. All kinetic studies
were performed in duplicates.

The pseudo first-order rate constant (kobs) was estimated for each IEDDA reaction
between the DOTA-TZ probe and TCO by fitting the reaction yields with time to the one-phase
association model using Graphpad PRISM 7 (U.S.). The second order rate constant (K 2) was
calculated by dividing the Kobs over the TCO concentration (87).
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3.2.6

In vitro cleavage of multi-block HPMA copolymer
The in vitro cleavage studies using the Cat S enzyme was conducted for the desired HPMA

copolymer according to our previously published paper (120). Briefly, the desired copolymer was
added to 250 µL of the cleavage buffer containing sodium acetate (50 mM), DTT (10 mM), and
EDTA (1 mM) to keep a concentration of 1 mg/mL. To this solution was added human cath S
enzyme (2.50 µg/mL) and incubated at 37 °C. At the desired time point, a 50 µL aliquot of the
mixture was pipetted out and mixed with 50 μL of SEC eluent (40% ACN in PBS). The 100 μL of
sample was injected into a SEC-HPLC (equipped with an Asahipak GF-510 HQ column and Waters
2489 UV detector (λ = 494 nm)) to identify the intact and cleaved copolymers.

3.2.7

Cell culture
Ovarian cancer (OVCAR-3) cells were obtained from American Type Culture Collection

(ATCC). The cells were cultured in our laboratory, as per ATCC protocol, in RPMI-1640 medium
containing 20% FBS, 2 mM L-glutamine, 10 mM HEPES, 1 mM sodium pyruvate, and 0.01 mg/ml
bovine insulin. Cells were incubated at 37 °C at 5% CO2.

3.2.8

Biodistribution and in vivo DOTA-TZ-TCO reactivity (single- and dualradioisotope experiments)

3.2.8.1

Biodistribution in a CF-1 mouse model (single-radioisotope experiment)
The biodistribution of the desired copolymer was investigated in CF-1 mice (Charles River,

U.S.) weighing ~ 27 g. The mice (5 mice per group) were injected with the desired

177

Lu-TCO-

HPMA copolymer (10 µCi, 0.37 MBq) in 100 μL PBS. The mice were sacrificed after 72 h. Their
tissues were excised and weighed.
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3.2.8.2

Biodistribution and in vivo DOTA-TZ-TCO reactivity in ovarian-cancer models (dualradioisotope experiments)
Four-week old female NOD-SCID mice (Jackson Laboratory, U.S.) were injected

subcutaneously with 100 μL OVCAR-3 cells (5 × 106) suspended in Matrigel® into the flanks.
Tumor growth was regularly monitored until it reached ~ 50 mm 3. The mice (weighing ~ 18 g)
were then randomly allocated into three groups (5 mice per group). The groups were intravenously
injected with 100 μL PBS containing the desired non-radiolabeled TCO-HPMA copolymers (TCO
content ~ 23 nmol) premixed with the corresponding 111In-radiolabeled copolymer (0.37 MBq, 10
μCi). After three days, all the mice were injected with 100 μL PBS containing 0.37 MBq (10 μCi)
of

177

Lu-DOTA-TZ-2. After 4 h, the mice were sacrificed, and their tissues were excised and

weighed. A similar study was also conducted in ovarian tumor bearing-NOD-SCID mice to
evaluate the biodistribution of

177

Lu-DOTA-TZ-2 (after 4 h of injection) in one group using a

single-radioisotope experiment. Additionally, the biodistribution and in vivo TCO/TZ reactivity of
uncapped NP-82-TCO-C was performed in another group using a dual-radioisotope experiment.
Another ovarian cancer model was similarly developed in female SCID mice
(Charles River, U.S.). The mice were (weighing ~ 18 g) then separated into three groups (5 mice
per group) and injected with the desired amount of non-radiolabeled TCO-HPMA copolymer (TCO
content = 23 nmol) premixed with the corresponding 111In-radiolabeled copolymer (0.37 MBq, 10
μCi). After three days, the mice from one group were injected with 100 µL PBS containing DP-TZ
(TZ content = 60 nmol). The other two groups were injected with 100 µL PBS (no DP-TZ). After
30 mins, all mice were injected intravenously with 100 μL PBS containing 0.37 MBq (10 μCi) of
177

Lu-DOTA-TZ-2. The mice were sacrificed after 4 h later, and their tissues were excised and

weighed.
All the injections performed with mice were via tail veins. The tissue radioactivity in all
the included mice was measured using a gamma counter. The signal of each radioisotope was
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identified based on the corresponding energy level. Data are expressed in terms of %ID/g of tissue
per each radioisotope.

3.2.9

Statistics
Statistical analyses were performed using a two-tailed unpaired Student's t-test (two

groups) or one-way ANOVA (more than two groups) with Bonferroni post-tests. A value of p <
0.05 was considered statistically significant.

3.3 Results and discussion
The off-target retention of radiolabeled nanomedicines (e.g., HPMA copolymers)
developed for cancer imaging and therapy is a major obstacle. Our previous reports showed that
the large (≥ 80 kDa) multi-block radiolabeled HPMA copolymers synthesized by linking multiple
polymeric chains using a Cat S-cleavable linker (CL) are cleared from the off-target tissues (e.g.,
liver, spleen, blood) at a faster rate relative to HPMA copolymers of the same size with no CL. We
aimed to combine this approach with the pretargeted approach (TCO/TZ bioorthogonal chemistry)
to improve radiolabeled HPMA copolymer's toxicity profiles further. We first optimized the
TCO/TZ reaction by modulating the TCO-linker (used for linking TCO with the HPMA copolymer)
and the TZ type (tetrazine versus methyltetrzaine) by conducting kinetic studies. The optimized
TCO-linker was used to synthesize a cathepsin S cleavable TCO-HPMA copolymer (> 100 kDa).
We investigated its biodistribution and in vivo TCO/TZ chemistry profiles in a normal and two
ovarian-cancer mice models.

3.3.1

Synthesis and characterization of TCO-linkers
As will be discussed later, TCO was incorporated into the copolymer post-polymerization.

Three TCO-linkers (TCO-A, TCO-B and TCO-C) of varying length were synthesized to examine
the impact linker length had in the IEDDA reaction kinetics (Figure 3.1). TCO-A (TCO-PEG 4NHS) was purchased from commercial source while the amine-reactive TCO-B (TCO-PEG 4-
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(D)Asp(NH-F3)-Gly-Gly-TFP) and the amine-reactive TCO-C (TCO-PEG4-(D)Gln-(D)Gln(D)Gln-(D)Asp(NH-F3)-Gly-Gly-TFP) were synthesized in our laboratory. The synthesis of the
TCO-B and TCO-C is described below.

TCO was synthesized by photoisomerization of the cis-cyclooctene (CCO) to yield two
stereoisomers designated as the major (equatorial hydroxy) and minor (axial hydroxy) TCO product
(Figure 3.1). The isomeric mixture was reacted with 4-nitrophenylchloroformate to give the
carbonate intermediates named TCO-NO2 major and TCO-NO2 minor which were subsequently
separated and purified by silica gel chromatography. In this proof of concept study, only the TCO
major was used due to the significantly larger yield relative to TCO minor. Future studies may be
needed to determine the reaction kineteics using TCO major versus TCO minor. Linkers B (PEG 4(D)Asp(NH-F3)-Gly-Gly) and C (PEG4-(D)Gln-(D)Gln-(D)Gln-(D)Asp(NH-F3)-Gly-Gly) were
synthesized by SPPS and purified by RP-HPLC. The amino acid derivative (D)Asp(NH-F 3) was
prepared by reaction of Fmoc-(D)Asp-(OtBu) with 2,2,2-trifluoroethylamine hydrochloride
followed by deprotection and purification. The (D)Asp(NH-F3) was incorporated into the TCOlinkers to allow for quantification of the TCO-linker incorporation into the polymeric constructs
using 19F-NMR. The deprotected peptides were subsequently reacted with the major TCO-NO 2
isomer to achieve the desired peptides, TCO-B and TCO-C. The TFP functionalized active esters
of these peptides, TCO-B-FTP and TCO-C-FTP, were prepared using the DIC coupling agent. The
1

H-NMR, 13C-NMR and mass spectrums for the intermediates and final products for TCO-B-TFP

and TCO-C-TFP are shown in Figure 3.2-3.5.
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A

B

Figure 3.1 Synthesis and structures of TCO-linkers. Synthesis of TCO-B-TFP and TCO-C-TFP is
shown in (A). The structures of the commercially purchased (TCO-A-NHS) and the synthesized
TCO-B-TFP and TCO-C-TFPA is shown in (B).
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Figure 3.2 1H-NMR and 13C-NMR spectra of CCO (A), TCO major (B), and TCO minor (C).
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Figure 3.3 1H-NMR (A), 19F-NMR (B), and MS (C) spectra of Fmoc-D-Asp(OtBu)-NH-F3 and
MS spectrum of Fmoc-D-Asp(OH)-NH-F3 (D).
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Figure 3.4 MS spectra of linker-B (A) and TCO-B (B).

96

Figure 3.5 MS spectra of linker-C (A), TCO-C (B), and TCO-C-TFP (C) and 19F-NMR spectrum
of TCO-C (D).
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3.3.2

Synthesis and characterization of the DOTA-TZ “chaser” agents

The synthesis of the DOTA-TZ probes were carried out in a five-step synthetic process outlined
in Figure 3.6. Starting from Fmoc-PEG2-COOH, N-Boc-ethylenediamine (EDA) was coupled to
the C-terminus using DIC/NHS/DIEA. The Fmoc-PEG2-EDA-N-Boc was treated with piperidine
to yield the Fmoc-deprotected primary amine which was subsequently reacted with DOTA-NHS
to yield DOTA-PEG2-EDA-N-Boc. The N-Boc was removed by treatments with TFA followed
by reaction of the resulting primary amine with the methyltetrazine-NHS ester or tetrazine-NHS
ester to give DOTA-TZ 1 or DOTA-TZ 2, respectively. Tetrazine has been reported to have faster
reaction kinetics relative to methyltetrazine, but methyltetrazine has a higher stability under
physiologic conditions (194, 205, 206). These two tetrazine analogs where chosen to compare and
contrast how these factors affect in vitro and in vivo performance. The 1H-NMR, 13C-NMR and
mass spectrums for the intermediates and DOTA-TZ 1 or DOTA-TZ 2 are shown in Figure 3.73.9.
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Figure 3.6 Synthesis of DTOA-TZ probes
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Figure 3.7 Profiles of intermediates for the synthesis of DOTA-TZ probes.
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Figure 3.8 1H-NMR (A) and MS (B) spectra of DOTA-TZ 1 and MS spectrum of natLu-TZ 1.
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Figure 3.9 1H-NMR (A), MS (B), 13C-NMR (C) spectra of DOTA-TZ 2 and MS spectrum of natLuDOTA-TZ 2.
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3.3.3

Synthesis and characterization of non-cleavable of TCO-incorporated HPMA
copolymers
To examine the impact polymer molecular weight has on IEDDA conjugation efficacy, a

small (NP-18) and large (NP-82) non-cleavable HPMA copolymer were prepared by RAFT
polymerization (Figure 3.10). Each polymerization included HPMA, APMA, DOTA-t(Bu) 3APMA, and FITC-APMA monomers at a 88.5:10:1:0.5 molar ratio. The APMA is included in the
copolymer for eventual post-polymerization TCO incorporation. DOTA-t(Bu) 3-APMA and FITCAPMA monomers are added to the copolymer for radiolabeling and to assist in
visualization/detection of the HPMA copolymer during purification and characterization,
respectively. The polymerization reaction was initiated using AIBN and carried out in the presence
of the commercially available chain transfer agent CTA-1. The ratio of AIBN and CTA-1 relative
to total monomer concentrations were adjusted to synthesize the desired small and large HPMA
copolymers. The resulting copolymers were deprotected with TFA, purified and characterized to
yield molecular weights of 18.3 and 82.1 kDa, correspondingly, for NP-18 and NP-82. The
characteristics of the copolymers including molecular weight, dispersity, yield and monomeric
content is outlined in Table 3.1.
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A

B

Figure 3.10 Schematic representations for the synthesis of non-cleavable (A) and cleavable (B)
TCO-HPMA copolymers. Capping was only performed for selected TCO-HPMA copolymers
(NP-18-TCO-C, NP-82-TCO-C, and MP-90-TCO-C).
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Table 3.1 Characteristics of TCO-HPMA copolymers and their polymeric precursors

a

copolymers

MWd
(kDa)

Ðd

APMAe
(mol.%)

DOTAe
(mol.%)

FITCf
(mol.%)

RAFT polymerization
yield (%)

TCO content (µmol / mg)h /
average number of TCO per
copolymer chain

NP-18a

18.3

1.07

9.2

0.53

0.32

76.8

0

NP-82b

82.1

1.08

9.1

0.48

0.20

82.1

0

BP-20c

20.2

1.10

8.5

0.62

0.29

79.0

0

MP-90

89.8

1.17

0

NP-18-TCO-C

22.7

1.10

0.262 / 6.4

NP-82-TCO-A

93.7

1.12

0.382e / 35.8

NP-82-TCO-B

100.5

1.10

0.257 / 25.8

NP-82-TCO-C

101.3

1.11

0.231 / 24.6

MP-90-TCO-C

108.7

1.20

0.208 / 23.6

Intermediate copolymer for the synthesis of NP-18-TCO-C
b
Intermediate copolymer for the synthesis of NP-82-TCO-A, NP-82-TCO-B, and NP-82-TCO-C
c
Intermediate copolymer for the synthesis of MP-90, which was used for the synthesis of MP-90-TCO-C
d
Estimated by gel permeation chromatography
e
Determined by 1H-NMR
h
Determined by 19F-NMR
f
Determined by UV/Vis spectrophotometry
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To examine the impact of linker length on the IEDDA kinetics, the previously described
TCO-linkers (TCO-A-NHS, TCO-B-TFP, and TCO-C-TFP) were conjugated to the primary
amines of the APMA contained within NP-82. This yielded the corresponding TCO-incorporated
copolymers, NP-82-TCO-A, NP-82-TCO-B and NP-82-TCO-C. For examining the impact of
copolymer molecular weight on the IEDDA reaction, TCO-C-TFP was similarly coupled to NP-18
under identical conditions to give the NP-18-TCO-C. The TCO content on the copolymers was
characterized by 1H- or

19

F-NMR, exemplar NMR spectrums are given in Figure 3.11. The

characteristics of the TCO-incorporated copolymers including molecular weight, dispersity and
TCO content is outlined in Table 3.1. For the larger copolymers, the estimated number of TCO
units per polymer was in the range of 23.6 – 35.8 TCO units per polymer chain with molecular
weights ranging from 93.7 to 108.7 kDa. NP-18-TCO-C exhibited a molecular weight of 22.7 kDa
and contained an average of 6.4 TCO moieties per polymer chain.
Excessive positive charge has been shown to lower the circulation time and increase the
MPS-associated sequestration of HPMA copolymers (110, 111, 203). Prior to all in vitro Cat S
cleavage and in vivo experiments, the remaining primary amines of the APMA moieties (i.e., not
coupled to TCO-linkers) were neutralized (i.e., capped) by reacting with glycolic acid that was
activated by EDC/NHS. The capping yields were high (> 85%) for all of the TCO-incorporated
copolymers, as estimated by ninhydrin assay.
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A

NP-82

B

NaBF4

NP-82-TCO-A
TCO-C
TFA
TFP

Figure 3.11 1H-NMR spectra of NP-82 (A top) and NP-TCO-A (A bottom), and 19F-NMR of NPTCO-C (B).
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3.3.4

Synthesis and characterization of Cat S-degradable, TCO-incorporated HPMA
copolymers
The synthesis of the Cat S-degradable, TCO-incorporated HPMA copolymer is largely

analogous to our original report (117). To synthesis the desired Cat S-degradable HPMA
copolymer, a chain transfer agent CTA-2 was synthesized that gives protected thiol on both
terminal ends (Figure 3.12A). Using CTA-2, a small HPMA copolymer was made by RAFT
polymerization, similar to procedures outlined above, to yield a 20.2 kDa telechelic-block
copolymer (BP-20) with protected thiols at the terminal ends (Figure 3.10B). The thiols groups of
the BP-20 copolymer were deprotected using hexylamine and TCEP. This was followed by
treatment with TFA to remove the t-Bu groups from the incorporated DOTA chelators to give the
deprotected BP-20 (d-BP-20). A maleimide-containing Cat S susceptible linker (CL – (MaleimidePMGLPG)2K) was prepared according to our previous report (Figure 3.12B) (117). Using thiolene click chemistry, the combination of the thiol containing d-BP-20 and the maleimide
functionalized CL resulted in a condensation reaction to form an extended multi-block copolymer.
This multi-block copolymer was fractionated by SEC (Figure 3.13A) to obtain predominantly
trimers and higher-order multimers with a molecular weight of 89.8 kDa (Ð = 1.17). Parallel to the
procedure outlined above, TCO-C-TFP was incorporated into MP-90 post-polymerization to yield
MP-90-TCO-C with a molecular weight of 108.7 kDa and a TCO-incorporation density of 23.6
units per polymer chain. The characteristics of the Cat S-degradable, TCO-incorporated HPMA
copolymer including molecular weight, dispersity and TCO content is outlined in Table 3.1. Similar
to the above, glycolic acid capping of the primary amines of MP-90-TCO-C was performing prior
to in vitro Cat S cleavage and in vivo biodistribution studies.
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Figure 3.12 Synthesis and MS spectrum of CTA 2 (A) and MS spectrum of Cat S cleavable peptidic
linker (CL) (B).

109
Dimer

A

MP-90

Monomer with linkers
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d-BP
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MP-90
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MP-90-TCO-C
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1 hr
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Figure 3.13 SEC-HPLC chromatograms of MP-90 and MP-90-TCO. Chromatograms of d-BP
before and after extension with CL (A). Chromatograms of MP-90 and MP-90-TCO-C after
incubation with Cat S enzyme (over 24 h) (B). The X-axis represents the absorbance at 494 nm,
and Y-axis represents the elution time in min.
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3.3.5

Synthesis and characterization of dextran polymer blood masking agent
Excessive amounts of TCO-incorporated copolymer could sequester the tetrazine chaser

agent prior to the chaser agent reaching the tumor. It has been demonstrated that the administration
of nanomedicine constructs functionalized with tetrazine can mask/inactive TCO in circulation
prior to introduction of the chaser agent thereby substantially reducing blood associated retention.
As part of our investigation, a dextran polymer (DP) functionalized with tetrazine was prepared
(Figure 3.14), as previously described (89), and used as a masking agent in our in vivo
biodistribution studies. The starting DP molecular weight was approximately 2000 kDa and after
functionalization contained 644 tetrazine units per DP.
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Figure 3.14 Synthesis of DP-TZ.
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3.3.6

Radiolabeling of DOTA-TZ probes and TCO-HPMA copolymers
The radiolabeling of DOTA-TZ probes was accomplished by incubation with

177

LuCl3 in

an ammonium acetate buffer (pH = 5.5) at 65 °C for 30 min. The yields of radiolabeling were very
high (> 90%) for both probes. The radiolabeling of TCO-HPMA copolymers was also performed
using similar conditions with the exception of using DI water instead of ammonium acetate buffer.
Depending on the desired experiment, 177LuCl3 or 111InCl3 was used for the radiolabeling of TCOHPMA copolymers. The radiolabeling yields for those copolymers were low to moderate (≈ 20 –
40%).

3.3.7

In vitro cleavage of multi-block HPMA copolymers (MP-90 and MP-90-TCO-C)
To examine the impact TCO incorporation has on the rate of multi-block copolymers

degradation by CatS, MP-90 and capped MP-90-TCO-C were incubated over a 24 h period with
Cat S at 37 °C. At specified intervals an aliquot from each mixture was analyzed by SEC to examine
the rate of Cat S degradation (Figure 3.13B). The degradation profiles showed a slightly slower
cleavage rate over the initial 4 h for the TCO-incorporated copolymer versus vs the unmodified
copolymer. Nevertheless, complete Cat S-cleavage is achieved for both polymers by 8 h of
incubation. These results indicate that the capped MP-90-TCO-C is indeed susceptible to cleavage
by the Cat S protease.
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3.3.8

Kinetics studies
Kinetic studies were performed using the unincorporated TCO-B and TCO-C linkers in

order to demonstrate their ability to undergo rapid IEDDA reactions as well as to eventually
compare the small molecule (i.e., TCO-linker not incorporated into copolymer) vs. the
macromolecule (TCO-linker incorporated into copolymer) reaction kinetics Table 3.2. Due to
TCO-A being a commercially validated linker, the kinetics of this unincorporated linker were not
explored. Using the

177

Lu-DOTA-TZ 1, the chaser agent (0.5 µM) was incubated with the TCO-

linkers (4 µM) in PBS at 37 °C. Analysis of the reaction was performed by taking aliquots of the
solution, quenching the unreacted TCO using excess of an unlabeled TZ and analyzed by radioRP-HPLC (Figure 3.15Error! Reference source not found.). For both the TCO-B and TCO-C
linkers, the reaction conditions resulted in more than 95% of the 177Lu-DOTA-TZ-1 reacting within
30 min and K2 rate constants of 373 ± 54 and 333 ± 12 M-1 S-1 (p > 0.05), respectively. The tetrazine
moiety utilized in 177Lu-DOTA-TZ 2 is known to exhibit higher rate constants compared to

177

Lu-

DOTA-TZ 1 (205). Using 177Lu-DOTA-TZ 2 (0.5 µM), the IEDDA reaction yield with the TCOC linker (2 µM) was already more than 95% complete after only 3 min with a K 2 rate constant of
9745 ± 742 M-1 S-1. It is worth noting that multiple peaks are observed as reaction products in the
chromatograms for the radio-HPLC analyses (Figure 3.15). RP-HPLC/MS analysis was performed
to confirm these peaks, dihydropyridazine isomers (15.8 and 17.0 min) and a pyridazine
rearrangement product (10.0 min), are the result of the IEDDA reaction (Figure 3.16) (207).
Next, the IEEDA reaction kinetics of the non-capped TCO-incorporated HPMA
copolymers were investigated. The noted concentrations for TCO-incorporated copolymer are
based on the TCO content of the copolymer and not the copolymer concentrations in order to allow
for easy comparison with the reaction kinetics of the unincorporated TCO-linkers. Using the 177LuDOTA-TZ-1, the chaser agent (0.5 µM) was incubated with NP-82-TCO-A, NP-82-TCO-B and
NP-82-TCO-C (4 µM based on TCO content) in PBS at 37 °C. Separation of the unreacted DOTA-
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TZ probe from the reaction mixture was performed using centrifugal filter (3 kDa). The
radioactivity for each sample was measured by gamma counter (in cpm unit) (Figure 3.15CError!
Reference source not found.). The rate constants, maximum observed reaction yield and time to
reach maximum yield are listed in Table 3.2. The maximum reaction yields for the copolymers
never reached higher than 30% over the 60 min study. This suggested to us that much of the TCO
content of the ~100 kDa copolymers is sterically inaccessible to the 177Lu-DOTA-TZ-1 chaser agent
(208). To account for this, the rate constants are given in Table 3.2 that do and do not consider the
observed reaction plateau as a complete IEDDA reaction. The K2 value for each reaction was
estimated by fitting the data two times in the one-phase association model by adjusting the plateau
parameter value at each time. This parameter was not constrained in the first time to estimate the
K2 value based on the accessible TCO within the copolymers. The plateau of the generated best-fit
curve using this method represents the maximum observed reaction yield for each TCO/TZ
reaction. Estimating the K2 value using this method would only take into account the accessible
(reacted) TCO. In the second time, the plateau parameter was constrained to a value 100, which
represents the maximum theoretical reaction yield (100%). NP-82-TCO-C, which contains the
longest linker, exhibited the highest reaction yield and a competitive rate constant. Due to this,
moving forward, only the HPMA copolymers utilizing the TCO-C linker were investigated.

To examine the impact of the molecular weight of the polymer on the IEDDA reaction,
177

Lu-DOTA-TZ-2 (0.5 µM) was reacted with the NP-18-TCO-C and NP-82-TCO-C copolymers

(2 µM). The reaction with NP-82-TCO-C plateaued after 5 min suggesting, as mentioned above,
that all of the easily accessible TCOs on the surface of the copolymer had undergone reaction. For
the NP-18-TCO-C copolymer, the IEDDA reaction proceeded to nearly 90% over the course of 30
min. This indicates that the lower molecular weight reduces steric hindrance and increases TCO
accessibility to the 177Lu-DOTA-TZ 2 chaser agent. The rates constant for the smaller NP-18-TCOC (556 ± 47 M−1s−1) was nearly an order of magnitude higher than NP-82-TCO-C ( 67.9 ± 8.5
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M−1s−1). Lastly, the reaction kinetics of MP-90-TCO-C with

177

Lu-DOTA-TZ 2 was also

investigated and found to statistically identical rate constants and reaction yields compared to the
NP-82-TCO-C. This suggests that the Cat S-degradable peptides does not influence the IEDDA
reaction. However, based on the faster reaction kinetics and higher reaction yields of the NP-18TCO-C outlined above, reaction kinetics of MP-90-TCO-C would be expected to increase upon
fragmentation to smaller TCO-containing copolymer blocks.
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Table 3.2 The characteristics of kinetic studies for the reactions between TCO-compounds and
DOTA-TZ probes
TCOa

Type of
DOTA-TZ
probe

Kob ⅹ 105 (s−1)b

K2 (M−1 s−1)b

Kob ⅹ 105 (s−1)c

K2 (M−1 s−1)c

TCO-B

1

149 ± 22

373 ± 54

> 95%

Maximum
reaction yield
reached at X
(min)
30

TCO-C

1

133 ± 5

333 ± 12

> 95%

30

TCO-C

2

1949 ± 148

9745 ± 742

> 95%

3

NP-82-TCO-A

1

8.1 ± 0.3

20.3 ± 0.8

31.9 ± 9.9

79.7 ± 24.8

24 %

60

NP-82-TCO-B

1

3.8 ± 0.3

9.6 ± 0.7

47.6 ± 5.6

119 ± 13

12 %

60

NP-82-TCO-C

1

10.0 ± 2.0

24.9 ± 4.9

28.6 ± 4.3

71.4 ± 10.7

30 %

60

NP-18-TCO-C

2

111.2 ± 9.4

556 ± 47

89.0 ± 10.1

445 ± 50

90%

30

Maximum
reaction
yield

NP-82-TCO-C
2
13.6 ± 1.7
67.9 ± 8.5
807 ± 69
4036 ± 346
~15%
5
MP-90-TCO-C
2
12.6 ± 1.7
63.0 ± 8.5
838 ± 189
4190 ± 946
~15%
5
a
TCO concentration was 4 µM and 2 µM when DOTA-TZ-1 and DOTA-TZ-2, respectively, were utilized
b
Data fitted in one-phase association model with two constrains (Y0 = 0, Plateau = 100) to obtain the observed first-order rate constants (K ob), which were
utilized for calculating the corresponding estimated the second-order rate constants (K 2)
c
Data fitted in one-phase association model with one constrain (Y0 = 0) to obtain K ob values, which were utilized for calculating the corresponding
estimated K2 values
All the TCO-HPMA copolymers used in the kinetic studies are non-capped.
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177Lu-DOTA-TZ

A

1

t = 0 min
TCO / TZ products

t = 1 min
t = 5 min
t = 15 min
t = 30 min
t = 60 min

B

177Lu-DOTA-TZ

2

t = 0 min
TCO / TZ products

t = 20 s
t = 40 s
t = 60 s
t = 120 s
t = 180 s

C

*

***

*

Figure 3.15 Radio-HPLC chromatograms for the reactions between TCO-C and 177Lu-DOTA-T
1(A) and 177Lu-DOTA-TZ 2 (B), and profiles of kinetic studies between DOTA-TZ probes and
TCO-linkers / TCO-HPMA copolymers (C). All studies were performed in PBS at 37 ºC. All TCOHPMA copolymers used for the kinetic studies are non-capped. Data expressed as mean ± SD. *
Indicates significance at p < 0.05. *** Indicates significance at p < 0.001.
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Figure 3.16 LC/MS profile for the reaction between TCO-C and DOTA-TZ 1. The spectrum for a
28-min run (washing phase began at t = 15 min) using gradient separation (90 - 75%) is shown in
(A). The molecular weights (M+1) for each of the three new formed peaks due to the TCO/TZ
reaction are shown in (B). The spectrum of TCO-C without DOTA-TZ 1 is shown in (C) using a
different gradient (75 – 68%).
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3.3.9

Stability of the 177Lu-DOTS-TZs in human serum
In order to better understand the potential in vivo stability of the 177Lu-DOTA-TZ analogs,

the in vitro serum stability of

177

Lu-DOTA-TZ 1 and

177

Lu-DOTA-TZ 2 in human serum was

examined over 4 h at 37 °C. At the 0 and 4 h timepoints, an aliquot of each sample was analyzed
by the radio-RP-HPLC. As expected,

177

Lu-DOTA-TZ 1, which contains the methyltetrazine,

exhibited less degradation (~ 89.0) than 177Lu-DOTA-TZ 2 (~ 74.5%) (205). Based on the results
from the kinetic and stability studies,

177

Lu-DOTA-TZ 2, with its substantially higher IEDDA

reaction rate constant and good serum stability, was selected for utilization in all in vivo
experiments.
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3.3.10 In vivo Studies
It is known that the large HPMA copolymers (> 50 kDa) circulate for longer times than the
smaller copolymers (< 50 kDa), and therefore the large HPMA copolymers show greater tumor
accumulations (97, 100). However, the long circulation times of these copolymers lead to greater
retentions in the MPS-associated tissues (e.g., liver and spleen) (55, 209). These retentions are
considered a major obstacle against the clinical translation of radiolabeled HPMA copolymers (and
nanomedicines in general) for radioimaging and radiotherapy of cancer. Previously, our lab
developed a strategy to improve the SPECT imaging of pancreatic cancer based on developing
large radiolabeled HPMA copolymers (MW ≈ 80 kDa) that can be cleaved by Cat S at the nontarget tissues into smaller fragments, which leads to their clearance from these tissues and
eventually from the body (117). The strategy is based on the extension of the small single-block
HPMA copolymer (MW ≈ 18 kDa) with a Cat S susceptible linker (CL) to afford a larger multiblock HPMA copolymer (MW ≈ 80 kDa). The biodistribution profile of the radiolabeled multiblock HPMA copolymer had similar tumor accumulation (in a pancreatic cancer model) with
reduced retentions in the non-target tissues (e.g., liver, spleen, and blood) relative to HPMA
copolymers of the same molecular weights but with no CL. The results showed improved SPECT
imaging of pancreatic cancer when using the radiolabeled cat S cleavable multi-block HPMA
copolymer relative to the non-cleavable HPMA copolymers. These results encouraged us to
combine this strategy with an already established pretargeting strategy (in vivo TCO/TZ
bioorthogonal reaction) that has been shown to improve the tumor to normal tissues (T/NT) ratios
of the radiolabeled antibodies/nanomedicines (90, 192, 206, 210). Instead of injecting already
radiolabeled antibody/nanomedicine, TCO-modified antibody/nanomedicine is first injected, and
the necessary time (e.g., 2 – 3 days) is allowed for the construct to accumulate in the tumor tissues.
Then, a radiolabeled TZ probe "chaser agent" is injected to react (ultra-fast reaction rates suitable
for radiotracer level) with the already accumulated TCO-modified antibody/nanomedicine at the

121
tumor tissues to form irreversible covalent bond formation and reside for a long time. The unreacted
TZ probe is rapidly excreted from the body with a plasma half-life is in minutes (88).
The feasibility of this approach is dependent on several factors, including efficient tumor
accumulation of the TCO-modified construct and its clearance from the non-target tissues (mainly
the blood). Unfortunately, injecting the TZ probe in the presence of the TCO-modified construct's
traces level can cause a significant premature in vivo TCO/TZ reaction in the blood (89, 90).
Therefore, we proposed to explore the use of cat S cleavable strategy to reduce the concentration
of the HPMA copolymer in the non-target tissues (e.g., blood, liver, and spleen) before injecting
the radiolabeled TZ probe. Our goal is to reduce the retention of the TCO-HPMA copolymer in the
normal tissues, which would afford improved radioimaging and radiotherapy when the TZ probe
is injected. The in vitro cat S study revealed that the optimized cat S cleavable TCO-HPMA
copolymer (capped MP-90-TCO-C) could indeed be cleaved by cat S into small fragments. These
results encouraged us to conduct in vivo studies to evaluate our approach.
3.3.10.1Biodistribution in a normal (CF-1) mouse model
We first evaluated the biodistribution of the optimized cat S cleavable TCO-HPMA
copolymer (MP-90-TCO-C) and the optimized non-cleavable (NP-82-TCO-C) in a normal (CF-1)
mouse model. Both copolymers were capped with glycolic acid (to limit the effect of the positive
charges from the unreacted primary amines of the APMA units within the copolymers on the
biodistribution of the copolymers) and radiolabeled with

177

Lu. The mice were sacrificed after 72

h. As expected, both copolymers showed high retention in the MPS-associated tissues (e.g., liver,
spleen, and blood) relative to the remaining tissues Table 3.3. However, the cat S cleavable
copolymer (MP-90-TCO-C) showed nearly 36%, 39%, and 42% reduction in the retention (%ID/g)
in the liver, spleen, and blood, respectively, relative to the non-cleavable TCO-HPMA copolymer.
These retention reductions were accompanied by ~ 22% (%ID) increased excretion of the Cat S
cleavable copolymer. The two copolymers had similar molecular weights (108.7 vs. 101.3 kDa).
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Therefore, the difference in the biodistribution and excretion profiles were likely due to the in vivo
degradation of the Cat S cleavable copolymer, which is in agreement with our previous report (117).
These results were encouraging, and therefore further evaluations in tumor models were performed.
The full data for the biodistribution profiles of the capped NP-82-TCO-C and capped MP-90-TCOC in the normal (CF-1) mouse model are found in Table 3.3

3.3.10.2 Biodistribution and in vivo TCO/TZ reactivity in ovarian cancer models (OVCAR-3
bearing-NOD-SCID and -SCID)
As stated previously, the immune cells such as monocytes and macrophages are associated
with MPS uptake, leading to the retention of nanomedicines in tissues like the liver and spleen (55).
Cat S is highly expressed in such immune cells, including monocytes, macrophages, and
professional antigen-presenting cells (APCs) (e.g., B-lymphocytes and dendritic cells) (114).
Therefore, since our strategy using a Cat S cleavable HPMA copolymer is exploiting the expression
of Cat S in these immune cells, conducting biodistribution and TCO/TZ reactivity studies for the
Cat S cleavable HPMA copolymer in mouse models with different immunity profiles (e.g., normal
vs. deficient macrophages) can lead to different results.

Unlike CF-1 mouse model that has normal immunity profiles (e.g., normal counts of T and
B lymphocytes and macrophages), SCID mice lack mature B and T lymphocytes due to nonhomologous end-joining defects in Prkdcscid mutants (211). In addition, NOD mice have defects in
the macrophage function, complement pathway, and natural killer cell activity (211-213).
Transferring SICD mutation onto a NOD background to afford NOD-SCID mice results in a more
severe immune deficiency that combines both NOD and SCID mice's defects. Therefore, to
accounts for these variations in the counts of immune cells, which can lead to variations in the
expression level of Cat S, we conducted biodistribution and in vivo TCO/TZ reactivity studies in
two ovarian cancer models (OVCAR-3 bearing-NOD-SCID and -SCID mice).
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To perform biodistribution and in vivo TCO/TZ reactivity studies, each mouse was injected
with two radiolabeled constructs, a

111

In-radiolabeled TCO-HPMA copolymer and a

177

Lu-

radiolabeled TZ-DOTA 2 probe. Unless otherwise indicated, the term biodistribution describes the
biodistribution of

111

In-radiolabeled TCO-HPMA copolymer, and the term in vivo TCO/TZ

reactivity describes the biodistribution of

177

Lu-DOTA-TZ 2 probe (0.37 MBq, 10 μCi) in mice

pre-injected with TCO-HPMA copolymer based on TCO content of 23 nmol (mixed with

111

In-

radiolabeled of the same TCO-copolymer, 0.37 MBq (10 μCi)). After the mouse was sacrificed, a
dual-isotope strategy was performed to trace the

111

In-TCO-HPMA copolymer and

TZ 2 probe in the same excised tissue. To differentiate the

111

In signal from the

177

177

Lu-DOTA-

Lu signal, we

selected a region of interest (ROI) in the NaI (Tl) well detector based on the energy spectra of the
two radioisotopes. We were able to identify the signal (and count) of each radioisotope from the
same sample (e.g., excised tissue). We also prepared a standard curve for each radioisotope to
confirm the accuracy of the counts. The selected ROI is shown in Figure 3.17. In the top image of
Figure 3.17A, the selected ROI is shown in the presence of no radioisotope (background counts).
Representative examples of

111

In and

177

Lu spectra are shown in the middle and bottom images,

respectively. The 111In and 177Lu signals appeared in the high and low energy levels, respectively.
The corresponding standard curves for the

111

In and 177Lu counts (at high and low energy levels)

vs. different radioactivity amounts (in µCi) are shown in Figure 3.17B snd 3.17C respectively.
3.3.10.2.1 Biodistribution and in vivo TCO/TZ reactivity study in ovarian tumor-bearing NODSCID mice
A total of five groups (5 mice per group) was included in the biodistribution and in vivo
TCO/TZ reactivity study in ovarian tumor-bearing NOD-SCID mice. Each group received either
non-capped NP-82-TCO-C, capped NP-18-TCO-C, capped NP-82-TCO-C, capped MP-90-TCOC, and no treatment (control). Each TCO-HPMA copolymer was mixed with the corresponding
111

In-radiolabeled copolymer. For example, non-capped NP-82-TCO-C was premixed with

111

In-
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radiolabeled non-capped NP-82-TCO-C. After 72 h of administration, all the five groups (including
the control group) were injected with 177Lu-DOTA-TZ 2, and the mice were sacrificed 4 h later.
3.3.10.2.1.1 Biodistribution profile of DOTA-TZ 2
As expected, the DOTA-TZ 2 (control group) was almost completely excreted (98 ± 1
%ID) from the body at the time of sacrifice (4 h) (Table 3.4). The kidneys showed nearly 1.3 ID%/g,
which was the organ with the highest %ID/g of 177Lu-DOTA-TZ 2. These results indicate the rapid
excretion of 177Lu-DOTA-TZ 2, which agree with reports using similar probes (88, 205).
3.3.10.2.1.2 Biodistribution and in vivo reactivity profiles of capped NP-18-TCO-C
We investigated the biodistribution and the in vivo TCO/TZ reactivity of a small-molecular
size TCO-HPMA copolymer (22.7 kDa), capped NP-18-TCO-C, to predict the behavior of the
small fragments of Cat S cleavable HPMA copolymer after cleavage by Cat S. We found nearly
97% of this small TCO-HPMA copolymer was excreted, with no tumor accumulation Table 3.4.
This result was expected based on the molecular size that is less than the renal threshold (< 50 kDa)
(97, 107). This copolymer's high excretion profile led to very poor in vivo TCO/TZ reactivity when
177

Lu-DOTA-TZ 2 was administered.

3.3.10.2.1.3 Biodistribution and in vivo reactivity of the large copolymers (capped NP-82-TCOC and capped MP-90-TCO-C)
The larger capped TCO-HPMA copolymers (capped NP-82-TCO-C and capped MP-90TCO-C) showed lower excretion rates than the smaller capped TCO-polymer conjugate. The
excretions of the NP-82-TCO-C and MP-90-TCO-C were 8.8 ± 2.5 and 11.3 ± 2.8 %ID,
respectively (Table 3.4). However, there was no difference (p > 0.05) in the biodistribution profiles
of the two large capped TCO-HPMA copolymers. The organs with the highest retentions were the
spleen (capped NP-82-TCO-C = 21 ± 7 %ID/g and MP-90-TCO-C = 26 ± 12) and the liver (capped
NP-82-TCO-C = 20 ± 2.5 %ID/g and MP-90-TCO-C = 14.8 ± 5.2 %ID/g). The average retentions of
the two copolymers in the blood were comparable to the tumor retentions, 12.4 ± 6.0 vs. 11.6 ± 5.0
%ID/g for the capped NP-82-TCO-C and 11.5 ± 0.6 vs. 9.8 ± 3.0 %ID/g for the capped MP-90-TCO-C.
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The similar biodistribution profiles of both capped NP-82-TCO-C and capped MP-90-TCO-C
(specifically in the spleen, liver, and blood) indicate that the in vivo cleavage of the latter copolymer
in this mouse model was insignificant. A possible explanation of the lack of biodegradation in this
tumor-bearing mouse model is the lack of some immune cells (e.g., macrophages ) associated with
increased expression of Cat S enzyme (114, 116, 212, 214).
The in vivo TCO/TZ reactivity profiles of the two copolymers (capped NP-82-TCO-C and
capped MP-90-TCO-C) were very high relative to the control (no TCO pre-injection), but they did
not differ from each other. The %ID of

177

Lu-DOTA-TZ 2 remained in the body after 4 h of

administration were 58% and 64% (p > 0.05) in the mice pre-injected with the capped NP-82TCO-C and the capped MP-90-TCO-C, respectively, relative to only 2% in the control group (p <
0.001). The %ID/g found in the tumor tissues were 2.5 ± 1.6 and 2.0 ± 0.7% (p > 0.05) in the mice
pre-injected with the capped NP-82-TCO-C and the capped MP-90-TCO-C, respectively,
indicating the in vivo TCO/TZ reactivity at the tumor tissues. However, the majority of the reacted
177

Lu-DOTA-TZ 2 was found in the blood for both copolymers. The %ID/g of

177

Lu-DOTA-TZ 2

in the blood was approximately ten-fold greater than the %ID/g in the tumor tissues of mice preinjected with either of the copolymers. The tumor tissues ranked the seventh in terms of excised
organs/tissues with the highest %ID/g of 177Lu-DOTA-TZ 2 in mice pre-injected with either of the
two copolymers, after the blood, lung, heart, kidneys, liver, and spleen.
3.3.10.2.1.4 Biodistribution and in vivo reactivity of the large non-capped non-cleavable
copolymer (non-capped NP-82-TCO-C)
To evaluate the effect of the charge on the biodistribution and in vivo TCO/TZ reactivity,
we also evaluated the non-capped NP-82-TCO-C. The unreacted primary amines of APMA units
within this copolymer were not reacted with glycolic acid. Therefore, it is expected at physiologic
condition (pH = 7.4), the copolymer becomes positively charged. An earlier investigation of the
charge effect on the biodistribution of HPMA copolymers showed faster clearance for the positively
charged vs. neutrally charged copolymers (107). Indeed, after 76 h of administration, the non-
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capped NP-82-TCO-C showed greater excretion value relative to the capped NP-82-TCO-C ( 48 ±
8 vs. 8.8 ± 2.5 %ID/g, p < 0.001) (Table 3.4). Increased excretion was associated with increased renal
retention (167, 215). It was also associated with reduced tumor accumulation by more than 50% relative to
the capped copolymer (5.2 ± 0.3 vs. 11.6 ± 6.0) and retention in non-target tissues (e.g., blood and liver). The
faster clearance rate of non-capped NP-82-TCO-C relative to the capped NP-82-TCO-C was also associated
with reduced in vivo TCO/TZ reactivity. While nearly 58 %ID of 177Lu-DOTA-TZ 2 remained in the body
of the mice pre-injected with the capped NP-82-TCO-C, only 7 %ID/g remained in the body of the mice preinjected with non-capped NP-82-TCO-C. Similar to the profile of the capped NP-82-TCO-C, the blood
contained the highest %ID/g of

177

Lu-DOTA-2, with the tumor tissues being the seventh-highest %ID/g

among the excised organs/tissues. In addition, the %ID/g of the probe in the tumor tissues was approximately
13-fold lower when mice pre-injected with the non-capped relative to the capped NP-82-TCO-C. Therefore,
in the next in vivo study, we used only the capped copolymers.

3.3.10.2.2

Biodistribution and in vivo TCO/TZ reactivity studies in ovarian tumor-bearing SCID
mice

In an attempt to address the high TCO/TZ reaction in off-target tissues (mainly the blood)
and the insignificant in vivo degradation of the cleavable copolymer (MP-90-TCO-C), the
biodistribution and TCO/TZ reactivity studies were also evaluated in tumor bearing-SCID mouse
model (Table 3.5). Unlike the NOD-SCID model, the SCID mouse model does not have a
deficiency in dendritic and macrophage cells, which are highly expressing Cat S (211, 212).
Therefore, we anticipated the cleavable copolymer would be degraded into smaller fragments, due
to Cat S cleavage, in the SCID mouse model. In addition, due to the high retentions of the large
TCO-HPMA copolymers (including the capped MP-90-TCO-C) in the previous in vivo study using
NOD-SCID, we explored the utility of a masking agent (DP-TZ). This masking agent consists of a
dextran-polymer that is modified with TZ moieties. It has been demonstrated in a previous report
that injecting this masking agent several minutes to one hour before injecting the TZ probe can
deactivate the remaining TCOs (due to the presence of TZ moieties) in the blood without affecting
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the TCOs in the tumor tissues (89). We utilized this masking agent to reduce the TCO/TZ reactivity
at the non-target tissues (mainly the blood).
The mice were injected with either the capped NP-82-TCO, capped MP-TCO-C without
the masking agent, or capped MP-TCO-C with masking agent (TZ content = 60 nmol) followed by
injection of 177Lu-DOTA-TZ 2. The masking agent was injected 30 min before injecting the 177LuDOTA-TZ 2. The biodistribution profiles of the TCO-HPMA copolymers were also comparable in
the NOD-SCID model, with no apparent advantages of using the Cat S susceptible linker in MPTCO-C (Table 3.5). The lack of the difference in the biodistribution profiles between the cleavable
and non-cleavable copolymers indicates the lack of biodegradation of the cleavable copolymer.
Although no attempt was made to explore the reasons, a possible explanation would be the negative
impact of the hydrophobic TCO on the in vivo biodegradation (216). The excretions (%ID) were
nearly 11% for both copolymers, with no statistical difference in the group administered DP-TZ
(12.7 ± 8.5 %ID).
The estimated TCO/TZ reactions were also similar between the two copolymers. The
%ID/g of 177Lu-DOTA-TZ 2 remained in the body were 45 and 43 %ID/g in the mice pre-injected
with the capped NP-82-TCO-C and capped MP-90-TCO-C, respectively. Similar to the previous
in vivo TCO/TZ reactivity studies using NOD-SCID, the majority of the TCO/TZ reaction occurred
in the blood. The administration of the masking agent (30 min before the 177Lu-DTOA-TZ 2 probe)
before the 177Lu-DOTA-TZ probe administration reduced the in vivo TCO/TZ reactivity (between
the capped MP-90-TCO-C and the TZ probe) to afford only 11 versus 47 %ID (with no preadministered DP-TZ) of

177

Lu-DOTA-TZ 2 remained in the body. This reduction in the TCO/TZ

reactivity is mainly attributed to the reduction of reactivity in the blood due to the deactivation of
the circulating TCOs within the capped MP-90-TCO-C. The %ID/g of

177

Lu-DOTA-TZ 2 was

reduced in all the excised tissues, but the blood had the highest reductions (16.4 versus 0.7 %ID/g,
p < 0.001), which afforded nearly 23 folds reduction.
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Poor T/NT ratios were found for the 177Lu-DOTA-TZ 2 in the groups that were preinjected
with either the capped NP-82-TCO-C or capped MP-90-TCO-C (with no masking agent). However,
in the group pre-injected with both the capped MP-90-TCO-C and the masking agent, T/NT ratios
were significantly improved. Using the masking agent led the tumor tissues to contain the secondhighest %ID/g of 177L-DOTA-TZ 2 (after only the kidney) relative to the seventh-highest %ID/g in
the group with no pre-injection of the masking agent (Table 3.5 and Figure 3.18). Due to the limited
extravasation of the masking agent outside the systemic circulation (89), this improved T/NT ratio
is mainly based on the deactivation of the reactive TCOs remaining in the blood without impacting
the TCOs in the tumor tissues.

129

Table 3.3 Biodistribution of TCO-HPMA copolymers in normal (CF-1) mice
177

Blood
Heart
Lung
Liver
Pancreas
Stomach
Spleen
Small intestine
Large intestine
Kidney
Muscle
Bone
Brain
Excretion (%ID)

Lu-NP-82-TCO-C
(%ID /g)
6.2 ± 0.9
3.0 ± 0.3
4.3 ± 4.0
11.0 ± 1.6
2.6 ± 1.0
1.0 ± 0.3
18 ± 4
1.1 ± 0.4
0.75 ± 0.16
3.5 ± 0.8
1.0 ± 0.1
1.4 ± 0.4
0.54 ± 0.10
32 ± 2

Values represent mean ± SD (n = 5).

177

Lu-MP-90-TCO-C
(%ID / g)
3.6 ± 0.6
2.4 ± 0.5
2.6 ± 0.7
7.0 ± 0.8
1.1 ± 0.5
0.88 ± 0.27
11.0 ± 2.2
0.7 ± 0.22
0.91 ± 0.22
2.6 ± 0.4
1.1 ± 0.3
1.0 ± 0.6
0.57 ± 0.20
39 ± 4
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Figure 3.17 The selected region of interest (ROI) used for the dual-radioisotope studies. The
spectrum with no radioisotope, with only 111In, and only 177Lu are shown in (A). The counts at high
and low energy areas for 111In and 177Lu are shown in (B) and (C), respectively.
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Table 3.4 Biodistribution and TCO/TZ reactivity profiles of selected TCO-HPMA copolymers
and biodistribution of 177Lu-DOTA-TZ 2in NOD-SCID mice (%ID/g)

Blood
Heart
Lung
Liver
Pancreas
Stomach
Spleen
Small intestine
Large intestine
Kidney
Tumor
Muscle
Bone
Brain
Excretion
(%ID)

Capped NP-18-TCO-C

Capped NP-82-TCO-C

Capped MP-90-TCO-C

Non-capped NP-82-TCO-C

111

111

111

111I

In
0±0
0±0
0±0
0.60 ± 0.01
0±0
0±0
0.18 ± 0.30
0.04 ± 0.02
0.12 ± 0.10
2.9 ± 0.9
0.03 ± 0.05
0±0
0±0
0±0
97 ± 1

177

Lu
0±0
0±0
0±0
0.29 ± 0.17
0±0
0±0
0±0
0.04 ± 0.01
0.51 ± 0.17
2.1 ± 1.1
0±0
0±0
0±0
0±0
98 ± 1

Values represent mean (%ID/g) ± SD (n = 5).

In
12.4 ± 6.0
8.3 ± 3.3
3.7 ± 0.6
20.0 ± 2.5
3.5 ± 0.8
2.4 ± 0.6
21 ± 7
3.8 ± 0.7
2.3 ± 0.3
6.9 ± 1.1
11.7 ± 5.0
2.5 ± 0.4
2.9 ± 3.6
0.26 ± 0.09
8.8 ± 2.5

177

Lu
22 ± 4
6.6 ± 3.8
7.3 ± 0.9
3.6 ± 0.7
1.8 ± 0.7
1.0 ± 0.2
3.7 ± 1.7
1.4 ± 0.4
1.7 ± 0.7
4.3 ± 1.0
2.5 ± 1.6
1.0 ± 0.2
1.4 ± 0.6
0.64 ± 0.13
42 ± 6

In
11.5 ± 0.6
7.7 ± 4.7
5.2 ± 1.1
14.8 ± 5.2
2.8 ± 0.8
1.8 ± 0.3
26 ± 12
1.9 ± 0.6
2.4 ± 0.4
8.5 ± 1.3
9.8 ± 3.0
2.7 ± 0.6
5.9 ± 3.4
0.40 ± 0.06
11.3 ± 2.8

177

Lu
23 ± 1
6.6 ± 4.5
7.0 ± 2.2
4.0 ± 0.2
1.5 ± 0.4
1.3 ± 0.5
3.7 ± 2.5
1.2 ± 0.4
1.8 ± 0.7
4.6 ± 0.5
2.0 ± 0.7
0.85 ± 0.20
2.0 ± 1.2
0.63 ± 0.13
36 ± 2

n
5.6 ± 1.0
2.6 ± 0.5
3.5 ± 0.9
8.8 ± 1.8
1.9 ± 0.9
1.1 ± 0.6
20 ± 10
1.4 ± 0.4
1.6 ± 0.4
42 ± 7
5.2 ± 0.3
1.0 ± 0.3
2.1 ± 0.9
0.16 ± 0.06
48 ± 8

177

Lu
1.8 ± 0.3
0.2 ± 0.2
0.5 ± 0.2
0.6 ± 0.1
0.04 ± .06
0.12 ± 0.14
0±0
0.16 ± .04
0.6 ± 0.3
1.5 ± 0.2
0.19 ± 0.18
0.05 ± 0.06
0.03 ± 0.03
0±0
93 ±1

177

Lu-DOTATZ 2
177
Lu
0±0
0±0
0.03 ± 0.03
0.21 ± 0.05
0 ±0
0.02 ± 0.04
0±0
0.10 ± 0.07
0.48 ± 0.14
1.3 ± 0.3
0±0
0±0
0±0
0±0
98 ± 1
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Table 3.5 Biodistribution and in vivo TCO/TZ chemistry profiles of the capped TCO-HPMA
copolymers in SCID mice based on dual-radioisotope study ( 111In-TCO-HPMA copolymer and
177
Lu-DOTA-TZ 2 probe)a

Blood
Heart
Lung
Liver
Pancreas
Stomach
Spleen
Small intestine
Large intestine
Kidney
Tumor
Muscle
Bone
Brain
Excretion (%ID)
a

Capped MP-90-TCO-C
111 b
177
In
Luc
12.2 ± 0.6
16.4 ± 1.5
4.8 ± 1.4
2.6 ± 0.6
6.4 ± 0.6
5.4 ± 1.3
13.6 ± 0.8
3.2 ± 0.4
2.4 ± 0.2
1.1 ± 0.3
1.6 ± 0.3
0.8 ± 0.3
42 ± 11
4.2 ± 2.0
2.0 ± 0.5
1.1 ± 0.4
1.8 ± 0.5
4.1 ± 1.4
7.2 ± 2.4
2.5 ± 0.7
12.0 ± 2.8
2.5 ± 0.7
2.4 ± 0.4
0.81 ± 0.24
2.8 ± 0.4
0.71 ± 0.57
0.30 ± 0.05
0.28 ± 0.08
10.8 ± 2.4
53 ± 5

Capped MP-90-TCO-C + DP-TZ
111 b
177
In
Luc
12.5 ± 3.5
0.70 ± 0.28
4.2 ± 1.0
0.06 ± 0.07
6.3 ± 1.3
0.93 ± 0.40
12.4 ± 1.2
0.60 ± 0.09
2.6 ± 0.2
0.09 ± 0.06
1.6 ± 0.2
0.02 ± 0.04
35 ± 15
0.12 ± 0.24
2.2 ± 0.4
0.29 ± 0.09
1.7 ± 0.4
0.84 ± 0.53
8.1 ± 1.9
1.8 ± 0.5
14.1 ± 1.8
1.2 ± 0.5
2.2 ± 0.4
0.18 ± 0.26
2.6 ± 0.4
0±0
0.34 ± 0.08
0±0
12.7 ± 8.5
89 ± 1

Two reading counts (from high and low energy areas) were obtained for each tissue to estimate the

b

c

Capped NP-82-TCO-C
111 b
177
In
Luc
15.4 ± 2.1
17.4 ± 2.9
5.4 ± 0.7
2.9 ± 0.8
6.0 ± 1.8
5.1 ± 1.1
13.0 ± 1.0
3.8 ± 0.8
2.3 ± 0.2
0.83 ± 0.30
1.4 ± 0.3
0.59 ± 0.19
39 ± 13
7.5 ± 3.2
1.6 ± 0.2
0.66 ± 0.34
1.0 ± 0.4
1.0 ± 0.3
5.6 ± 1.2
3.6 ± 1.0
13.9 ± 3.2
2.4 ± 0.6
2.5 ± 0.5
0.65 ± 0.15
2.6 ± 0.4
0.42 ± 0.33
0.48 ± 0.21
0.24 ± 0.19
11.0 ± 0.8
55 ± 4

111

177

Lu-TZ-2
Lud
0±0
0±0
0.03 ± 0.03
0.21 ± 0.05
0±0
0.02 ± 0.04
0±0
0.10 ± 0.07
0.48 ± 0.14
1.3 ± 0.3
0±0
0±0
0±0
0±0
98 ±1
177

In and 177Lu signals

Data for the biodistribution profiles of 111In-labeled TCO-HPMA copolymer (76 h)

Data for the biodistribution profiles of 177Lu-DOTA-TZ 2 (4 h) in mice pre-administered with the designated TCO-HPMA copolymer (72 h)

d

Data for the biodistribution profiles of 177Lu-DOTA-TZ 2 (4 h) in NOD-SCID mice (control), with no pre-administered compound

Data expressed as mean ± SD (n = 5)
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Figure 3.18 Effect of DP-TZ on tumor / normal tissues (T/NT) ratios. Blue columns represent
data from SCID mice that were injected with MP-90-TCO-C followed by injection of 177LuDOTATZ 2 before animal sacrifice. Green columns represent data from SCID mice that were
injected with MP-90-TCO-C followed by injection DP-TZ and finally injection of 177Lu-DOTATZ 2 before animal sacrifice. Data expressed as mean (n = 5).
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3.4 Conclusion
In this study, a multi-block Cat S-susceptible HPMA copolymer modified with TCO (MP90-TCO-C) was synthesized and characterized for in vivo pretargeting via bioorthogonal reaction.
We evaluated the effect of the TCO linker length, TZ moiety type, molecular size, and the
introduction of a Cat S cleavable linker to the HPMA copolymer on the reaction kinetics. The in
vitro Cat S cleavage study revealed the optimized Cat S cleavable copolymer's susceptibility to the
enzyme. The in vivo studies were conducted to evaluate the biodegradation of the cleavable TCOHPMA copolymer in mouse models with different immunity profiles, the feasibility of in vivo
TCO/TZ pretargeting in ovarian-cancer models, and the effect of the charge on the biodistribution
and in vivo TCO/TZ pretargeting of the TCO-HPMA copolymers. The biodistribution of MP-90TCO-C in a CF-1 mouse model showed in vivo biodegradation. The in vivo TCO/TZ reactivity
studies in ovarian cancer models showed the feasibility of using HPMA copolymer for the
pretargeting approach, with excellent T/NT ratios when a masking agent was pre-injected. The
positively-charged copolymer containing free amines showed greater clearance with lower in vivo
TCO/TZ reactivity profiles relative to the capped copolymers, indicating a significant role for the
charge. Overall, these results are promising and present a proof of concept for further optimization.
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4 Chapter 4. Prophylactic Chelation Therapy Using DTPA-HPMA
Copolymer (P-DTPA): In vitro and In vivo Evaluations

4.1 Introduction

Actinides such as plutonium, uranium and americium are widely used for medical,
industrial, and military purposes (134). Their release, caused by natural disasters, industrial or
military accidents, or terrorist attacks, remains a major potential public health concern (217).
Internal contamination by actinides can occur via inhalation, ingestion, and absorption through
wounds. Once absorbed, these radiometals make their way to the blood circulation where they are
systemically distributed throughout the body. This leads to the actinide being either excreted from
the body or being deposited in tissues, most commonly the liver and bone (217). Tissue deposition
of these radioactive metals is known to cause serious adverse effects (e.g., cancer) as a result of
long-term exposure (218).

The current clinical treatment for internal contamination is chelation therapy (219). This
approach involves the administration of small organic ligands that selectively form stable and
water-soluble complexes with deposited actinides to enhance clearance from the body. Currently,
DTPA (as CaNa3 and ZnNa3 salt forms) is the only FDA-approved medication for the chelation
therapy for individuals contaminated with plutonium, americium or curium (220). While clearly an
important treatment regimen, DTPA is not a panacea for all actinide-based cases of internal
contamination. The oxidation state and coordination chemistry of the actinide and localization
(intracellular vs. extracellular) greatly impacts the efficacy of the chelation agent. Due to this, a
variety of investigators are pursuing the development of chelation agents with more optimal
chelation and bioavailability characteristics (134, 221, 222).
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The development of prophylactic chelation therapy approaches has been of interest for the
protection of individuals at risk of exposure due to the intentional or accidental release of actinides
into the environment. DTPA is not ideal for this purpose due to its poor oral bioavailability and
rapid clearance from the blood circulation limiting its duration of prophylactic protection (139).
One approach in the development of effective prophylactic chelation therapies is to incorporate
chelation agents into nanomedicine constructs (e.g., liposomes, micelles, and polymeric
conjugates) (144, 145, 223-225). This approach is attractive due to its ability to greatly increase the
circulation time of the chelation agent in the blood thereby allowing the maintenance of effective
concentrations to intercept absorbed actinides before tissue deposition occurs. Additionally, the
versatility of nanomedicine constructs allows for the design and development of multi-functional
platforms (226). For instance, in the context of chelation therapy, this could include the creation of
formulations that contain two or more chelators to optimize the capture and clearance of a specific
or a broad set of actinides from the body.
Herein, we explore the development of a nanomedicine-based prophylactic chelation
therapeutic. Specifically, we have designed and synthesized a polymer conjugate construct in which
DTPA is incorporated into a N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer. HPMA
copolymers were chosen as the carrier platform due to their non-immunogenic, biocompatible, and
non-toxic nature (97, 227) as well as being able to be administered via different routes (e.g., i.v.
and s.c.) (228). Additionally, HPMA copolymer constructs have undergone multiple clinical trials
and demonstrated their safety as nanomedicine drug carriers (164, 229). Our aim is to examine if
a DTPA-incorporated HPMA copolymer (P-DTPA) exhibits increased radionuclide removal and
prophylactic protection relative to DTPA. To achieve this goal, the lanthanide Lu-177 served as
our actinide model due to our institutions’ regulatory prohibition on actinide possession. Lutetium
has a similar oxidation state, coordination chemistry and DTPA formation constant (Lu = 10 22.4
and Am=1023.1) compared to americium (230). P-DTPA was characterized using a variety of in
vitro studies to examine the selectivity, stability, and cytotoxicity of the carrier. In vivo studies were
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carried out in a CF-1 mouse model to investigate the prophylactic protection of P-DTPA against
exposure to radiometal contamination.

4.2 Materials and methods
4.2.1

Chemicals
If not otherwise indicated, all solvents used for the polymer reactions and silica gel

purifications were ACS grade obtained from Fisher Scientific. Water was deionized using a MilliQ® Integral Water Purification System (Millipore Corp., U.S.). Acetonitrile (ACN) was HPLC
grade and purchased from Fisher Scientific (U.S.). N,N-dimethylformamide (DMF) was purchased
from Fisher Scientific (U.S.). Fluorescein isothiocyanate (FITC), 4-cyano-4-(phenylcarbonothioylthio)pentanoic acid (chain transfer agent, CTA), 2,2′-Azobis(2-methylpropionitrile) (AIBN),
and ethylenediaminetetraacetic acid (EDTA) were purchased from Sigma-Aldrich (U.S.). N-(2Hydroxypropyl)methacrylamide (HPMA) and N-(3-aminopropyl)methacrylamide (APMA) were
obtained from Polysciences (U.S.). S-2-(4-Isothiocyanatobenzyl)-diethylenetriamine pentaacetic
acid (p-SCN-Bn-DTPA) was purchased from Macrocyclics (U.S.). Diethylenetriaminepentaacetic
acid calcium trisodium salt (DTPA) was acquired from TCI America (U.S.). N,NDiisopropylethylamine (DIEA) was obtained from ChemPep (U.S.). Phosphate buffered saline
(PBS) was purchased from Fisher Scientific (U.S.). Human type AB serum was obtained from
Fisher BioReagents (U.S.). Ham's F-12K medium and fetal bovine serum (FBS) were obtained
from Gibco (U.S.). L-glutamine and PrestoBlue® were purchased from Thermo Fisher Scientific
(U.S.). Endothelial cell growth supplement was obtained from R&D Systems (U.S.). Zeba™ Spin
Desalting Columns (7K MWCO, 0.5 mL) were purchased from Thermo Fisher Scientific (U.S.).
Silica Gel 60 A was obtained from Sigma-Aldrich (U.S.).

4.2.2

Instrumentation
A Waters Qtof Micro electrospray ionization mass spectrometer (U.S.) was used to perform

mass characterization of the small molecules. A Bruker Avance-III HD 600 MHz instrument (U.S.)
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was used to record 1H-NMR. Weight and size measurements of the HPMA copolymer was
performed using a Viscotek TDA max system (Malvern Instruments Inc., U.S.) equipped with a
Shodex Asahipak GF-510 HQ size exclusion chromatography column (SEC-TDA). Evaluation
and/or purification of radiolabeled chelators were performed on a Waters 1515 binary pump
equipped with a Waters 2489 absorption detector and a Bioscan Flow Count radiometric detector
system. A Shodex Asahipak GF-510 HQ GPC column was employed for the purification and
evaluation of the radiolabeled copolymeric chelator. Autoradiography was recorded via BAS
storage phosphor screens and scanned by a GE Lifesciences Typhoon FLA 9500 variable mode
imager. A Multi-Wiper nuclear medicine gamma counter (LTI, U.S.) was used for counting the
radioactivity in the selectivity and in vitro chelation studies. A Tecan Infinite F200 Fluorescence
Microplate Reader (Switzerland) was used for the cytotoxicity studies. A CRC-25R dose calibrator
(U.S.) was used for measuring the radioactivity for the serum chelation study. Quantitative
measurement of the in vivo administered

177

Lu was performed using a NaI (Tl) well detector

constructed by AlphaSpectra Inc. (U.S.).

4.2.3

Synthesis and characterization of the DTPA-modified HPMA copolymer (PDTPA)

4.2.3.1

Synthesis of monomers
The APMA-DTPA monomer was synthesized according to a published report (231).

Briefly, to a solution of APMA (0.154 mmol, 27.5 mg) in 300 µL dry DMF was added to a solution
of p-SCN-Bn-DTPA (0.154 mmol, 100 mg) in 500 µL dry DMF followed by the addition of DIEA
(0.769 mmol). The reaction mixture was stirred at room temperature under nitrogen. After 24 h,
the crude product was concentrated by purging with nitrogen and was purified by silica gel column
chromatography using an elution system containing isopropyl alcohol/water/NH 4OH (8:1:1). The
solvent was evaporated under vacuum to afford the product as a solid residue (53.3 mg, 50.7%).
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The product was characterized by 1H-NMR and mass spectrometry ([M+H]+ = 683.1). APMAFITC was synthesized according to a previously published report (168).
4.2.3.2

Reversible addition-fragmentation chain transfer (RAFT) polymerization
With modifications made to our previously described published method (203), reversible

addition-fragmentation chain transfer (RAFT) polymerization was employed to synthesize the
HPMA-DTPA copolymer (P-DTPA). Briefly, HPMA, APMA-DTPA, and APMA-FITC
monomers were dissolved in dioxane/DI water (2:1) at a molar ratio of 89.5, 10.0, and 0.5,
respectively, with a total monomer concentration of 0.269 mmol. To this mixture was added CTA
(1.34 µmol, 0.375 mg) and AIBN (1.54 µmol, 0.254 mg). The final volume of the reaction solution
was 600 µL. The mixture was transferred to a glass amber ampule and purged with nitrogen for 40
min. The ampule was flame sealed, and the reaction mixture was stirred at 50 ºC for 48 h. The
reaction mixture was cooled to room temperature, and the copolymer was subsequently purified by
a Sephadex LH-20 column using methanol as an eluent to afford 27.2 mg (yield = 51%) of PDTPA. The molecular weight analysis was performed using size exclusion chromatography (SECTDA) with an ACN/PBS (40:60) elution. The DTPA and FITC contents within the copolymer were
characterized by 1H-NMR and UV spectroscopy (absorbance at 494 nm) (203), respectively.

4.2.4

Selectivity studies
Selectivity studies were conducted in solutions containing endogenous metals to examine

the impact of their presence on

177

Lu sequestration. A solution containing similar concentrations

(1X) of biologically relevant metals (Zn+2, Ca+2, Fe+2/+3, and Cu+2) found in human serum (232) and
another solution containing ten times (10X) these concentrations were prepared to conduct the
selectivity studies. To prepare the 1X solution, FeCl 2 (51.06 µg), FeCl3 (65.35 µg), ZnCl2 (56.28
µg), CaCl2 (8.3 mg), NaHCO3 (1 mg), CuSo4 (0.15 µg), Na₂HPO₄ (4.26 mg), and KCl (0.258 mg)
were dissolved in 30 mL of PBS (pH = 7.4). The 10X solution was prepared analogously using tenfold the endogenous metal content.

140
To carry out the DTPA selectivity studies, 190 µL of either the 1X or 10X biological metal
solution described above were added in a microcentrifuge tube and preheated to 37 ºC. To this
solution was added

177

LuCl3 (5 µL in PBS) followed by the addition of DTPA (5 µL in PBS) to

make a 2 or 20 µM solution. The final volume of the above solution was 200 µL and the
concentration of 177Lu was ≈ 6 nM (100,000 cpm / 50 µL). The mixture was heated to 37 ºC. After
15 min a sample was withdrawn (6 µL), and the 177Lu-DTPA complex was separated from the free
177

Lu by thin-layer chromatography (TLC) using an eluent mixture of water/methanol/NH 4OH

(2:1:0.1). Under these conditions, the 177Lu-DTPA complex migrates with the solvent front while
the free 177Lu remains at the origin point (233, 234). Autoradiographic images of the TLC plates
were collected, analogous to our previous report (235), for

177

LuCl3 and

177

Lu-DTPA controls to

confirm this behavior. To quantify the free 177Lu vs. 177Lu-DTPA, the TLC plate was cut into two
halves, and the radioactivity in each half was recorded using a gamma counter. This study was
performed in triplicate.
For the P-DTPA selectivity studies, 190 µL of either the 1X and 10X biological metal
solutions described above were added to a microcentrifuge tube and preheated to 37 ºC. To this
solution was added 177LuCl3 (5 µL in PBS) followed by the addition of P-DTPA (5 µL in PBS) to
make a 2 or 20 µM (based on DTPA amount) solution. The final volume of the above solution was
200 µL and the concentration of the 177Lu was ≈ 6 nM (100,000 cpm / 50 µL). After 15 min a 50
µL aliquot of the solution was withdrawn and analyzed. The

177

Lu-bound P-DTPA was separated

from free 177Lu using a desalting spin column following the manufacturer’s protocol. Briefly, the
excess liquid in the column was first removed (1,500 ⅹ g for 1 min). Then, the 50 µL sample aliquot
described above was added to the center of compacted resin and centrifuged for 2 min at 1,500 ⅹ
g. The radioactivity remaining in the column (free

177

Lu) or eluted (177Lu-bound P-DTPA) was

measured using a gamma counter. This study was done in duplicate.

4.2.5

Chelation in human serum
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The efficacy of DTPA and P-DTPA to sequester 177LuCl3 in human serum was examined.
To 195 µL of human serum was added the desired amount of DTPA dissolved in PBS (5 µL) to
achieve a 20 µM (based on DTPA content) solution. The mixture was preheated to 37 ºC. To this
mixture was added 350 µCi (≈ 488 nM) of 177LuCl3 (2.5 µL in DI water). After 15 min, a 100 µL
aliquot was analyzed by radio-HPLC (equipped with an analytical Proteo C 12 column) using
isocratic separation (95% DI water in ACN) with a flow rate of 1.5 mL/min. The percentage of the
bound 177Lu-DTPA complex in solution was determined by the integration of the associated peak
relative to the unchelated 177Lu peak. Similarly, the chelation of 177Lu by P-DTPA in human serum
was examined at 20 µM, based on the content of DTPA. After 15 min, a 100 µL aliquot was
analyzed by radio-SEC (equipped Shodex Asahipak GF-510 HQ GPC column) using ACN/PBS
(40:60) elution with a flow rate of 0.6/mL to collect the fraction of 177Lu-P-DTPA. The radioactivity
in the collected fraction was measured using a dose calibrator. The radioacitivity in the collected
fraction was divided by the total injected radioacitivity (to the radio-SEC) to estimate the chelated
177

Lu.

4.2.6

Stability of 177Lu-P-DTPA in human serum
To examine the stability of the 177Lu-bound P-DTPA in human serum, P-DTPA was first

radiolabeled with

177

LuCl3 and purifed. Briefly, 500 µCi of

177

LuCl3 was added to a solution

containing 100 µg of P-DTPA in 50 µL DI water and heated to 37 ºC for 30 min. The

177

Lu-P-

DTPA was purified by the radio-SEC system following the previously described conditions. Once
purified, 177Lu-P-DTPA (200 µCi) was added to 500 µL of human serum and heated at 37 ºC for
144 h. Aliquots were withdrawn and analyzed using a desalting spin column, as previously
described, followed by injection into the radio-HPLC to evaluate the

177

Lu-bound to P-DTPA or

serum proteins. Another sample was withdrawn, diluted in PBS to obtain 100,000 cpm /50 µL, and
desalted using a spin column. The eluted and column-associated radioactivity was counted, as
described previously, to estimate the 177Lu in unbound form.
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4.2.7

Cell viability
Cell viability studies using human umbilical vein endothelial cells (HUVEC) were

performed for DTPA and P-DTPA at concentrations ranging from 31.25 to 1000 µM. The cells
were seeded in 96-well plates at a density of 3000 cells (100 µL) per well. After 24 h, the media
was replaced with fresh media-containing the desired concentration of DTPA or P-DTPA and
incubated at 37 ºC. After 48 h, the media was aspirated out and fresh media containing the
PrestoBlue® reagent (10% by volume) was added and incubated at 37 ºC for 1 h. The fluorescence
measurements were then recorded using a plate reader (excitation: 560 nm and emission: 590 nm).
A one-binding site model using Graphpad Prism 7 (U.S.) was employed to determine the IC 50
values.

4.2.8

Cell culture
Human umbilical vein endothelial cells (HUVEC) (ATTC, U.S.) were cultured in F-12K

medium containing heparin (0.1 mg/mL), endothelial cell growth supplement (0.2 mg/mL), FBS
(1mL / 10 mL), L-glutamine (2 mM), and sodium bicarbonate (1500 mg/L) at 37 ºC in a humidified
environment of 5% CO2.

4.2.9

In vivo prophylactic studies
All animal protocols conformed to the Guide for the Care and Use of Laboratory Animals

of the National Institutes of Health and were approved by the Institutional Animal Care and Use
Committee (IACUC) at the University of Nebraska Medical Center. The mice used in the studies
were female CF-1 mice (Charles River Laboratories, U.S.) weighing ~ 27 g. They were housed in
a room with a controlled temperature (~ 22 ºC) and a 12-h light cycle. A total of 30 mice were
randomly allocated into two arms (15 mice per arm) based on the prophylactic chelator
administration time (either 6- or 24-hr) and post-contamination with 177LuC3. In each arm, 15 mice
were randomized into three groups (five mice per group) to receive either no chelator treatment,
DTPA (30 µmol/kg), or P-DTPA (30 µmol/kg based on the DTPA content). After 6 or 24 hr,
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177

LuCl3 (20 µCi per mouse) in 100 µL of PBS was administered intravenously via the tail vein.

The mice were singly-housed, and the bedding material was collected and replaced every other day
(a total of six collections over the course of the study). The radioactive content of the bedding
materials was analyzed to examine the excretion/clearance of 177Lu over time. At 14 – 15 days postadministration of the

177

Lu, biodistribution studies were conducted by sacrificing the mice,

excising, and determining the mass of select tissues and measuring the associated radioactivity for
each. From this data, percent injected dose (%ID) or %ID/gram of tissue (%ID/g) could be
determined.

4.2.10 Statistical analysis
Data is presented as mean ± standard deviation (SD). GraphPad Prism version 7.0
(GraphPad Software Inc., U.S.) was used to perform the Student’s t-test (two groups) or one‐
way ANOVA with Bonferroni post-tests (> two groups). A p-value of less than 0.05 was considered
significant.

4.3 Results and discussion
Upon the unintended or deliberate release of actinides into the environment, internal
contamination by actinides will results in the retention of the radionuclides in vital organs, mainly
the liver and skeleton, leading to acute and long-term radiotoxicity (134). Chelation therapy with
DTPA is currently the only FDA-approved therapy to remove select actinides from the body (219).
DTPA is a small, hydrophilic molecule capable of rapidly distributing to the extracellular tissue
compartments and chelating actinides to facilitate their removal from the body. However, the
efficacy of this decorporation therapy is highly dependent on the lag time between exposure to the
actinide contaminate and the administration of chelation therapy. Prompt administration of the
chelators is necessary to ensure efficient decorporation and, as a result, better therapeutic outcomes
are achieved when compared to delayed treatments (236). In situations of mass population exposure
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to actinides or when prompt and in-depth medical treatment may not be viable, a prophylactic
chelation therapy would be valuable to mitigate risks to individuals with the potential of exposure.
Unfortunately, the rapid plasma clearance of DTPA, with a half-life measured in minutes, does not
readily lend itself to prophylactic applications (140, 237).
Similar to other innovative reports (144, 223-225), we seek to explore if nanomedicine
constructs can be utilized to increase the circulation time and prophylactic action of chelation
therapies and reduce the irreversible deposition of actinides in the body. HPMA copolymers have
been widely investigated in preclinical studies and several promising constructs have entered into
clinical trials (100). The molecular weight of these copolymers can be adjusted to increase plasma
retention from hours to days, with increased molecular weight promoting longer circulation times
(107, 228). The molecular weight of the copolymers also impacts the primary clearance pathway
with copolymers below approximately 45 kDa clearing via renal excretion and copolymers above
this threshold clearing predominately through the hepatobiliary system. With this in mind, DTPA
was incorporated into a HPMA copolymer (P-DTPA, 33.9 kDa) with a molecular weight that would
allow for adequate plasma retention (days) but still predominately clear renally. Using this P-DTPA
copolymer, we hypothesized that the enhanced plasma retention of this construct would increase
the prophylactic decorporation efficacy relative to DTPA treatment.

4.3.1

Synthesis and characterization of P-DTPA
The DTPA chelation moiety was incorporated into the polymeric construct by initially

synthesizing the APMA-DTPA monomer. This was accomplished by using p-SCN-Bn-DTPA, a
common bifunctional chelator that allows for a chemo-selective conjugation to amine functional
groups within molecules (238) while still retaining all eight coordination sites present in DTPA that
are needed to strongly chelate metals. p-SCN-Bn-DTPA was conjugated with the primary amine
of the APMA monomer via a thiourea linkage yielding the desired APMA-DTPA monomer (Figure
4.1A). Characterizations of APMA-DTPA included 1H-NMR and mass spectrometry, as shown in
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Figure 4.1A. With the HPMA, APMA-FITC (168) and APMA-DTPA monomers in hand, the
copolymeric construct was synthesized using RAFT polymerization. HPMA copolymers with
molecular weights greater than 45 kDa are unable to efficiently be cleared by the renal systems
resulting in extensive blood circulation times and clearance primarily by the hepatobiliary system
(97, 228). To avoid hepatobiliary clearance, an HPMA copolymer molecular weight of less than 45
kDa was targeted to allow efficient renal clearance of the polymeric decorporation agent while also
allowing sufficient blood circulation times (i.e., days). The polymerization yielded the desired
DTPA-incorporated polymeric construct (P-DTPA, Figure 4.1B) with a molecular weight of 33.9
kDa and a narrow dispersity (Ð = 1.09) as given in Table 4.1. The DTPA content was calculated
based on 1H-NMR and yielded a value of 5.2 mol% which translates to an average of 10.2 DTPA
units per polymer chain (Table 4.1).
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Figure 4.1 1H-NMR (in D2O)and MS spectra of APMA-DTPA (A) and 1H-NMR spectrum of PDTPA (in D2O) (B).
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Table 4.1 Characteristics of P-DTPA
Estimated MW (kDa)a
Ða
Rh (nm)
DTPA content (mol%)b
FITC content (mol%)c
a

P-DTPA
33.9
1.09
4.23
5.2
0.5

As determined by SEC-TDA system
As estimated by 1H-NMR
c
Based on UV/visible spectrometric analysis
b
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4.3.2

Selectivity studies of DTPA and P-DTPA
Previous investigations of DTPA have explored the impact other competing metals in

solution can have on the sequestration efficacy of the chelator for

177

Lu (233, 239). From these

studies, it was found that the identity of the metal and its relative concentration to the 177Lu played
the greatest role in impacting chelation efficacy. For example, in one study, substantial decreases
in

177

Lu chelation yields were observed when the ratio of Fe2+/177Lu3+ and Zn2+/177Lu3+ increased

above 1 and 10, respectively (233). However, no change in DTPA chelation efficacy for 177Lu was
observed when Ca2+ was added at concentrations up to100-fold equivalent excess. In order to
examine how endogenous biologically relevant metals might interfere with the chelation of

177

Lu,

selectivity studies were performed with DTPA and P-DTPA in the presence of competing metals
Na+, K+, Mg2+, Ca2+, Zn+2, Fe2+/+3 and Cu+.
For the selectivity studies, two solutions were prepared. The first solution (1X) contains
concentrations of the above mentioned metals at levels commonly found in human blood (232).
The second solution (10X) was prepared in based on metal concentrations that were 10-fold higher
than the 1X solution. In each of these solutions, 2 or 20 µM of DTPA and P-DTPA (based on the
DTPA content) was incubated with 6 nM of 177LuCl3. For the DTPA selectivity studies, the analysis
of the chelation efficacy was monitored by radio-TLC which separated the remaining free

177

Lu

(remains at the origin) from the 177Lu-DTPA (moves with the solvent front). With respect to the PDTPA copolymer, the chelation efficacy was determined using a spin desalting column (7 kDa) to
separate free

177

Lu from

177

Lu-bound to the copolymer. The results of these studies are given in

Figure 4.2.
For the selectivity studies utilizing DTPA, the 20 µM concentration of the chelator gave a
complexation yield of 93.0 ± 2.0% in the 1X solution but fell to 36.2 ± 7.2% in the 10X solution.
This observation agrees well with previously reported literature in which increasing competitive
metal concentrations was inversely related to complexation yields of

177

Lu (233). In contrast, the

149
complexation yields of

177

Lu by P-DTPA showed no change between the 1X (79.1 ± 2.0%) and

10X (76.8 ± 0.6%) at the 20 µM concentration (based on DTPA content of the copolymer). At a 2
µM concentration of DTPA, the 177Lu complexation yield was 21.5 ± 3.5% in the 1X solution and
was reduced over 13-fold to 1.6 ± 0.3% in the 10X solution. Similarly, the complexation yield at 2
µM of P-DTPA for 177Lu was 43.0 ± 1.2% in the 1X solution but showed a more modest 4.9-fold
reduction to 8.7 ± 0.7% in the 10X solution.
These results indicate that DTPA is the better chelator at higher concentrations but is
substantively poorer at chelating

177

Lu at lower concentrations or when it is in the presence of

higher competitive metal concentrations. In contrast, P-DTPA demonstrated chelation efficacies
that were significantly better at lower concentrations and were not as detrimentally impacted when
higher competitive metal concentrations were present. One possible explanation for these
observations is the fact that different chelators were employed. The chelator of P-DTPA utilizes
the p-SCN-Bn-DTPA derivative. Compared to the parent DTPA, the introduction of a rigid benzene
ring has been shown to not only increase the kinetic stability of the metal-DTPA complex (238,
240, 241) but also to enhance its complexation kinetics (221). Additionally, we postulate that steric
shielding might also play a role in the increased chelation efficacy of the P-DTPA. After
thermodynamically favorable chelation of 177Lu is achieved by P-DTPA, the increased steric bulk
of the copolymer may impede transchelation thereby increasing the kinetic stability of the complex.
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***

***

***

Figure 4.2 Selectivity study profiles of DTPA and P-DTPA after 15 mins incubation with 1X and
10X solutions containing 177LuCl3. Values represent mean ± SD.
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4.3.3

Chelation and stability in human serum
An in vitro chelation study was performed to evaluate the ability of DTPA and P-DTPA to

sequester free 177Lu in human serum. The study was conducted at equivalent 20 µM DTPA and PDTPA (based on total DTPA content for the polymer) concentrations in the presence of 350 µCi
(488 nM) of 177LuCl3 at 37°C. After 15 min, the complexation yields were 94.2 ± 2.5 and 50.0 ±
0.3 for DTPA and P-DTPA, respectively. This observation is in agreement with the results from
the selectivity studies using the 1X formulation in which the DTPA exhibited a higher sequestration
efficacy than P-DTPA at this concentration (233, 239).
Once chelated to the radiometal, a decorporation agent is expected to exhibit minimal
transchelation and maintain complexation until eliminated from the body. To examine the ability
of P-DTPA to maintain stable complexes to

177

Lu, the in vitro stability of

177

Lu-labeled P-DTPA

was examined in human serum at 37°C for six days (144 h). Analysis of the stability of the

177

Lu-

labeled polymeric complex was conducted by employing a desalting spin column to segregate large
from small molecular weight molecules in the serum. The large molecular weight fractions were
subsequently analyzed by radio-SEC analysis. Radiometric analysis of the low- and high-molecular
weight fractions shows that 12% of 177Lu was released from P-DTPA. These results indicate there
is a limited release of the 177Lu from the chelator over an extended time, which is in agreement with
previously published reports (242, 243).

4.3.4

Cytotoxicity
The HUVEC cell line is commonly used for investigating the cytotoxicity of

nanomedicines due to prolonged exposure (i.e., long blood circulation times) of the nanomedicine
constructs with the vasculature (244). The HUVEC cells were exposed to DTPA and P-DTPA
(based on DTPA content) concentrations ranging from 31.25 to 1000 µM for 48 h and evaluated
for viability using a commercial fluorescence assay. Up to 125 µM, the DTPA and p-DTPA
demonstrated no statistically significant differences in cellular viability (Error! Reference source
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not found.). At concentrations of 250 µM, a statistically significant 15% decline in cellular viability
was observed for the P-DTPA relative to DTPA (p < 0.001). For the P-DTPA, declines in cellular
viability continued as the concentration of the polymeric construct increased resulting in a minimal
cellular viability of 28% at the highest (1 mM) concentration. A statistically significant 25% decline
relative to the untreated controls (p < 0.01) was observed for the DTPA at the 1 mM concentration.
The cytotoxicity of DTPA has been demonstrated to be due to interference with cellular
proteins and DNA synthetic pathways (245). The cytotoxicity of the P-DTPA may also be due, in
part, to the presence of DTPA units within the copolymer. However, the P-DTPA also contains a
diothiobenzoate functional group on one of the termini of the copolymer. It has been demonstrated
that the diothiobenzoate terminal end of HPMA copolymers can cause cytotoxicity at elevated (>
200 µM) concentrations (incubated for 24 h) (246). Based on our data, the calculated IC 50 after 48
h P-DTPA incubation was 371 ± 45 µM (based on the DTPA concentration that is approximately
10 folds higher than the concentration of diothiobenzoate within P-DTPA). The higher observed
cytotoxicity using P-DTPA may also be attributed the presence of the diothiobenzoate within the
copolymer. In practice, chelation therapy using DTPA is commonly administered at i.v. doses of
30 µmol / kg (134, 220, 247). The administration of the copolymer at doses equivalent to this DTPA
concentration would result in a 650 µM concentration of the copolymer in the plasma, but this
concentration would be short-lived (< 1 h) with the copolymer rapidly distributing to other tissue
compartments as well as being renally excreted (97, 248). Therefore, despite the higher observed
cytotoxicity of P-DTPA compared to DTPA, these results indicate that the P-DTPA would likely
be well tolerated at the proposed prophylactic administration dose (30 µmol / kg based on DTPA
content).
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Figure 4.3 Cell viability profiles of DTPA and P-DTPA after two days incubation with HUVEC
cell line. # and † indicate significance at p < 0.001 compared to the control (no chelator
treatment). Values represent mean ± SD.
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4.3.5

In vivo prophylactic studies
To examine the prophylactic capabilities of P-DTPA and DTPA, the decorporation agents

were administered at 6 and 24 h prior to the administration of the 177Lu contaminate (timepoint = 0
day) (Figure 4.4A). These time points were chosen in order to observe if there was a time-dependent
effect on prophylactic administration and decorporation efficacy. Each 6 or 24 h prophylactic arm
includes an untreated control, DTPA (30 µmol/kg), or P-DTPA (30 µmol/kg based on the DTPA
content) groups. The excretion of the radioactivity was monitored over 14 – 15 days by radiometric
analysis of the bedding material every other day and is represented by an overall %ID excretion
format illustrated in Figure 4.4C. The enhanced excretion of the 177Lu contaminate over time in the
DTPA and P-DTPA groups relative to the untreated control group can be visualized in Figure
4.4BError! Reference source not found.. Finally, at the end of the decorporation experiments,
the mice were sacrificed to examine the differences in the

177

Lu tissue deposition between study

arms (6 and 24 h) and groups (untreated control, DTPA, and P-DTPA) (Figure 4.5).
Examination of the rate of excretion over time (Figure 4.4B and C) revealed that DTPA
and P-DTPA enhanced the decorporation of

177

Lu in both prophylactic arms. For the 6 h

prophylactic arm, analysis of excretion relative to the control demonstrated that DTPA and PDTPA had a maximal decorporation enhancement at day 4 with a respective 3.8- and 4.5-fold
increase in clearance relative to the untreated control group. From that point, the decorporation
enhancement for the DTPA group gradually declined, but was statistically higher than the control,
until day 10. Conversely, for the P-DTPA group, a greater than 3-fold enhancement in clearance
relative to the control was observed in the remaining time points of the study. At the end of the 14
day study for the 6-h prophylactic treatment arm, the P-DTPA and DTPA groups decorporated 56.4
± 3.1 and 43.4 ± 2.0 %ID, respectively, relative to 20.6 ± 1.6 %ID for the untreated control.
For the 24 h prophylactic arm, the enhancement in decorporation for the DTPA and PDTPA groups was more modest. DTPA enhancement of 177Lu clearance plateaued at a value 1.7 to
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1.8-fold greater than the control but, similarly to the 6 h arm, by day 10 had a comparable excretion
rate as the control. For the P-DTPA group, with the exception of day 2, all time points demonstrated
a greater than 2-fold increase in 177Lu clearance relative to the control. At the conclusion of the 15
day study for the 24 h prophylactic arm, 45.4 ± 1.9, 32.7 ± 2.7, and 23.6 ± 1.4 %ID of the 177Lu had
decorporated from the mice for the P-DTPA, DTPA, and untreated control groups, respectively. As
expected, the 6 h prophylactic treatment arm demonstrated significantly higher rates of excretion
relative to the 24 h arm. This is almost certainly due to the higher concentration of the decorporation
agents in the plasma and tissue compartments improving sequestration efficacy in the 6 h
prophylactic treatment arm compared to the 24 h arm.

The capability of DTPA to enhance the decorporation of

177

Lu in the 6 and 24 h

prophylactic treatment groups is, at first glance, surprising given its relative rapid plasma clearance.
However, a small but significant amount of DTPA is known to be retained in intracellular reservoirs
within tissues (249). Through slow externalization of the DTPA decorporation agent and chelation
of internalized

177

Lu, the DTPA is able to substantially increase decorporation relative to the

untreated control group. Similar results were reported by Grémy and co-workers when examining
the plutonium and americium decorportation efficacy of DTPA (249). In contrast to DTPA,
polymer conjugates such as P-DTPA can circulate in the blood for many hours to days. Previous
studies of HPMA copolymers of similar molecular weights to P-DTPA demonstrated that these
copolymers circulate in the blood for more than 24 h (107, 248, 250-252). For example, a study
reported that after i.v. injection in tumor-bearing mice, an HPMA copolymer (MW = 35.7 kDa)
modified with five DTPA units per chain showed a rapid reduction of blood levels from 7%
(%ID/g) to nearly 3% after 6 h, followed by a slower reduction over 48 h to 1% (248). Similar to
DTPA, nanomedicine constructs, such as P-DTPA, are known to be substantially internalized,
particularly by hepatocytes and immune cells composing the mononuclear phagocyte system (253).
These nanomedicine platforms can enter cells through a number of mechanisms and are most
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predominately trafficked to the endolysosomal compartments of the cell (254). Coincidently, this
is also the predominant subcellular storage site for several known actinides (i.e., plutonium and
americium) (255-257). The selective trafficking, concentration and colocalization of drug delivery
systems and actinides into these cellular compartments may give the nanoconstruct an advantage
with regard to intracellular decorporation. Taking the above into account, the more effective
decorporation rates of the P-DTPA relative to DTPA over the course of these studies is likely due
to improvements in both extracellular and intracellular chelation of the
more prolonged clearance of the

177

177

Lu. Additionally, the

Lu for the P-DTPA groups is likely reflective of the slower

release from tissue compartments and the inherently longer circulation time of the polymeric
decorporation agent.
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Figure 4.4 Schematic representation of in vivo studies and the excretion profiles. In the schematic
representation for the timelines for the two arms of in vivo studies (A), the top and bottom timelines
represent the 6 h- and 24 h-arms, respectively. In the excretion ratios (B) of 177Lu for the DTPA
and P-DTPA to the control, the average of % ID excreted per interval for the control (no chelator)
is normalized to give a value of 1.0. # and † indicate significance at p < 0.001 compared to the
control (no chelator treatment). Cumulative excretion of 177Lu over 14-15 days (C). Values
represent mean ± SD (n = 5).
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At the end of the study, the mice were sacrificed and underwent a biodistribution study to
examine the remaining 177Lu tissue deposition (Figure 4.5). Excluding the liver, spleen, kidneys,
and femur (skeleton), the total radioactivity (%ID) retained in the internal organs was minimal (<
1 %ID) for all the groups. The femur was used as a proxy for measuring skeletal uptake. The
majority of the radioactivity remaining in the carcass after tissue excision is almost certainly due
to the known skeletal adsorption of free 177Lu (258, 259). As expected, for all treatment arms, the
liver and skeleton were the major sites of

177

Lu deposition (258-260). In the 6 h prophylactic

treatment arm, P-DTPA and DTPA reduced liver retention to 19.3 ± 3.0 and 30.8 ± 1.1 %ID,
respectively, compared to 47.2 ± 1.1 %ID for the untreated control group. Likewise for the femur,
P-DTPA and DTPA reduced femur deposition to 0.50 ± 0.04 and 1.27 ± 0.10 %ID, respectively,
relative to 1.47 ± 0.07 %ID for the untreated control group. Similar tissue deposition reductions
were observed in the carcass values which is attributed primarily to the remaining skeletal activity.
For the 24 h prophylactic treatment arm, a similar pattern was observed with the exception of a
diminished liver decorporation efficacy for the experimental groups. The P-DTPA and DTPA
groups reduced liver retention to 30.6 ± 2.6 and 39.0 ± 2.9 %ID, respectively, relative to 46.1 ± 3.8
%ID for the untreated control. Interestingly, femur decorporation with P-DTPA and DTPA in the
24 h arm provided statistically identical decorporation amounts compared to the 6 h arm,
suggesting, at least in this study’s timeframe, that the skeletal decorporation was not impacted by
the increased timeframe of prophylactic administration.

One detriment to the utilization of the P-DTPA as a decorporation agent was the substantial
increase in kidney uptake and retention. For both prophylactic treatment arms, renal uptake for the
untreated control or DTPA groups was minimal (≤ 0.2 %ID) with no significant difference (p >
0.05) amongst the groups. However, in 6 and 24 h study arms, the P-DTPA group exhibited a
substantially higher renal retention of 9.3 ± 1.2 and 7.6 ± 1.8 %ID, respectively (p < 0.001
compared to the control and DTPA groups). This increased renal uptake is likely attributable to the
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anionic charge of the copolymer due to the incorporation of the DTPA moieties. Previous reports
of polymers modified with anionic functional groups (e.g., methacrylic acid) indicate that this can
substantially increase the renal uptake primarily due to increased recognition and internalization by
the proximal tubule cells of the kidney (107, 261, 262). Modification of the copolymer to reduce
the net anionic charge or the incorporation of metabolizable linkers to increase renal clearance may
be approaches that could help ameliorate this renal uptake in future optimization studies.
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Figure 4.5 Total 177Lu body content and distribution after 14 and 15 days of 177Lu contamination
for the 6-h and 24-h prophylactic treatments, respectively. Organs represent combined data from
heart, lungs, pancreas, stomach, small and large intestines, brain, and an average of 0.60 g of
muscle tissues. * p < 0.05, ** p < 0.01, *** p < 0.001. Values represent mean ± SD (n = 5).
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4.4 Conclusion
In this study, a DTPA-incorporated HPMA copolymer was synthesized and its potential as
a prophylactic decorporation agent against radiometal deposition was examined relative to DTPA.
The P-DTPA demonstrated chelation efficacies that were better than DTPA at lower concentration
of the decorporation agent. In addition, the chelation efficacy of P-DTPA was not as negatively
impacted by the presence of competitive metals as was DTPA. The P-DTPA demonstrated good
chelation efficacy to 177Lu and chelate stability in human serum. Cytotoxicity studies revealed that
the P-DTPA copolymer exhibited toxicity only at concentration ranges exceeding 200 µM and was
determined to be viable for in vivo examination. The in vivo decorporation studies in mice showed
a greater decorporation effect for P-DTPA compared to the FDA-approved DTPA in the context of
prophylactic treatment. These results are promising and represent a proof of concept that justifies
the further development of DTPA-incorporated HPMA copolymers as prophylactic decorporation
agents.
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5 Chapter 5. Summary and future directions
5.1 Summary
Depending on the type, polymeric drug delivery systems can be easily multifunctional.
They can be designed to carry radionuclides, targeting ligands, chemotherapeutic drugs, and other
agents. In this dissertation, we aimed to explore the advantages that the HPMA copolymer offers
using various strategies to improve cancer therapy and radionuclide corporation.
Radiolabeled bombesin (BBN) peptide analogs are widely evaluated in preclinical and
clinical trials for prostate cancer imaging and therapy due to their nanomolar affinity for GRPR,
which is overexpressed in prostate cancer. One of the main drawbacks of using receptor-targeted
peptides for therapy is their short tumor residence time due to intrinsically high diffusion and efflux
rates. On the contrary, large polymeric systems (e.g., HPMA copolymers) can retain for an
extended time, exploiting the tumor tissues' lack of drainage. Inspired by the need for targeted
polymeric delivery systems to improve prostate cancer radiotherapy, we developed BBN-modified
HPMA copolymers. The synthesized BBN peptide analogs included charged residues (arginine or
glutamic acid) to improve their solubility because the majority of amino acids in the active moiety
of BBN peptide analogs are hydrophobic. The introduction of charged residues decreases the selfassembly of hydrophobic peptides within the polymeric delivery systems (216). To test the effect
of the peptide and charge content of the BBN-HPMA copolymers, we varied the peptide type and
content on the HPMA copolymers to afford four positive, four negative, and two zwitterionic BBNHPMA copolymers. Only the positive copolymers showed high GRPR-based uptake, with
internalization percentages ranging from 0.7 to 20% over 4 h. The blocking experiment study using
BBN peptide antagonist confirmed this finding. These positive BBN-HPMA copolymers were then
evaluated in a normal (CF-1) mouse model to evaluate the immune response. Unfortunately, the
majority of the injected dose of these positive copolymers (except the copolymer with the lowest
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BBN content) were found in the liver and spleen after only 4 h of administration, indicating rapid
recognition by the immune cells. These results show the need for further optimization to the current
design.
The field of in vivo bioorthogonal reaction via IEDDA has been an active research area in
the past ten years. This chemistry was extensively explored to improve the safety profiles of
radiolabeled antibodies. Due to their large sizes relative to small molecules and targeted peptides,
antibodies circulate long times (e.g., few days) before they are eliminated from the blood and retain
high tumor to non-target ratios. Using the in vivo bioorthogonal chemistry via IEDAA, TCO-tagged
antibodies are first injected and allowed to accumulate in the tumor tissues and cleared from the
circulation. Then, a radiolabeled TZ probe is injected. This probe has high specificity and affinity
to react with TCO, which is presumably found in the tumor tissues tagged to the antibody. The
probe usually has a very short plasma half-life (several minutes). Therefore, any unreacted TZ
probe is quickly cleared from the body. The TZ probe that reacted with the TCO-tagged antibody
at the tumor tissues will reside for long times. We wanted to explore this strategy using HPMA
copolymer because of its attractive properties over antibodies (e.g., multifunctionality and capacity
to carry folds higher of TCO units). TCO-tagged copolymer's molecular weight (≈ 110 kDa) was
larger than the renal threshold because we wanted this copolymer to circulate for an extended time
to allow high tumor accumulation. The copolymer was synthesized to exploit the abundant
cathepsin S enzyme in MPS-associated tissues (e.g., liver and spleen). The copolymer was
synthesized by extension of small molecular weight HPMA copolymers (≈ 20 kDa) with a linker
cleaved by cathepsin S enzyme. The in vitro cathepsin S enzyme study showed that this copolymer
could be cleaved by the enzyme into smaller fragments.
The reaction kinetics were evaluated between the TCO-HPMA copolymer and two
different types of TZ probes. The optimized TZ probe (DOTA-TZ 2) was used for the in vivo
analysis. Relative to a non-cleavable TCO-HPMA copolymer (NP-82-TCO-C) having a similar
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molecular size, the cleavable TCO-HPMA copolymer (MP-90-TCO-C) was cleared from the
blood, liver, and spleen at a faster rate in a normal mouse model, indicating that this copolymer
was likely biodegraded by cathepsin S enzyme. This copolymer failed to show a significant
difference relative to the non-cleavable copolymer in immunocompromised ovarian cancer mouse
models (NOD and SCID), indicating the major role of normal immunity. The in vivo TCO / TZ
chemistry was achieved for the non-cleavable and cleavable copolymers at the tumor tissues, but
most TZ probe signal was found in the blood (in both NOD and SCID models). This issue made us
investigate the utility of a masking agent (dextran modified with TZ), which was previously shown
to deactivate the residual TCO in the blood without a significant effect on TCO in the tumor tissues.
This masking agent was injected 30 min before injecting the TZ probe. We found a huge reduction
in the TZ probe signal from mainly the blood. The tumor / non-target ratio was higher than one for
all the non-target tissues (except kidneys). These results show the feasibility of the in vivo TCO/TZ
bioorthogonal chemistry approach.

The release of actinides in case of an accident is a major public health concern. Internal
contamination via inhalation ingestion or through wounds can lead to their retentions in the liver
and skeleton for years, which leads to long term exposure. The lag time between internal
contamination and starting chelation therapy is crucial for effective therapy. Delaying the chelation
therapy leads to poor decorporation results. The currently approved chelation therapy is based on
DTPA. It has a short half-life (< 2 h), which does not render itself a good candidate for prophylactic
application. We aimed to develop a DTPA-modified HPMA copolymer (P-DTPA) that can
circulate for hours to a few days to address this issue. Our in vitro analysis showed P-DTPA's ability
to chelate the actinide model even in the presence of biological competing metals at concentrations
that are ten folds higher than their serum concentrations. We also found that P-DTPA has superior
decorporation efficacy in a mouse model when compared head to head with DTPA. We found that
P-DTPA increased the actinide model's excretion (177Lu) over two weeks of monitoring when
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administered 6- and 24-h before contamination with 177Lu. However, we found higher retention of
177

Lu in the kidneys of mice injected with P-DTPA. A similar issue was reported previously using

radiolabeled negatively charged polymers. Such polymers can retain in the proximal tubes of
kidneys for days to a few weeks. Overall, P-DTPA showed enhanced decorporation and proved to
be feasible for prophylactic applications.

5.2 Future directions

5.2.1

Charge-switch BBN-HPMA copolymer

As discussed earlier, while the in vitro studies showed enhanced internalization of positive
BBN-HPMA copolymers into PC-3 cells via GRPR targeting, the in vivo studies showed rapid
recognition by the immune cells. One approach to address this issue is by designing a charge-switch
BBN-HPMA copolymer. The positive BBN-HPMA copolymer can also be designed to contain an
acid-labile bond that links a carboxylic acid group to the copolymer's backbone, which will afford
a zwitterionic BBN-HPMA copolymer. For example, instead of modifying the BBN peptide analog
with two arginines, a modification is made so that it contains an arginine residue and a lysine
residue. The same strategy for BBN conjugation to the HPMA copolymer is applied, and the free
amines of lysine amino acids within the copolymer are reacted with 2,3‐dimethyl maleic anhydride
in the last step to afford acid-labile bonds (263, 264). If necessary, APMA-DTPA can replace the
APMA-DOTA to perform the radiolabeling with

177

Lu under physiologic conditions (e.g., 37 °C

and pH = 7.4). This approach is expected to increase the stability against easy recognition by
immune cells (due to a zwitterionic polymeric backbone instead of positively charged backbone
(265, 266)). It is also expected to render the BBN-HPMA copolymer GRPR-active (due to charge
switch into positive at the extracellular environment of the tumor tissues).
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5.2.2

Improving reaction kinetics by using a more strained TCO (sTCO)
In the third chapter, we discussed the reaction kinetics between the synthesized TCO-C

linker and DOTA-TZ 2. The second-order rate constant was estimated to be ~ 10,000 M -1 S-1. The
type of TCO used in our study is considered a first-generation. Recent studies showed that using a
more strained TCO (sTCO) leads to second-order constants 100,000 to 3,300,000 M -1 S-1 (92, 267,
268). The development of an sTCO-HPMA copolymer can show better in vivo reactivity at the
tumor tissues. For this approach, using a masking agent (e.g., DP-TZ) is necessary to deactivate the
highly reactive sTCO in the blood.

5.2.3

Optimizing the DTPA content to reduce kidney retention of P-DTPA
The observed kidney retention of

177

Lu in the group of mice injected with P-DTPA

indicates the retention of complexed 177Lu-P-DTPA. It has been reported that HPMA copolymers
with higher carboxylic acid content (e.g., carboxylic acid-containing monomer) retain in the
kidneys for longer times than HPMA copolymers with lower content (261, 262). The mol.
concentration of the DTPA per HPMA copolymer in our system, P-DTPA, was 5.2%. The
development of HPMA copolymers with DTPA contents that are lower than the tested DTPA
content may lead to lower retention of the copolymers in the kidneys.
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